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ABSTRACT 
 
Adipose tissue induced chronic low-grade inflammation is a critical link between obesity 
and insulin resistance. Despite studies implicating adipose tissue T cells (ATT) in the initiation 
and persistence of adipose tissue inflammation, fundamental gaps in knowledge regarding ATT 
function impedes progress towards understanding their role in type II diabetes. This dissertation 
explores the mechanisms of ATT maintenance via interactions with antigen presenting cells 
(APC), the tissue specific characteristics of ATTs, and how obesity regulates ATT inflammatory 
function upon activation. We find that the network between ATTs and peptide-
majorhistocompatability complex II (pMHCII) presented on the cell surface of adipose tissue 
dendritic cells (ATDC) is required for ATT maintenance.  Knocking down MHCII on dendritic 
cells with CD11cCre x MHCIIfl/fl (M11cKO) mice reconfigures ATT composition, but does not 
significantly impact systemic glucose or insulin sensitivity. To address gaps in the understanding 
of how obesity alters ATT function, we employed an in-vitro activation assay to analyze T cell 
activation in visceral adipose.  Our findings challenge the dogma that ATTs acquire pro-
inflammatory potential in obese fat, and show that measures of ATT activation based on cellular 
markers, proliferation, and cytokine secretion are impaired in obese mice and humans. Chronic 
antigen presentation or soluble mediators from obese stromal vascular cells are sufficient for 
driving ATT impairment. Single cell RNA sequencing of mouse CD3+ ATTs shows diversity in 
T cell subsets and gene expression dependent upon adipose tissue depot of origin and obesity. 
There are nine distinct subsets of ATTs and 12 weeks of high fat diet (HFD) feeding influences 
xi		
their proportions. In visceral adipose tissue depots where functional ATT impairment was 
observed, we see HFD induces genes enriched in models of T cell exhaustion. Further studies are 
required to pinpoint the specific mechanisms leading to ATT exhaustion and to determine 
whether ATT inflammatory impairment influences insulin resistance in the context of obesity. 
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Chapter 1 - Introduction 
 
 This dissertation is comprised of three primary studies that aim to address critical 
questions regarding adipose tissue T (ATT) cell activation in the context of obesity-induced 
chronic low-grade inflammation. Chapter 1 will focus on introducing obesity and its burden on 
public health by describing its epidemiology and associated co-morbidities. I will discuss the 
importance of adipose tissue in its capacity to regulate systemic metabolism in health, and how 
adipose tissue dysfunction develops when forced to compensate for excess energy intake. I will 
highlight the importance of adipose tissue-derived inflammation and its regulation of systemic 
metabolism in obese individuals. Although adipose tissue is a complex heterogeneous niche for a 
range of leukocytes that regulate inflammation in obesity, I will focus on what is know about the 
network of antigen presenting cells, how they communicate with T cells, and the critical gaps in 
knowledge that exist. Then I will describe murine and human models used to study ATT cells 
and the scope of the projects undertaken in this dissertation. Chapter 2 will detail ATT regulation 
via adipose tissue dendritic cells and the importance of major histocompatibility complex II-
mediated antigen presentation in maintaining ATTs. Chapter 3 will characterize tissue-specific 
properties of ATTs and their function in lean and obese adipose tissue. I will focus on describing 
a novel finding of ATT inflammatory impairment in obese adipose tissue. Chapter 4 will use 
single cell RNA sequencing to profile the range of ATT subsets, accounting for the adipose 
depot of origin and identify signaling pathways differentially regulated between lean and obese 
mice. Finally, I will discuss the contribution of this work to the understanding of obesity-induced 
inflammation and type II diabetes in Chapter 5.  
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Defining obesity and its effects on health 
Epidemiological studies indicate that 18% of all deaths among Americans 40-85 years of 
age result from obesity-related diseases (1). However, the emergence of obesity is historically 
recent and its contribution to severe cardiometabolic morbidities is still vastly underexplored. Up 
until the 1990s, obesity was not recognized as public health burden in the United States; 
however, 30 years later it is evident that obesity has become incredibly prevalent. According to 
the latest CDC statistics collected in 2018, 42.4% of US constituents are obese (2). Although 
obesity is often emphasized in the United States population, obesity is a global phenomenon due 
in part to production and consumption of more processed, affordable, and effectively marked 
food (3, 4). Therefore, understanding the biology of overweight and obese individuals will be 
vital for developing therapeutics for a growing population of patients with metabolic diseases.  
Obesity is commonly measured by body mass index (BMI), where: 𝐵𝑀𝐼 =  !"#$%&$ !"#$ !"#$!! (!")!!"#!!! (!)   
The Centers for Disease Control groups people as underweight, healthy weight, overweight, 
obese, and class 3 obese based upon body mass index (BMI) measurements (See Table 1A).  
Table 1A – Weight status based on BMI 
BMI Weight Status 
Below 18.5 Underweight 
18.5 - 24.9 Normal/Healthy Weight 
25 - 29.9 Overweight 
30 – 34.9 Obese – Class I 
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35 – 39.9 Obese – Class II 
40 and Above Obese – Class III 
  
Although BMI correlates with metabolic disease outcomes like glucose intolerance and 
type II diabetes, BMI is a poor surrogate for body fat content and does not distinguish lean mass 
from and fat mass (5-7). Therefore, high BMI can either indicate that an individual has higher 
than average lean mass or fat mass, particularly in children.  Techniques like dual energy x-ray 
absorptiometry (DXA) and BODPOD are better determinants of fat mass (8, 9). 
Increased body fat percentage is caused by an imbalance in energy intake and energy 
expenditure. Fat mass and body weight are maintained when energy input is equal to energy 
expenditure. Weight loss occurs when energy expenditure exceeds energy input, while weight 
gain occurs when energy intake exceeds energy expenditure (10). Therefore, obesity most 
usually occurs due to over-consumption of foods that contain macronutrients with high energy 
density and/or a sedentary lifestyle. Some groups are more prone to developing obesity than 
others. Gene/environment interactions contribute to obesity (11). Socioeconomic status can also 
determine environmental conditions which influences chronic weight gain (12). Since the steep 
increase in obesity is predicted to continue, it is essential to be able to define obesity and 
understand the physiological underpinnings of increased fat mass. 
 
Comorbidities of obesity 
Rising prevalence of obesity is a major public health concern because people with obesity 
have an increased chance of developing an array of metabolic and non-metabolic morbidities. 
Increased adiposity is tightly associated with metabolic syndrome, an umbrella term 
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encompassing metabolic disorders such as fatty liver disease, atherosclerosis, hypertension, 
stroke, and Type II diabetes (13-16). Type II diabetes occurs due to insulin resistance, which 
results in hyperglycemia (17). This occurs due to the inability of cells to sense insulin in the 
periphery and upregulate glucose transporter proteins that are required to shuttle glucose from 
blood into cells. When glucose is unable to be utilized by cells, it remains in the blood and over 
time results in end-stage diabetic outcomes like diabetic retinopathy and poor wound healing (18, 
19). Several mechanisms are responsible for mediating insulin resistance in obese conditions. 
Hormones that regulate hunger, increased adipose tissue mass, increased lipolysis, and adipose 
tissue mediated inflammation all play a role in pathogenesis of obesity-associated morbidities. 
Each of these factors will be described later in this chapter. 
In addition to cardiometabolic diseases, obesity is a risk factor for a spectrum of diseases 
that are influenced by immune cells outside of adipose tissue. Studies have shown that obese 
individuals have a higher risk of developing cancer (20).  The International Agency for Research 
on Cancer has determined that colon, postmenopausal breast, endometrial, kidney, and 
esophageal cancer are associated with obesity (21). It has been hypothesized that 
hyperinsulinemia, sex steroid hormones, adipokine secretion, and chronic low-grade 
inflammation induced by obesity can all individually contribute to cell proliferation and 
dysregulation of the cell cycle, creating cancerous cells (22). Studies have also shown that 
immune responses against cancer cells are impaired in obese states, but these cells are also more 
easily targetable by immunotherapies than T cells from lean cancer patients (23).  
Consistent with the observations of immune dysfunction in people with obesity, obesity 
is also associated with an increased risk for more severe morbidity associated with viral 
infections. Both bacterial and viral pulmonary infections including tuberculosis, influenza, and 
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coronaviruses have been shown to cause more severe morbidity and mortality in people with 
obesity (24-27). While the exact mechanisms are not yet fully understood as to why obesity and 
diabetes are risk factors for adverse outcomes with viral infections, both metabolic and immune 
functions are hypothesized to play a role. Hyperglycemia and hyperinsulinemia impair immune 
cell function because ATP utilization is required for pro-inflammatory responses (27). People 
with obesity may also upregulate receptors needed for viral entry into cells and result in 
increased viral load compared to lean subjects (26). Overall, it can be hypothesized that chronic 
low-grade inflammation dampens the immune response required for an activating stimulus (28). 
In addition to worsened outcomes in cancer and infectious diseases, obese diabetic individuals 
also have a poor response to vaccines (29).  
Therefore, people with obesity have paradoxical regulation of the immune system that 
both contribute to chronic low-grade inflammation in adipose tissue, and result in inadequate 
inflammatory responses to caner and viral infections in non-adipose tissue locations. 
Understanding the mechanisms that mediate these differences and reconciling how both pro- and 
anti-inflammatory responses can result from obesity is a big picture question that we set to 
address in this dissertation. The following sections will focus on the basics of adipose tissue and 
immune cell function and how each is regulated by the development of obesity. 
 
Adipose tissue structure and function 
 While adipose tissue was initially overlooked as a simple connective tissue that cushions 
and insulates the body, adipose tissue is now known to be a dynamic and important physiologic 
modulator. Since adipose tissue can regulate lipid storage, de novo lipogenesis, thermodynamics, 
and secretion of inflammatory mediators and hormones, it has the capacity to induce major 
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systemic changes in nutrient availability and storage (30-33). Adipocytes, the parenchymal cells 
of adipose tissue, are the primary mediators of energy storage and release. In times of energy 
excess, nutrients are converted into neutral lipids and stored in adipocytes, so that in times of 
nutrient deficit (e.g. fasting) lipids can be broken down and released in a process called lipolysis 
(34). This results in the release of free fatty acids into the bloodstream, which can be utilized for 
energy in peripheral tissues. Once free fatty acids are released into the blood stream, they 
become available substrate for ATP production. Being able to sense systemic states of energy 
excess or depletion make adipose tissue a “rheostat” for regulating systemic metabolism.  
In addition to lipid storage and release, adipocytes are important in regulating appetite via 
communication with the brain. Adipose tissue mediates the production and release 
adipocytokines (adipokines), which are hormones that regulate hunger and inflammation (35). 
Two of the most studied are leptin and adiponectin. In lean individuals, leptin is a satiety 
hormone with pro-inflammatory properties that signals through the hypothalamus and indicates 
energy intake is not needed (36). Leptin secretion is directly proportional to the body fat content 
of an individual, where more secretion occurs with increased body fat thereby acting as a 
negative feedback mechanism to maintain a healthy weight (37). Adiponectin is another 
adipokine secreted by adipose tissue but has opposite properties of leptin. Like leptin, 
adiponectin plays an important role in systemic metabolism, specifically through the modulation 
of glucose and lipid metabolism in insulin-sensitive tissues. However, high adiponectin levels in 
the circulation are seen in lean individuals and have anti-inflammatory properties (38). Insulin 
resistant individuals have much lower adiponectin than lean individuals, and increasing 
adiponectin levels improves systemic metabolism and decreases inflammation (39, 40).      
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 However, adipose tissue function is also dependent upon the proper functioning of non-
parenchymal cells, which includes the endothelium, neurons, stem cell-like preadipocytes, and 
immune cells. Obese adipose tissue is associated with damage induced by hypoxia due to 
inadequate vascularization of adipose tissue as it expands to accommodate excess lipid (see 
Adipose tissue expansion). Innervation and neuronal regulation of adipocytes are also vital for 
thermogenesis and brown adipose tissue function (described in Distribution of Adiposity). Pre-
adipocytes are crucial mediators of hyperplasia and metabolically healthy adipose tissue 
expansion (see Adipose tissue expansion in response to nutrient excess). 
 
Adipose tissue expansion in response to nutrient excess 
While we know that obesity is associated with the risk of metabolic syndrome, not all 
obese people become diabetic.  Both lean and obese people can be metabolically healthy or 
unhealthy (41). It is apparent that the quantity of adipose tissue isn’t the most important aspect of 
obesity, and the quality of obese adipose tissue drives metabolic syndrome (42). Adipose tissue 
undergoes major changes to accommodate chronic energy imbalance and prolonged periods 
where energy intake exceeds energy expenditure. One of the primary functions of adipocytes is 
to store excess energy in the form of lipid. Although adipocytes can expand their capacity for 
lipid storage, there is a limit to their storage capacity. When lipid content exceeds adipose tissue 
storage capacity, excess lipid overflows and is deposited in organs in which lipid deposition is 
detrimental (43). Metabolic organs like the liver and muscle often accumulate lipid after adipose 
tissue can no longer store excess energy, which causes lipotoxicity and tissue damage.  
 Adipocyte remodeling is an important feature of adipose tissue expansion to 
accommodate increased lipid storage. Adipocytes undergo hyperplasia, which is the production 
of new adipocytes and hypertrophy, the enlargement of existing adipocytes, in order to increase 
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lipid storage capacity. It is metabolically beneficial for adipose tissue to increase its volume as 
much as possible (44). Since adipocytes have limited ability to increase their size, enhanced 
hyperplastic ability is metabolically beneficial. Extra cells provide excess storage without 
stressing adipocytes to store lipids to a point where their capacity is exceeded. Even though 
hyperplasia results in increased fat mass, it prevents ectopic lipid deposition. Unhealthy 
adipocyte expansion also leads to increased basal lipolysis, which results in increased release of 
FFA into the bloodstream. Therefore, increased fat tissue in the absence of excess hypertrophy 
and lipolysis is metabolically beneficial as it prevents lipid deposition and damage in metabolic 
tissues like the liver and smooth muscle (43).  
 
Adipose tissue distribution creates functional heterogeneity among depots  
Unlike most organs, adipose tissue is not a contiguous tissue and is divided into depots 
that are distributed throughout the body. Adipose tissue exists in many localized fat pads both 
subcutaneously and viscerally. Each depot is classified based upon anatomic location. 
Environmental signals vary throughout the body corresponding to various organ systems and 
associated depots (renal, mesenteric, gonadal, subcutaneous, etc). Depots are very heterogeneous 
based upon adipocyte function, and stromal vascular composition/function (45). Broadly, 
adipose tissue can be divided into 3 subsets of depots depending on their primary functions. 
Brown, beige, and white adipocytes all have different developmental origins, locations, and 
functions.  
White adipose tissue (WAT) is known for its lipid storage/release, and hormonal 
regulation described previously. Brown adipose tissue (BAT) is typically only found in 
subscapular regions of infants and serves as a thermogenic organ before the development of 
skeletal muscle needed for shivering thermogenesis seen in adults (46). Heat generation in brown 
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adipose tissue has been attributed to the expression of uncoupling protein 1 (UCP1), a 
transmembrane protein in mitochondria responsible for decreasing proton gradient that is 
generated by oxidative phosphorylation (47). UCP1 moves protons from the inter-membrane 
space into the mitochondrial matrix in a fast substrate oxidation process that generates heat 
instead of ATP. Beta-3 adrenergic signaling and cold exposure are known to induce UCP1 and 
heat generation in brown adipose tissue depots (48, 49).  
Adults retain properties of brown fat in depots that are called beige or brite (the 
portmanteau of brown and white). Subcutaneous depots have properties of white adipose tissue 
when in thermoneutrality, but can transform by upregulating expression of UCP1. Therefore, 
beige adipose tissue has properties of thermogenic tissue in times of prolonged cold exposure.  
Although brown and brite adipose tissue is responsible for maintaining temperature homeostasis 
in times of cold, scientists have been interested in utilizing UCP1 as an energy sink that burns 
through excess protons in mitochondria (50). This would allow for the rapid consumption of 
excess energy stores in obese individuals. Significant research aims to harness brite fat in this 
process to burn off excess energy in a safe manner.   
In addition to function of adipocytes, WAT location and aggregation also have important 
implications in obesity co-morbidities. Enlargement of visceral adipose tissue depots around the 
abdominal organs is associated with metabolically unhealthy obesity while increased 
subcutaneous fat is less detrimental (51). Subcutaneous fat expansion is more common in 
females, while males are prone to storing lipid in visceral depots (52). This correlates with 
increased risk for men developing type II diabetes and cardiovascular disease. In humans, the 
omentum is the predominant visceral adipose tissue depot and covers the abdominal cavity, 
underneath the peritoneum (53). There are also renal, epicardial, intramuscular depots, and fat 
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surrounding lymph nodes and blood vessels. All of these depots can lead to dysregulated 
homeostasis of associated organs in the context of obesity. When they forced to store excess that 
exceeds the capacity of associated adipose tissue depots, ectopic lipid accumulation can occur 
once associated depots lose the ability to expand and store excess lipid.  
 
Adipose tissue resident leukocytes have specialized functions 
Many obesity-associated morbidities such as type 2-diabetes and metabolic syndrome are 
related to insulin resistance, which is mechanistically linked to adipose tissue dysfunction and 
inflammation (54-56). Clinical and preclinical studies have identified chronic low-grade 
inflammation as a critical link between obesity and insulin resistance and have coined the term 
“metainflammation” (57-60). Adipocytes and adipose tissue macrophages in individuals with 
obesity produce elevated levels of TNFα, resulting in impaired insulin receptor signal 
transduction and lipolysis in adipocytes (57, 61, 62). Adipocytes in obese tissue also secrete pro-
inflammatory factors like CCL2, which result in monocyte migration and trafficking into adipose 
tissue where they are polarized into inflammatory macrophages (63). This immune regulation 
directly regulates metabolism within white adipose tissue where crosstalk between immune cells 
and adipocytes contributes to the development of insulin resistance (64, 65).  
One study that highlights this, is an RNA-seq analysis performed by our lab used to 
identify pathways in adipose tissue that are features of human diabetes in an unbiased manner 
(66). Pathway analysis indicated that the top five pathways distinguishing diabetic adipose tissue 
from the metabolically healthy samples were immune-related. Studies have shown that when 
adipose tissue inflammation is abrogated using techniques like immunotherapy, metabolic 
parameters are improved and glucose intolerance can be reversed (67). Therefore, our overall 
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objective is to diminish adipose tissue inflammation as a method of alleviating disease in obese 
patients independent of their fat mass.   
Adipose tissue inflammation occurs as adipose tissue changes to accommodate chronic 
energy imbalance and increase its lipid storage capacity. In lean tissue, immune cells are mostly 
tolerogeneic and contain predominantly anti-inflammatory cells such as Tregs and resident 
adipose tissue macrophages (ATMs) (68, 69). With chronic energy imbalance, the NFκB 
signaling pathway is activated in adipocytes resulting in pro-inflammatory chemokine and 
cytokine release (64). MCP-1 secretion results in the recruitment of monocytes, which 
differentiate into pro-inflammatory ATMs (68). However, blocking NFκB signal transduction is 
not an option for improving chronic low-grade inflammation, since downstream IKKβ is critical 
for preventing apoptosis of adipocytes and exacerbated macrophage infiltration (70). In addition 
to ATMs, it has been reported that pro-inflammatory dendritic cells, T cells, B cells expand, 
while anti-inflammatory cells such as Tregs, and natural killer T (NKT) cells decrease (71-75). 
These changes in leukocyte number and function result in increased secretion of IFNγ, IL1β, and 
MCP-1 into circulation. These cytokines then influence insulin-sensitive tissues such as the liver 
and smooth muscle, by activating the NFκB pathway, downregulating the insulin depending on 
glucose transport protein Glut4, thereby reducing insulin sensitivity and increasing blood glucose 
levels (See Figure 1-1). 
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Figure 1-1 – Pro-inflammatory cytokine secretion from obese adipose tissue inhibits insulin signaling 		
 The molecular mechanisms of immune-mediated insulin resistance are mediated by 
cytokine signaling that directly inhibits insulin signaling transduction pathways. In homeostatic 
conditions, insulin – insulin receptor ligation leads to signaling through the IRS/PI3K/AKT 
pathway, resulting in translocation of Glut4 to the cell surface (76). This allows for glucose 
transport from the bloodstream, which is required for energy generation. However, inflammatory 
conditions lead to inhibition of this signaling pathway via induction of JNK. Negative feedback 
proteins, like suppressor of cytokine signaling proteins (SOCS), are induced by cytokine 
signaling to maintain cellular homeostasis and prevent hyper-inflammatory states. However, 
SOCS are also are responsible for IRS inhibition and prevention of Glut4 translocation and 
resulting glucose import (77) (See Figure 1-2).  
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Figure 1-2 – Integration of inflammatory and insulin signal transduction pathways 
Insulin signaling occurs via IRS/PI3K/AKT signal transduction, resulting in translocation of glucose transporter 
Glut4 to the cell surface. However, inflammatory signaling cascades are responsible for modulating the insulin-
signaling cascade. In inflammatory environments, cytokine signaling via TNFα induces phosphorylation of IKK and 
JNK, which in turn activate transcription factors NFκB and AP1. Signal transduction through this pathway leads to 
transcription of additional inflammatory genes, and negative feedback signaling proteins, likes SOCS. In addition to 
AP1 induction, JNK directly inhibits IRS and prevents Glut4 translocation. 
 
Since JNK and SOCS induction is conserved in signaling cascades of multiple pro-inflammatory 
cytokines, inhibiting a single cytokine would be ineffective at improving insulin sensitivity in 
states of chronic low-grade inflammation. Therefore understanding the processes that initiate 
cytokine secretion in locations like obese adipose tissue is important for potential targets for 
diabetes therapeutics.  
Both innate and adaptive immune cells are responsible for pro-inflammatory cytokine 
secretion in obese adipose tissue. However, these cells are not regulated independently and 
network with each other to regulate inflammation. This dissertation focuses on one of these 
leukocyte networks that have been implicated in obesity-induced inflammation: antigen 
presenting cell (APC) activation of adipose tissue T cells (ATT). Understanding how ATTs are 
activated and function lean and obese environments will elucidate potential targets for reducing 
Insulin signaling occurs via IRS/PI3K/AKT signal transduction, resulting in ransloca i  of glucose transporter 
Glut4 to the cell surface. However, inflammatory signaling ascad s are responsible for m dulating the i sulin 
signaling cascade. In inflammatory environ ents, cytokine signaling via TNF alpha induces phosphorylation of 
IKK and JNK which in turn activate transcription factors NFkB and AP1. Signal transduction through this pathway 
leads to transcription of additional inflammatory genes, and negative feedback signaling proteins, like SOCS. In 
addition to AP1 induction, JNK directly inhibit IRS and prevents Glut4 translocation.
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metabolically driven inflammation. Although studies have detailed the process by which APCs 
induce T cell activation in the lymphatic system, immune cell properties depend upon their local 
environments.  Leukocyte function can have a vastly different function depending upon their 
surroundings and environmental factors, and T cell activation and function in adipose tissue are 
incompletely understood. 
 
Antigen presentation and T cell activation 
 
Canonical antigen presentation in lymphoid tissues 
Antigens, or antibody generators, are foreign non-self proteins that are inducers of an 
adaptive immune response. B cells and T cells, also known as lymphocytes, are the primary 
mediators of the adaptive immune response and target removal of antigens via antibody 
production and cytotoxic destruction of infected host cells. In the context of infections, antigens 
can be either intracellular (viruses), or extracellular (bacteria) and specific immune responses can 
be mounted against both cell endogenous and exogenous insults.  Even though immune 
responses are described in the terms of infections, inflammatory responses can also occur due to 
autoimmune reactions, transplantation, or in response to microbial products form the microbiome 
(78). Antigens induce this targeted inflammation is via processing and presentation by innate 
immune cells – called antigen presenting cells (APCs). APCs phagocytose exogenous antigens or 
process endogenous antigens; break them down into peptides and present peptides on 
majorhistocompatabiliy complex (MHC) molecules.  
 
Antigen presenting cells in adipose tissue 
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Three distinct immune cell populations mediate exogenous antigen presentation and are 
known as professional antigen presenting cells: dendritic cells, macrophages, and B cells. Each is 
capable of employing phagocytosis to ingest extracellular proteins. Adipose tissue macrophages 
(ATM) are important regulators of pro-inflammatory T cell activation in obese adipose tissue 
(79). Studies using LysMCre x MHCIIfl/fl transgenic mice fed high fat diet have decreased CD4 
T cell content and improved insulin sensitivity and glucose tolerance (80). However, dendritic 
cells are the primary professional APCs in lymphoid organs and canonically phagocytose antigen 
and drain to lymph nodes where they present peptide to T cells.  
Adipose tissue dendritic cells (ATDC) studies have been limited because of the difficulty 
of distinguishing macrophages from dendritic cells.  It has been suggested that CD11c+ ATDCs 
are responsible for ATM infiltration and contribute to the inflammatory milieu in the context of 
obesity (81). A high proportion of ATMs in obese tissue also express CD11c, which is an 
important marker for ATDC.  However CD64 cleanly separates ATMs from ATDC, making 
terminal analyses of these cells possible (73). ATDC content is increased due to CCR7 
chemoattraction in the context of obesity (73). Zbtb46 has also been identified as an ATDC 
specific protein that distinguishes these cells from ATMs. Using Zbtb46-GFP mice, functional 
implications for ATDCs in lean and obese adipose tissue has been elucidated. Adipocyte 
mediated release of PPARβ and β-catenin in lean tissue maintain tolerogenic capacity of ATDCs, 
but as secretion of these factors are decreased in obese adipose tissue, ATDCs begin to mediate 
an inflammatory response (82). Despite these studies, little is known about the process adipose 
ATDC mediated antigen presentation. The ability to bridge the innate and adaptive immune 
response via peptide-MHCII is the major role of dendritic cells in classic immune reactions. 
Myeloid-derived dendritic cells canonically undergo endocytosis antigen and migrate to 
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lymphoid organs to survey a large pool of T cells. ATDCs do not drain to lymph nodes, yet they 
are capable of forming MHCII – TCR interactions within adipose tissue. Since ATDCs express 
high levels of MHCII, they could be important modulators of T cell activation in WAT. 
 
Canonical T lymphocyte function  
T cells remain quiescent until they are activated through their T cell receptors (TCR) and 
co-receptors. TCRs are rearranged during development to recognize a single distinct peptide, 
which is only recognized when it is presented on an MHC complex. Co-stimulation of CD28 
from surface receptors on antigen presenting cells (e.g CD80, CD40), and cytokine signals in the 
local environment (e.g. IL-12, TGFβ) (83-85) must also accompany cognate peptide TCR 
interactions. The result of this antigen-specific signaling engagement is the activation of T cells 
and a directed inflammatory response to the antigen it recognizes. T cells proliferate in a clonal 
manner and secrete additional effector cytokines. Although activated effector T cells have 
heterogeneous inflammatory functions depending upon polarizing cytokines in their environment 
at the time of activation, they are all characterized by expression of IL-2Ra (CD25) on the cell 
surface and IL-2 secretion (86).  
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Figure 1-3 – Antigen presenting cells facilitate T cell activation and function 		
T cells also have negative feedback mechanisms that prevent prolonged inflammation 
after recognition of peptide MHC complexes and removal of the foreign antigen that induces 
activation. After activation and initiation of inflammatory responses, co-receptors are decreased 
on the cell surface of T cells. Instead co-inhibitory receptors like PD-1, Lag3+, and CTLA-4 are 
expressed (87, 88). Co-inhibitory receptor engagement results in inhibition of Ras signaling in 
addition to AKT and subsequent survival/metabolism signaling pathways. NFkB pathways are 
also induced downstream of TCR signaling engagements, and subsequent SOCS production also 
serves as a negative feedback mechanism to dampen inflammation after an initial inflammatory 
burst. After effector T cell activation occurs and the cognate antigen is cleared from the system, 
~90% of the T cells that had expanded in response to pMHCII recognition undergo apopotosis. 
The remaining cells survive and return to a quiescent state, but retain memory to the antigen it 
responded to previously. These memory cells are capable of enacting a quick response (within 2 
days instead of 7) after a second encounter with their cognate antigen, and are responsible for 
memory to previous infections. 
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Functional T cell impairments: exhaustion, senescence, and anergy 
 There are several mechanisms by which T cells can fail to elicit an inflammatory 
response when they come into contact with their cognate antigen. Exhaustion, senescence, and 
anergy are all well described processes by which T cell hyporesponsivenes can occur. The result 
of T cell impairment is decreased proliferation, and secretion of granzyme and/or effector 
cytokines. 
 Exhaustion occurs when T cells are subjected to chronic activation due to constant 
exposure to their cognate antigen (87). This usually occurs in the context of chronic viral 
infections, cancer, and autoimmune environments. Molecular mechanisms responsible for 
exhaustion include increased and lasting expression co-inhibitory TCR receptors such as PD1 
and CTLA-4 (89). Inhibition of signaling pathways downstream of the TCR including 
PI3K/AKT is also a hallmark of exhaustion and result in inflammatory dysfunction (90).  
Additionally, dysfunction in the context of T cell exhaustion can occur due to inefficient 
metabolic activity (91)  
 Senescence is associated with aging and is marked by shortened telomeres, cell cycle 
arrest, and loss of co-activating receptor expression (CD28) (92, 93). Although senescence can 
naturally occur with ageing, it is also associated with autoimmune diseases and chronic 
infections after prolonged proliferation. This phenotype is usually identified by increased 
expression of cell cycle inhibition proteins like P16, p21, and p53, in addition to Tim3 and 
CD57. 
 Anergy is another form of induced inflammatory impairment, but is induced by 
incomplete activation and signaling through the TCR and associated receptors. Usually cognate 
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TCR –MHCII engagement occurs in the absence of co-receptor engagement. This is thought to 
be a mechanism that prevents excessive T cell inflammation and exits as a peripheral means to 
prevent autoimmunity and induce tolerance to self-antigens (94).   
 Although T cell exhaustion, senescence, and anergy can all be beneficial negative 
feedback mechanisms that prevent excessive inflammation and cytokine storms, when there are 
chronic infections, persistent antigen exposure, or enduring proliferation, these mechanisms can 
prevent resolution of infections, autoimmunity, chronic inflammation, or cancer. 
 
Diversity of T cell subsets and functions 
T cells are divided according to their response to exogenous or endogenous origin of 
peptide presentation. Dendritic cells, macrophages, and B cells are known as professional 
antigen presenting cells that phagocytose antigens from the extracellular space and present 
peptides on MHCII molecules. MHCII specifically interfaces with CD4 T helper cells. CD4 is a 
glycoprotein expressed on the surface of T cells, and its engagement with MHCII results in 
phosphorylation of intracellular Lck, which is required for TCR signal transduction in addition to 
the 3 primary signals indicated above. CD4 cells can either have inflammatory characteristics or 
anti-inflammatory properties and are known as T conventional (Tconv) and T regulatory (Treg) 
subsets, respectively. Tconv cells can be further subdivided based upon signal 3 - the cytokine 
signaling they receive during activation. Different cytokines result in polarization of T cells and 
direct them to secrete cytokines necessary to resolve the antigenic stimulus (85). See Table 1B 
for effector CD4 Tconv subpopulations. 
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Table 1B – Identifying Tconv effector T cell subsets 
Effector Subset Polarizing cytokine Effector cytokine Transcription factor 
Th1 IL-12, IFNy IFNy, IL-2 T-bet 
Th2 IL-4 Gata3 IL-4, IL-5, IL-13 
Th17 TFGb, IL-6 RORyt IL-17 
Treg TFGb, IL-2 FoxP3 TGFb, IL-10 
Tfh IL-6, IL-21 Bcl6 IL-21, IL-17 
 
Additionally, all nucleated cells are capable of presenting endogenous antigens that are 
processed and loaded onto MHC class I molecules. MHCI associates with CD8 glycoproteins on 
cytotoxic T cells which results in perforin/granzyme mediated death of the endogenous APC. 
Similar to CD4, CD8 associates with MHCI and is responsible for Lck phosphorylation and TCR 
signaling, activation, and inflammation/perforin generation. 
 
Figure 1-4 – Exogenous and endogenous antigens are responsible for CD4 and CD8 T cell activation 
 
Figure 1.4 - Exogenous and endogenous antigens are responsible for CD4 and CD8 T activation
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stimulatory molecules such as CD40, CD80/CD86 (B7), and CTLA4 have altered insulin sensitivity.30,32,44,45 
Since many of these models have impaired central and peripheral Treg generation and are expressed on non-
leukocytes (e.g. adipocytes), it is unclear if these co-stimulatory pathways are harmful or beneficial.32  
The functional relevance of CD11c+ ATMs in insulin resistance has long been recognized,46-48 but since their 
identification by our group, the question of how these cells overlap with CD11c+ ATDCs has been unclear. A 
handful of reports have identified putative ATDCs, however overlap in surface markers between activated 
macrophages and DCs complicates these analyses.4,29,49 This challenging distinction has led the 
Immunological Genome Project (ImmGen) to use systems biology to address this problem resulting in several 
revisions to how macrophages and DCs are defined in mice and humans.50,51  The goal of this aim is to 
disentangle the properties of ATM and ATDC and their interactions with ATT cells. In addition, we will evaluate 
mechanisms by which ATDC signals regulate ATT responses.  Completing this aim will have a significant 
impact on the understanding of how the balance betwe n toleranc  and immunostimulation is controlled in 
adipose tissue and identify specific modifiable pathways to attenuate obesity-induced inflammation.  
Preliminary data for Aim 1  
1. Unambiguous identification of ATDCs. Most studies define 
ATMs by CD45+F4/80+CD11b+, but we and others have found this 
definition to be imprecise since DCs, neutrophils, and eosinophils 
overlap with this gate. ImmGen has identified CD64 as a specific 
marker for tissue macrophages including ATMs.2,50 We found that 
CD45+CD64+CD11c- cells in lean mice identified resident ATMs 
and excluded CD64- neutrophils and eosinophils (Fig. 2A). In 
obese mice (20 weeks high fat diet (HFD;60%)), a new population 
of CD45+ CD64+ CD11c+ ATMs (CD11c+ ATMs) was induced. A 
distinct CD64-CD11c+ population was found in both lean and 
obese mice that we define as adipose tissue dendritic cells 
(ATDC). Gene expression microarray analysis of FACS sorted 
populations validated these definitions based on the ImmGen 
Core Macrophage and DC profiles. In vitro APC assays with 
FACS sorted ATMs and ATDCs from lean mice showed that ATDC 
have a higher capacity to stimulate CD4+ T cell proliferation 
compared to ATMs. (Fig. 2B). Flow cytometry profiling showed 
that 70% of ATDCs are conventional CD11b+CD103- DCs (cDC) 
with minor populations of CD103+, plasmacytoid, and CD8+ DCs 
in epididymal fat (EWAT). ATDC were more prominent in EWAT 
compared to inguinal subcutaneous adipose tissue (IWAT), but 
IWAT ATDCs were induced to a greater degree with short term 
HFD (Fig. 2C).  
2. ATDCs express markers of regulatory DCs.  Pathway 
analysis from the microarray data showed enrichment in genes 
related to antigen presentation (Cytokine-receptor interactions 
and GVHD) and inflammation in ATDC while ATMs were 
enriched in metabolic and lysosomal genes. (Fig. 2D) Genes 
important in regulatory DC function and Treg production27 such 
as Pd-l1/Cd274 53, Cd205/Ly75/Dec20554, and Cd25/Il2ra55 
were expressed higher in ATDC compared to ATMs in both lean 
and obese mice. This suggest that ATDCs have regulatory 
functions that may instruct ATTreg formation.   
3. ATDC are induced with early obesity in association with Treg 
expansion. Time course experiments examined how ATM and 
ATDC change with chronic HFD induced obesity (Fig. 3A). In 
lean mice, ATDCs are the dominant CD11c+ population. With 8 
weeks of HFD, there is an increase in both CD11c+ ATM and ATDC, and ATDC remain the primary CD11c+ cell 
(Fig. 3A). ATDC expansion correlated with a preferential increase in ATTreg compared to ATTconv resulting in 
a decrease in the Tconv/Treg ratio (Fig. 3B). This observation is consistent with our gene expression studies 
and studies demonstrating early Treg expansion with HFD as % total SVF.24 With 16 weeks of HFD, CD11c+ 
ATMs were induced and ATDCs decreased (ATDC/CD11c+ ATM ratio <1). This correlated with an induction of 
ATTconv and suppression of ATTreg (increase in Tconv/Treg ratio). Therefore, ATDCs correlate positively 
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stimulatory molecules such as CD40, CD80/CD86 (B7), and CTLA4 have altered insulin sensitivity.30,32,44,45 
Since many of these models have impaired central and peripheral Treg generation and are expressed on non-
leukocytes (e.g. adipocytes), it is unclear if these co-stimulatory pathways are harmful or beneficial.32  
The functional relevance of CD11c+ ATMs in insulin resistance has long been recognized,46-48 but since their 
identificati  by our group, the question of how these cells ov rlap with CD11c+ ATDCs has been unclear. A 
handful of reports have identified putative ATDCs, however v rl  in surface markers between activated 
m crophag s and DCs complicates thes  analyses.4,29,49 This ch lle ging distinction has led the 
I munological Genome Project (ImmGen) to use systems biology to address this problem resulting in several 
revisions to how macrophages and DCs are defined in ice and hum ns.50,51  The goal of this aim is to 
disentangle the properties of ATM and ATDC and their interactions with ATT cells. In addition, we will evaluate 
mechanisms by which ATDC signals regulate ATT responses.  Completing this aim will have a significant 
i pact on the understanding of how th  balance betwee  tolerance and immunostimulation is controlled in 
adi ose issue and identify specific m difi ble pathways to tenuate obesity-induced inflammati .  
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1. Unambiguous identification of ATDCs. Most studies define 
ATMs by CD45+F4/80+CD11b+, but we and thers have found this 
definition to be imprecise since DCs, neutrophils, and eosinophils 
overlap with this gat . ImmGen has identified CD64 as a pecific 
marker for tissue macrophag s including ATMs.2,50 We found that 
CD45+CD64+CD11c- ells in l an mice identified resident ATMs 
and excluded 64- n utrophils and eosinophils (Fig. 2A). In 
obes  mice (20 weeks high fat diet (HFD;60%)), a new population 
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IWAT ATDCs were induced to a greater degree with short term 
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important in regulatory DC function and Treg production27 such 
as Pd-l1/Cd274 53, Cd205/Ly75/Dec20554, and C 25/Il2ra55 
were expressed higher in ATDC compared to ATMs in both lean 
and obese mice. This suggest that ATDCs have regulatory 
fu ctions that may in tr ct ATTreg formation.   
3. ATDC are induced with early obesity in association with Treg 
expansion. Time course experiment  examined how ATM and 
ATDC change with chronic HFD induc d obesity (Fig. 3A). I  
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We know each of these 3 subsets (Tconv, Treg, and CD8+ cytotoxic) T cells reside within 
adipose tissue and are regulated by the development of obesity. However, the exact function of 
the cells and their tissue-specific characterization after activation is unknown. 
 
Innate Lymphoid Cells mediate inflammation and metabolism in adipose tissue 
Innate lymphoid cells (ILC) have functional similarities to Tconv and CD8+ effector 
cells, but lack Rag2 mediated TCR rearrangement and adaptive immune cell characteristics. 
Although they do not express TCRs or recognize specific antigens presented by MHCII, they are 
known to amplify inflammatory signals found in their environment, maintain immune 
surveillance, and contribute to metabolic homeostasis. There are three groups of ILCs: ILC1, 
ILC2, and ILC3 which secrete effector cytokines that correspond with Th1, Th2, and Th17 
Tconv. Natural killer (NK) cells are also considered a subset of ILCs, which possess cytotoxic 
function similar to CD8+ T cells. Instead of recognizing antigen, ILCs are responsive to innate 
immune activating signals like PAMPS via pattern recognition receptors and cytokines that drive 
T cell function like IL-1β and TGFβ. Although ILCs are usually associated with mucosal 
surfaces, they have also been identified as important mediators of adipose tissue inflammation. 
ILC2 cells, prominent in lean individuals, have been shown to regulate adipocyte differentiation 
and promote the development of beige fat that has thermogenic characteristics (65). However, 
non-adipose tissue NK cells in have reduced cytolytic capacity in subjects with obesity and 
contribute to increased risk for cancer (95). Again this highlights the paradox between decreased 
inflammatory capacity of immune cells in outside of adipose tissue in obesity, while immune 
cells within adipose tissue mediate chronic low grade inflammation.  
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Adipose tissue T lymphocytes (ATTs) have unique tissue resident properties 
There are multiple subsets of ATTs that either maintain inflammatory homeostasis in lean 
conditions (Tregs) or contribute adipose tissue inflammation in the context of obesity (Tconv, 
CD8+, γδ T cells).  
Anti-inflammatory Tregs (ATTreg) act to maintain homeostasis in lean adipose tissue 
(96). In lean adipose tissue, resident Tregs (ATTregs) comprise ~40% of total CD4+ T cells, 2-3x 
more than is seen in lymphoid organs like the spleen (96). Fat resident Tregs are derived from 
the thymus and have a distinct transcriptional profile which features upregulation of PPARγ (69, 
75). With obesity, the frequency of ATTregs is reduced and their anti-inflammatory functions are 
inhibited (96). ATTregs have a distinct clonal T cell receptor (TCR) repertoire suggesting they 
may be maintained by antigen(s) present in adipose tissue (96). Since TCR-antigen specificity is 
required for T cell proliferation, this finding indicates that there could be a clonal expansion of 
Tregs in lean WAT. Therefore, finding the antigens within WAT that stimulate proliferation and 
activation of Tregs is highly sought-out due to their potential influence on meta-inflammation 
therapy.    
With obesity, CD4+ Th1 conventional ATT cells and CD8+ cells are expand and 
contribute to insulin resistance in mice and humans (67, 97). There are several studies that 
indicate Tconv and CD8+ ATTs contribute to chronic low-grade inflammation. Neutralizing 
ATTs in obese adipose tissue using αCD3 antibody injections improve glucose sensitivity (67). 
CD8+ ATTs accumulate in mice fed HFD prior to pro-inflammatory macrophage recruitment 
and contribute to insulin resistance themselves (97). The literature describing Tconv cells are 
indicates these cells also contribute obesity mediated inflammation and insulin resistance. Obese 
macrophage specific MHCII knockout mice (LsyMCre x MHCIIfl/fl) have improved glucose and 
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insulin sensitivity compared to wild type controls. However, more recent studies indicate that 
Tconv inflammation is not due to canonical T cell activation and effector cytokine secretion. 
Tconv in obese adipose tissue have markers of cell cycle arrest and senescence, and secrete high 
levels of osteoponin instead of IL2 and IFNγ (98). Adipose tissue Th1 Tconv cells have 
restricted TCR repertoires, indicating they are proliferating in response to one or several antigens 
(99, 100). Strikingly, the TCR repertoires in lean and obese adipose tissue are distinct suggesting 
that different antigenic signals control their appearance, proliferation and activation. Once 
activated, Th1 cells release IFNγ, potentiating inflammatory profiles of ATMs and subsequent 
insulin resistance (101). In obese conditions, Th1 TCR repertoires are also restricted, but to a 
different set of antigens than adipose tissue Tregs (99). Since the proliferation of T cells 
classically occurs in an antigen-specific manner requiring peptide presentation by antigen 
presenting cells (APCs), it appears that Tconv are activated in response to antigens found 
exclusively in obese fat.  
 
Mouse models of obesity 
There are several ways to model obesity using animal models. Mice are the choice of 
immunologist because there are abundant reagents available to assess and manipulate DNA, 
RNA, and proteins in mice. We use the C57Bl/6J mouse strain because male mice are 
susceptible to robust adipose tissue expansion, adipose tissue immune cell activation, and the 
development of insulin resistance. Other common strains like BALBc mice are resistant to 
weight gain and obesity-induced morbidities (102, 103). C57Bl/6J mice are used for diet-induced 
obese models (DIO) when placed on high fat diets (HFD) starting at 6 weeks of age. The 
standard HFD chow used in the field is composed of 5.24kcal/gm 20% protein, 60% fat, 20% 
carbohydrate. However, there is some criticism that 60% HFD this does not model diet of obese 
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humans. Therefore, diets composed of 40% fat and increased carbohydrates are used in studies 
that are interested in modeling diet. Normal diet (ND) chow maintains lean and metabolically 
healthy C57Bl/6J mice and is composed of 4.09kcal/gm 29.8% protein, 13.4% fat, 56.7% 
carbohydrate.  
Several transgenic mouse strains are also commonly used in obesity studies. Lepob 
(Ob/Ob) mice have a spontaneous mutation in their leptin gene. Without leptin signals, satiety is 
never achieved and animals continuously feel hungry, causing hyperphagia, hyperglycemia, 
glucose intolerance, and elevated plasma insulin. Another leptin related mutant mouse that is 
used for obesity research are Db/Db mice, which have a spontaneous mutation in the leptin 
receptor. Metabolic disease in these mice is more severe than DIO mice and occurs 
independently of high fat diet feeding. However, leptin signaling plays an important role in 
leukocyte function, therefore Ob/Ob and Db/Db models have limitations in immunologic studies. 
 
Weight loss and bariatric surgery 
Weight loss is recommended to all obese individuals because it is a proven way to 
improve metabolic syndrome and alleviate insulin resistance. Despite metabolic improvements, 
adipose tissue macrophage accumulation is not reduced with weight loss in mice (104). Whether 
this has long-term implications on adipose tissue health, or whether exercise mediated weight 
loss would result in the reversal of ATM infiltration is yet to be determined. Increasing energy 
expenditure over energy consumption results in weight loss and is achieved through both diet 
and exercise. However, it is difficult for obese individuals to lose weight and maintain reduced 
body weight. In morbidly obese individuals bariatric surgeries can aid in starting and maintain 
weight loss. 
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When obesity causes severe co-morbidities or it is difficult to lose weight via diet and 
exercise, bariatric surgery is considered. Most people considered for these surgeries have a BMI 
over 40. Bariatric surgery candidates have to undergo intense screening and make lifestyle 
changes that promote healthy eating and exercise habits.  Surgeries result in permanent changes 
to the digestive system and healthy habits need to be established. By decreasing the volume of 
the stomach, the absorption of nutrients through the gut, or both bariatric surgeries aid in 
reducing calorie consumption. Roux-en-Y surgeries are the most commonly performed. These 
procedures entail reducing the stomach with a normal capacity of 3 pints down to a 1-ounce 
pouch by sealing off the top of the stomach. Additionally, the duodenum (beginning of the small 
intestine) is bypassed and the jejunum is connected to the re-sized stomach to reduce nutrient 
absorption. Sleeve gastrectomy is another method of reducing the absorption and volume of food 
that can be consumed. This method removes around 80% of the stomach leaving a tube-shaped 
pouch. Reduced stomach size reduces food intake and can also result in decreased secretion of 
the appetite-stimulating hormone, ghrelin.  
Bariatric surgeries also allow us the opportunity to collect visceral adipose tissue from 
humans. Since abdominal fat requires invasive procedures to acquire, these surgeries are vital for 
studying human adipose tissue-resident immune cells. Unlike murine studies where lean animals 
can be used as normal controls, all bariatric surgery patients are obese. However, metabolically 
unhealthy and unhealthy patients can be grouped and compared. Blood is collected from each 
bariatric surgery patient along with omental biopsies. Hemoglobin A1c (HbA1c) is an indicator 
of long-term blood glucose levels and can be a method for determining whether an individual is 
diabetic without having to perform glucose tolerance tests. Measurements below 5.6 are 
considered normal, 5.7-6.4 is Pre-diabetic, and diabetic patients are 6.5 or higher.  
26		
 
Scope of the dissertation 
There are significant gaps in knowledge regarding how immune cells interact with each 
other to influence homeostatic maintenance of lean adipose tissue, and chronic low-grade 
inflammation in obese metabolically unhealthy individuals. One critical interconnection between 
innate and adaptive immune responses in adipose tissue is the activation of CD4 T cells by 
antigen presenting cells like macrophages and dendritic cells. This specific network between 
innate and adaptive immune cells is particularly interesting because there is evidence that Tconv 
cells in obese adipose tissue have restricted TCR repertoires (99). Therefore ATTs are activated 
in an antigen-specific manner. However, it remains to be determined the specific antigens that 
are required for ATT activation and downstream inflammation. Therefore, the goal of this 
dissertation was to assess both sides of the connection between antigen presenting cells and T 
cells to best understand this autoimmune-like component of type II diabetes. 
 
Context for Chapter 2- Adipose tissue dendritic cell signals are required to maintain T cell 
homeostasis and obesity-induced expansion 
Although dendritic cell-mediated T cell activation has been well described in the context 
of lymphoid organs, both APCs and T cells within tissues have specific properties depending 
upon the environment in which they reside. Although ATMs have been shown to mediate T cell 
activation via peptide MHCII presentation in obese adipose tissue, the role of ATDCs has not 
been explored (80). The major gap in the field and question I sought to answer in this chapter is: 
how do professional antigen-presenting cells communicate and contribute to ATT cell function 
in obesity? 
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Figure 1-5 – Hypothesis: ATMs and ATDCs differentially regulate T cell polarization and function 
 
The first step to answering this question was to distinguish whether there are differences 
in T cell activation via MHCII signaling by adipose tissue macrophages and dendritic cells. 
Since a cognate TCR interaction with a peptide-loaded MHCII has been identified as the 
mechanism that activates T cells in adipose tissue, further investigation of non-macrophage 
antigen presentation in WAT warranted scrutiny.  
Lean tissue contains higher frequencies of ATDCs than obese WAT. Interestingly, 
frequencies of ATDCs do not progressively decrease over time. Instead, their frequency 
increases during short-term high fat diet exposure, and decrease after pro-inflammatory 
macrophage infiltration occurs. ATDC population dynamics mirror those of WAT Tregs, while 
CD11c+ ATMs correspond with Th1 expansion (Figure 1-5). Therefore, we hypothesize that 
ATDCs and ATMs differentially regulated ATT polarization and function. If ATDCs and ATMs 
secrete different cytokines during T cell interactions, APCs may be responsible for the type of 
adaptive immune response elicited in WAT. Determining whether these APCs can differentially 
Figure 1.4 - Exogenous and endogenous antigens are responsible for CD4 and CD8 T activation
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Figure 1.5 - Do ATMs and ATDCs differentially regulation T cell polarization and function?
	
stimulatory molecules such as CD40, CD80/CD86 (B7), and CTLA4 have altered insulin sensitivity.30,32,44,45 
Since many of these models have impaired central and peripheral Treg generation and are expressed on non-
leukocytes (e.g. adipocytes), it is unclear if these co-stimulatory pathways are harmful or beneficial.32  
The functional relevance of CD11c+ ATMs in insulin resistance has long been recognized,46-48 but since their 
identification by our group, the question of how these cells overlap with CD11c+ ATDCs has been unclear. A 
handful of reports have identified putative ATDCs, however overlap in surface markers between activated 
macrophages and DCs complicates these analyses.4,29,49 This challenging distinction has led the 
Immunological Genome Project (ImmGen) to use systems biology to address this problem resulting in several 
revisions to how macrophages and DCs are defined in mice and humans.50,51  The goal of this aim is to 
disentangle the properties of ATM and ATDC and their interactions with ATT cells. In addition, we will evaluate 
mechanisms by which ATDC signals regulate ATT responses.  Completing this aim will have a significant 
impact on the understanding of how the balance between tolerance and immunostimulation is controlled in 
adipose tissue and identify specific modifiable pathways to attenuate obesity-induced inflammation.  
Preliminary data for Aim 1  
1. Unambiguous identification of ATDCs. Most studies define 
ATMs by CD45+F4/80+CD11b+, but we and others have found this 
definition to be imprecise since DCs, neutrophils, and eosinophils 
overlap with this gate. ImmGen has identified CD64 as a specific 
marker for tissue macrophages including ATMs.2,50 We found that 
CD45+CD64+CD11c- cells in lean mice identified resident ATMs 
and excluded CD64- neutrophils and eosinophils (Fig. 2A). In 
obese mice (20 weeks high fat diet (HFD;60%)), a new population 
of CD45+ CD64+ CD11c+ ATMs (CD11c+ ATMs) was induced. A 
distinct CD64-CD11c+ population was found in both lean and 
obese mice that we define as adipose tissue dendritic cells 
(ATDC). Gene expression microarray analysis of FACS sorted 
populations validated these definitions based on the ImmGen 
Core Macrophage and DC profiles. In vitro APC assays with 
FACS sorted ATMs and ATDCs from lean mice showed that ATDC 
have a higher capacity to stimulate CD4+ T cell proliferation 
compared to ATMs. (Fig. 2B). Flow cytometry profiling showed 
that 70% of ATDCs are conventional CD11b+CD103- DCs (cDC) 
with minor populations of CD103+, plasmacytoid, and CD8+ DCs 
in epididymal fat (EWAT). ATDC were more prominent in EWAT 
compared to inguinal subcutaneous adipose tissue (IWAT), but 
IWAT ATDCs were induced to a greater degree with short term 
HFD (Fig. 2C).  
2. ATDCs express markers of regulatory DCs.  Pathway 
analysis from the microarray data showed enrichment in genes 
related to antigen presentation (Cytokine-receptor interactions 
and GVHD) and inflammation in ATDC while ATMs were 
enriched in metabolic and lysosomal genes. (Fig. 2D) Genes 
important in regulatory DC function and Treg production27 such 
as Pd-l1/Cd274 53, Cd205/Ly75/Dec20554, and Cd25/Il2ra55 
were expressed higher in ATDC compared to ATMs in both lean 
and obese mice. This suggest that ATDCs have regulatory 
functions that may instruct ATTreg formation.   
3. ATDC are induced with early obesity in association with Treg 
expansion. Time course experiments examined how ATM and 
ATDC change with chronic HFD induced obesity (Fig. 3A). In 
lean mice, ATDCs are the dominant CD11c+ population. With 8 
weeks of HFD, there is an increase in both CD11c+ ATM and ATDC, and ATDC remain the primary CD11c+ cell 
(Fig. 3A). ATDC expansion correlated with a preferential increase in ATTreg compared to ATTconv resulting in 
a decrease in the Tconv/Treg ratio (Fig. 3B). This observation is consistent with our gene expression studies 
and studies demonstrating early Treg expansion with HFD as % total SVF.24 With 16 weeks of HFD, CD11c+ 
ATMs were i duced and ATDCs decreased (ATDC/CD11c+ ATM r tio <1). This correlated with an induction of 
ATTconv and suppression of ATTreg (increase in Tconv/Treg ratio). Therefore, ATDCs correlate positively 
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stimulatory molecules such as CD40, CD80/CD86 (B7), and CTLA4 have altered insulin sensitivity.30,32,44,45 
Since many of these models have impaired central and peripheral Treg generation and are expressed on non-
leukocytes (e.g. adipocytes), it is unclear if these co-stimulatory pathways are harmful or beneficial.32  
The functional relevance of CD11c+ ATMs in insulin resistance has long been recognized,46-48 but since their 
identificati  by our group, the question of how these cells ov rlap with CD11c+ ATDCs has been unclear. A 
handful of reports have identified putative ATDCs, however v rl  in surface markers between activated 
m crophag s and DCs complicates thes  analyses.4,29,49 This ch lle ging distinction has led the 
I munological Genome Project (ImmGen) to use systems biology to address this problem resulting in several 
revisions to how macrophages and DCs are defined in ice and hum ns.50,51  The goal of this aim is to 
disentangle the properties of ATM and ATDC and their interactions with ATT cells. In addition, we will evaluate 
mechanisms by which ATDC signals regulate ATT responses.  Completing this aim will have a significant 
i pact on the understanding of how th  balance betwee  tolerance and immunostimulation is controlled in 
adi ose tissue and identify specific modifi ble pathways to attenuate obesity-induced inflammati .  
Preliminary data for Aim 1  
1. Unambiguous identification of ATDCs. Most studies define 
ATMs by CD45+F4/80+CD11b+, but we and thers have found this 
definition to be imprecise since DCs, neutrophils, and eosinophils 
overlap with this gat . ImmGen has identified CD64 as a pecific 
marker for tissue macrophag s including ATMs.2,50 We found that 
CD45+CD64+CD11c- ells in l an mice identified resident ATMs 
and excluded 64- n utrophils and eosinophils (Fig. 2A). In 
obes  mice (20 weeks high fat diet (HFD;60%)), a new population 
f CD45+ CD64+ CD11c+ ATMs (CD11c+ ATMs  w s induced. A 
distinct CD64-CD11c+ population was found in both lean an  
obese mice that we define as adipose tissue dendritic cells 
(ATDC). G ne expression microarray analysis of FACS sorted 
populations validated these definitions based on the ImmGen 
C re Macrophage and DC profiles. I  vitro APC assays with 
FACS sorted ATMs and ATDCs from lean mice showed that ATDC 
have a higher capacity to stimulate CD4+ T cell proliferation 
comp red to ATMs. (Fig. 2B). Flow cytometry profiling sh wed 
that 70% of ATDC  are conventional CD11b+CD103- DCs (cDC) 
with minor populations of CD103+, plasmacytoid, and CD8+ DCs 
in epid dymal fat (EWAT). ATDC were more prominent in EWAT 
com ared to inguinal subcutaneous adip se tissue (IWAT), but 
IWAT ATDCs were induced to a greater degree with short term 
HFD (Fig. 2C).  
2. ATDCs express markers of regulatory DCs.  Pathway 
analysis from the microar ay data showed enrichment in genes 
rel ted to antigen presentation (Cytokin -receptor interactio s 
and GVHD) and inflammation in ATDC whil  ATMs were 
e riched in metabolic and lysosomal genes. (Fig. 2D) Genes 
important in regulatory DC function and Treg production27 such 
as Pd-l1/Cd274 53, Cd205/Ly75/Dec20554, and C 25/Il2ra55 
were expressed higher in ATDC compared to ATMs in both lean 
and obese mice. This suggest that ATDCs have regulatory 
fu ctions that may in tr ct ATTreg formation.   
3. ATDC are induced with early obesity in association with Treg 
expansion. Time course experiment  examined how ATM and 
ATDC change with chronic HFD induc d obesity (Fig. 3A). I  
lean mice, ATDCs are the domina t CD11c+ population. With 8 
weeks of HFD, there is an increase in both CD11c+ ATM and ATDC, and ATDC remain the primary CD11c+ cell 
(Fig. 3A). AT C expansio  co related with a preferential increase in ATTreg compared to ATTconv resulting in 
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activate T cells could significantly advance the understanding of adipose-specific immune health, 
and how it is modulated in different nutrient environments.  
Such a task proved to be difficult since ATMs and ATDCs share a common stem cell 
progenitor. Many of their cell surface markers and functions are similar, making experimental 
alterations difficult to produce. However, if ATDCs and ATMs are identified as differential 
regulators of T cell proliferation, it would narrow the search for antigens activating Tregs and 
Th1 cells in their respective environments. Since antigen identification is so difficult to pursue 
with given biomedical technology, isolating separate APCs would be an important first step in 
this process. Ultimately, determining antigens responsible for inflammation in WAT would 
provide a target that would suppress CD11c+ recruitment and pro-inflammatory cytokine 
production. Such a reversal would provide a significant breakthrough in creating therapies for 
type II diabetes.  
 
Context for Chapter 3 - Adipose tissue T cells have impaired inflammatory capacity in obese 
mice and humans 
It is unknown whether ATTs have the same response to cognate antigen presentation as T 
cells in lymphoid organs. The major gap in the field and question I sought to answer in this 
chapter was: what are the characteristics of activated ATT cells? 
 There are several critical gaps in our understanding of ATT cells and their function in 
insulin resistance. A few crucial and feasible questions that need to be addressed include: (1) 
What cytokines are secreted by CD4+ and CD8+ ATT cells upon activation and how does this 
change with obesity status and depot of origin? (2) What are the properties of human CD4+ and 
CD8+ ATT cells in relation to diabetes status in humans? (3) Which features of ATT cell 
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activation and maintenance in obesity contribute to metabolic dysfunction? Very little is known 
about the consequences of ATT cell activation in different adipose tissue depots and how this is 
changed with obesity. Even less is known about human ATT cell activation and how it relates to 
diabetes status. The objective of this aim is to evaluate the hypothesis that ATT cell activation 
profiles will have differences depending upon depot of origin and that in obese mice would have 
enhanced pro-inflammatory functions than ATT in lean tissue, contributing towards chronic low-
grade inflammation. 
 
   
Figure 1-6 – Hypothesis: ATTs in obese adipose tissue have enhanced inflammatory responses 
 
Previous limitations in studying ATTs have been insufficient substrate because ATTs are 
a rare cell population and difficult to maintain viability in-vitro. Therefore, a new assay was 
developed to perform basic functional assessments. Murine ATTs from two visceral depots 
(oWAT and eWAT) and human biopsies from normal and diabetic bariatric surgery patients 
were used to collect primary ATTs and test their function in response to an activating stimulus.  
Figure 1.6 - Hypothesis: ATTs in obese adipose tissue have enhanced infla matory response
Figure 1.7 - Interrogating ATT heterogeneity with single cell RNA-seq
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Context for Chapter 4- Heterogeneity of adipose tissue T cell subtypes 
 Immune cell functional capacity is often grouped by protein expression of transcription 
factors and cell surface receptors. However, defining cell populations based on known protein 
expression can be limiting and lead to a reductionist view of immune cell subsets. In the past 
decade, single-cell RNA sequencing has become more widely accessible. Improved analysis of 
ATTs using this technology can be achieved because of several important factors. First, each cell 
is sequenced independently of the others and can be clustered due to the similarity of 
transcriptional expression of thousands of genes instead of 10-20 proteins that can be detected 
with techniques like flow cytometry.  
 
 
Figure 1-7 – Interrogating ATT heterogeneity with single cell RNA-seq 
 
An additional benefit of SC RNA sequencing is detailed intracellular gene expression, 
which can be analyzed with pathway sequencing databanks like Gene Set Enrichment Analysis 
(GSEA) and protein annotation through evolutional relationship (PATHER). Rare cell 
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populations can be difficult to assess with conventional assays because sufficient protein or RNA 
cannot be obtained. Therefore, SC RNAseq allows us to assess potential mechanisms and 
functional differences between different ATT clusters, differences in clusters between depots, 
and modifications due to HFD feeding.  
 
Overall objectives 
The major question in the field, and overall objective of this dissertation was to make 
steps towards identifying adipose tissue antigens responsible for ATT activation in the context of 
obesity. Not only are these antigens a target for reducing ATT mediated metabolic inflammation, 
their presence and inflammatory induction have the potential for re-framing type II diabetes as an 
adipose tissue centric autoimmune disease. Interrogating questions regarding ATDC mediated 
ATT maintenance and activation, tissue-specific characteristics, diet-mediated changes in ATT 
functionality, and heterogeneity of CD3+ ATTs has resulted in significant novel information 
contributing to the field of adipose tissue inflammation. We have closed several gaps in what we 
know about ATTs in obesity-induced diabetes that inform next steps for identifying the 
activating antigens in question. However, equally important novel findings challenge the dogma 
that ATTs chronically produce pro-inflammatory mediators and suggest obesity induces ATT 
inflammatory impairment. Further studies will be required to determine the physiological 
implications for this finding in the context of metabolic diseases, and associated increased 
morbidities related to infections and cancer development in obese individuals.  
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Chapter 2: Adipose Tissue Dendritic Cell Signals are Required to Maintain T Cell 
Homeostasis and Obesity-Induced Expansion 	
This chapter has been published: 
 
Porsche CE, DelProposto JL, Patrick E, Zamarron BF, Lumeng CN. Adipose tissue dendritic cell 
signals are required to maintain local T cell homeostasis and obesity-induced expansion. Mol 
Cell Endocrinol. 2020 Apr 5; 505:110740. PubMed PMID: 31987897 
 
Author Contributions: BFZ bred transgenic mice, EP performed experiments in Figure 2-5, CEP 
and JLD both performed experiments in Figures 2-1, 2-2, 2-3, 2-6. CEP performed experiments 
in Figure 2-4. CEP and CNL conceived of experiments, wrote, and edited the manuscript.  
 
 
Abstract 
Adipose tissue derived chronic inflammation is a critical component of obesity induced type II 
diabetes. Major histocompatibility complex II (MHCII) mediated T cell activation within adipose 
tissue is one mechanism that contributes to this phenotype. However, the contribution of 
dendritic cells as professional antigen presenting cells in adipose issue has not previously been 
explored. Using ItgaxCre x MHCIIfl/fl (M11cKO) mice we observed adipose tissue specific 
changes in adipose tissue leukocytes. While there was a complete knockout of MHCII in 
dendritic cells, MHCII was also absent on the majority of macrophages. This resulted in 
reduction of TCR expression in CD4+ T cells in obese adipose tissue, and an increase in CD8+ 
and CD4+ CD8+ double positive T cells with decreased CD4+ T cells independent of diet type. 
Increased CD8+ cells were not observed in the spleen, suggesting adipose tissue T cell regulation 
is tissue specific. In vitro studies demonstrated more potent antigen presentation function in 
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adipose tissue dendritic cells compared to macrophages. Obese M11cKO mice had decreased 
CD11c+ adipose tissue macrophages. Despite the changes of immune cellularity in adipose 
tissue, M11cKO largely did not change inflammatory gene expression in adipose tissue and did 
not demonstrate differences in glucose and insulin intolerance. Overall MHCII expression on 
CD11c+ cells is important for maintaining CD4+ and CD8+ adipose tissue T cells, but these 
cellular changes fail to alter inflammatory output and systemic metabolism.  
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Introduction 
 
Type II diabetes is widely prevalent in the United States. The latest CDC statistics 
indicate that 9.4% of the entire population has diabetes, and that 87.5% of this group is 
overweight or obese (105). Obesity induced diabetes is characterized by insulin resistance, which 
is mechanistically linked to adipose tissue dysfunction and chronic inflammation (54-56, 106). 
Preclinical and clinical studies have shown chronic low-grade inflammation is a critical link 
between obesity and insulin resistance, and inhibiting adipose tissue inflammation improves 
insulin sensitivity and metabolic capacity (57-60). Therefore understanding the mechanisms 
inducing adipose tissue inflammation and developing methods to reverse this phenotype are 
critical steps in developing diabetes treatments.  
Components of both the innate and adaptive immune system reside within adipose tissue 
and their inflammatory output shifts with in- creased adiposity. Lean fat predominantly contains 
cells with anti-inflammatory phenotypes, such as arginase expressing adipose tissue 
macrophages (ATMs), group 2 innate lymphoid cells (ILC2) and regulatory T cells (Tregs), 
which maintain metabolic homeostasis (65, 68, 96). However with obesity, cross-talk between 
adipocytes and tissue resident leukocytes leads to adipose tissue inflammation characterized by 
qualitative and quantitative changes in adipose immune cells. With obesity, both CD4+ Th1 and 
CD8+ adipose tissue T cells (ATTs) are activated and contribute to insulin resistance in obese 
conditions (67, 97). CD4+ T conventional (Tconv) ATTs have restricted TCR repertoires in 
obese adipose tissue, indicating that they are being activated and proliferating by in response to 
specific antigens residing within the adipose tissue (99). Adipose tissue Tregs (ATTregs) 
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comprise ~40% of CD4+ T cells in lean mice, have a distinct transcriptional profile, and have a 
restricted TCR repertoire that contributes to metabolic homeostasis (75, 96). The quantity of 
ATTregs is diminished with obesity-induced inflammation contributing to the pro-inflammatory 
environment.  
MHC class II and the antigen presenting cells (APCs) control ATT cell content and 
activation, and appear to be diverse (69, 73, 107). Adipocytes have been implicated in antigen 
presentation, but professional phagocytes are also prominent features of adipose tissue (107). An 
extensive resident ATM population exists in lean mice, and with obesity activated CD9/CD11c+ 
macrophages accumulate in conjunction with pro-inflammatory CD4+ Th1 cells (72, 108). 
ATMs have potent APC capacity required for ATT activation in obesity. Using Lyz2Cre x 
MHCIIfl/fl mice, MHCII expression in ATMs was shown to be required for the obesity-induced 
generation of CD4+ conventional Th1 ATTs, but not the maintenance of adipose tissue CD4+ 
cells on normal diets (80). This mouse model also targeted some adipose tissue dendritic cells 
(ATDC), which have been shown to contribute to the inflammatory response to obesity in 
visceral adipose tissue depots and may explain the ability to maintain normal CD4+ ATT 
numbers (73, 82, 109)   
It is currently not well understood if ATDCs and ATMs have redundant functions in 
activating ATT cells, or whether they possess unique activation or polarization of ATTs in obese 
states. Since ATDC are the main CD11c+ cell in lean adipose tissue (73), we generated mice 
with knockout of MHCII (H2-Ab1) in CD11c expressing cells using CD11c(Itgax)cre drivers 
crossed to H2-Ab1fl/fl transgenic mice (M11cKO). We hypothesized that inhibiting ATDC 
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antigen presentation using CD11cCre would disrupt Treg populations and subsequently worsen 
glucose tolerance in lean mice. We observed that M11cKO mice had fewer CD4+ adipose tissue 
T cells along with increase in CD8+ ATT independent of diet type. Additionally M11cKO had 
impaired ATT TCR expression on CD4+ Treg and Tconv in obese settings. This phenotype was 
related to loss of MHCII in ATDC as well as most ATMs and contributed to a slight decrease in 
the accumulation of CD11c+ ATMs in obese mice. In vitro studies demonstrated that ATDC had 
stronger APC function than ATMs explaining the requirement for MHCII in ATDC for CD4+ 
cell maintenance. Overall our results suggest differential regulation of ATT cell maintenance and 
activation by ATDC and ATM.  
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Materials and Methods 
Animal Studies 
C57Bl/6J, CD11cCre (JAX stock 008068, B6.Cg-Tg(Itgax-cre)1- 1Reiz/J (110) and MHCIIfl/fl 
(B6.129X1-H2-Ab1tm1Koni/J) mice were obtained from the Jackson Laboratory. MHCIIfl/fl x 
CD11cCre (M11cKO) mice were generated by breeding Itgax/Cd11cCre with MHCIIfl/fl mice. 
Cre-negative and MHCIIfl/+ littermates were used as controls. Male mice were fed ad libitum 
either a normal diet (LabDiet PicoLab 5L0D 4.09kcal/gm 29.8% protein, 13.4% fat, 56.7% 
carbohydrate) or a high fat diet (HFD; Research Diets D12492, 5.24kcal/gm 20% protein, 60% 
fat, 20% carbohydrate) beginning at 6 weeks of age. All mouse procedures were approved by the 
University Committee on Use and Care of Animals at the University of Michigan and were con- 
ducted in compliance with the Institute of Laboratory Animal Research Guide for the Care and 
Use of Laboratory Animals.  
Metabolic evaluations  
Glucose tolerance tests (GTT) and Insulin Tolerance Tests (ITT) were performed after a 6 hour 
fast. For GTTs, mice were injected IP with D-glucose (0.7 g/kg). For ITTs, mice were injected IP 
with human insulin (Humulin 1 U/kg). For both GTTs and ITTs, blood glucose concentrations 
(mg/dL) were measured at 0, 15, 30, 45, 60, 90, and 120 min after injection from tail nick with a 
glucometer.  
Isolation of adipose tissue SVF and flow cytometry analysis  
The stromal vascular fraction (SVF) was isolated from whole adipose tissue as previously 
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described (111). Briefly, adipose tissue depots were dissected and weighed. Tissue was then 
mechanically disrupted by mincing, and chemically digested by rocking tissue in 1 mg/ml 
collagenase IV (Sigma Aldrich) at 37°C for 30 min. Cells were then quenched with RPMI media 
and filtered through 100 nm mesh prior to RBC lysis and subsequent filtering with 70 nm mesh 
filters.  
Cells were incubated in Fc Block for 5 min on ice and stained with indicated antibodies for 30 
min at 4°C: Anti-Mouse CD45 eFluor 450 [48-0451-82], Anti-Mouse CD8a FITC [11-0081-82], 
Anti-Mouse MHC Class II (I-A/I-E) PE-Cy7 [25-5321-82], Anti-Mouse CD4 APC [17-0041- 
82], Anti-Mouse CD11c APC-eFluor® 780 [47-0114-80], Anti-Mouse CD25 APC [17-0251-82] 
from eBioscience, anti-mouse CD3ε PerCP/ Cy5.5 [145-2C11] from Biolegend, and anti-Mouse 
CD64 a and b Alloantigens PE [558,455] from BD Pharmingen.  
Stained cells were washed twice with FACS buffer and fixed for intracellular staining with Anti-
Mouse Foxp3 PE [12-4771-82] from eBioscience, using a FoxP3 transcription kit (BD 
Biosciences). Analysis was performed on a FACSCanto II Flow Cytometer and analyzed with 
Flow Jo software (Treestar).  
Gating strategy 
Representative flow gating of eWAT was performed as the following: cells were gated on 
Singlets (FSC–W x FSC-H) → Scatter (FSC-A x SSC-A) → CD45+ → and then separated by 
CD3+ and CD3−. CD3+ cells were further sub-gated into specific T cell populations (CD4 by 
CD8). The CD4+ population was further divided into FoxP3+ (Treg) and FoxP3- (Tconv) groups. 
CD3− cells were used to assess APCs. ATDCs are CD11c + CD64−, and ATMs are CD64+.  
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Gene expression analysis 
 RNA was extracted from tissue by homogenizing epididymal white adipose tissue (eWAT) in 
Trizol, followed by phase separation with chloroform. The aqueous fraction was then processed 
using RNeasy Midi Kit purification (Qiagen) following standard protocol. cDNA was generated 
from 0.5 µg total RNA using high-capacity cDNA reverse transcription kits (Applied 
Biosystems). Power SYBR Green PCR Master Mix (Applied Biosystems) and the StepOnePlus 
System (Applied Biosystems) were used for real-time quantification PCR. Acidic ribosomal 
phosphoprotein P0 (Arbp) expression was used as an internal control for data normalization. 
Samples were assayed in triplicate, and relative expression was determined using the 2-ΔΔCT 
method.  
Adipocyte sizing 
Adipose tissue was fixed with 10% formalin, and imaged with an immunofluorescence 
microscope at 10X. Adipocyte circumference was measured using ImageJ.  
CFSE staining and T cell proliferation assays 
APCs. SVF was extracted and stained with CD45, CD11c, CD64, and CD3 flow antibodies 
(listed in section 2.3). A FACS sort was performed to isolate ATMs, ATDCs, CD11c- CD64− 
CD45+, and CD45−cell populations using a Sony MA900 sorter. CD3+ cells were excluded. 
Each of the 4 cell populations was plated overnight, before being pulsed with 10 µg/ml of OVA 
or BSA for 6 hours. CD3+ cells were isolated from the lymph nodes and spleen of an OTII 
mouse. These cells were then stained with CFSE Cell Trace Proliferation Kit (Life Technologies) 
and co-cultured with APCs at a 1:10 ratio. After 4 days cells were taken and stained for flow 
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cytometry analysis. Gating strategy is as follows: Singlets (FSC–W x FSC-H) → Scatter (FSC-A 
x SSC-A) → Live cells (Live/Dead Fixable Violet Dead Cell Stain Kit, Invitrogen) → CD4+ → 
FoxP3- → CD25+ CFSE- (antibodies listed in section 2.3).  
Hepatic triglyceride content 
Livers were weighed, snap frozen in liquid nitrogen, and stored at −80 °C. 50–100 mg of frozen 
liver was cut and homogenized in buffer containing NP-40, Tris-Hcl, and NaCl. Chloroform was 
added, vortexed, and samples dried overnight in a speed vacuum. Another round of chloroform 
extraction was performed on dried samples before residual lipid was dissolved in butanol. 
Triglycerides were measured using the Infinity Triglyceride Assay Kit (Sigma), and normalized 
to the initial mass of tissue homogenized.  
Statistical analysis 
 All values are reported as mean ±SEM. Differences between groups were determined using 
unpaired, two-tailed Students t-Test or two-way ANOVA with Tukey post hoc tests with Graph 
Pad Prism 7 software. P values less than 0.05 were considered significant.  
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Results 
MHCIIfl/fl x CD11cCre (M11cKO) deletes MHCII expression in ATDCs and most ATMs 
and decreases CD11c+ ATMs in obese mice  
In lean mice, the primary CD11c+ adipose tissue myeloid cells are ATDC (Cho et al., 
2016). Therefore, we sought to eliminate MHCII expression in ATDC by generating conditional 
dendritic cell knockout mice by crossing MCHIIfl/fl x CD11cCre (Itgaxcre) mice (M11cKO). 
Al- though transgenic lines such as Zbtb46Cre are more specific for targeting conventional DCs, 
off target effects like colitis that prevent weight gain and illicit off target gut inflammation limit 
their utility for obesity studies centered on adipose tissue biology (112, 113). M11cKO and 
littermate controls were fed either normal diet (ND) chow or high fat diet (HFD) for 15 weeks. 
Body weight of control and M11cKO mice on a ND did not differ significantly. After HFD 
feeding, both genotypes gained significant weight, but HFD fed M11cKO weighed slightly less 
than littermate controls (Figure 2-1A). Organ weight at termination demonstrated no significant 
differences in non-adipose tissues such as liver and spleen. Epididymal (eWAT) and inguinal 
(iWAT) adipose tissue mass in HFD fed M11cKO mice were mildly, but significantly, decreased 
compared to littermate controls (Figure 2-1B). When normalized to total body weight, fat mass 
in M11cKO mice was not significantly different than controls (Supplemental Figure 2-1A).  
    Adipose tissue leukocytes in eWAT were assessed by flow cytometry (Strategy shown in 
Supplemental Figure 2-1B). In both lean and obese mice, the quantity of total ATDCs 
(CD45+CD64−CD11c+) and ATMs (CD45+ CD64+ ) were not different between M11cKO and 
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controls. The frequency of ATDCs as percentage of immune cells was not significantly changed 
by diet or genotype. As expected, the frequency of total ATMs from the HFD fed cohorts was 
significantly elevated compared to ND controls. Obese M11cKO mice had a trend towards less 
total ATM content. CD11c− CD64− cells were unchanged by genotype, but decreased in HFD-
fed M11cKO compared to ND controls (Figure 2-1C). Using flow cytometry, we verified that 
M11cKO mice had absent MHCII expression on ATDCs. While nearly all ATDCs from controls 
expressed MHCII, almost all ATDC from Mc11KO mice had lost MHCII expression (2.27% 
±0.58 of M11cKO ATDC expressed MHCII) (Figure 2-1D). M11cKO mice also lacked MHCII 
expression on the majority of ATMs in ND and HFD fed mice (12.2%± 3.14 of the ATMs 
retained MHCII expression in M11cKO mice) (Figure 2-1E).  
Since obesity is known to induce CD11c+ ATMs, we quantified CD11c+ and CD11c− 
ATMs in control and M11cKO mice (Figure 2-1F). M11cKO and controls did not differ in the 
proportion of CD11c− or CD11c+ ATMs in lean mice fed ND. M11cKO mice fed HFD had 
fewer CD11c+ ATMs compared to controls. There were no differences in CD11c− ATMs in 
HFD fed M11cKO mice. Given the significant reduction in MHCII expressing CD64+ ATMs, 
we assessed MCHII expression on both CD11c+ and CD11c− subtypes in the M11cKO and 
controls (Figure 2-1G). Surprisingly, both CD11c+ and CD11c− ATMs had reductions in 
MHCII expression in M11cKO mice. This suggests that there may be transient CD11c 
expression in the CD11c− population or precursors that give rise to CD11c− ATMs. Overall, 
M11cKO mice lack MHCII in all ATDCs and also have lost MHCII in the most, but not all, 
ATMs. This contrasts with Lyz2Cre x MCHIIfl/fl, which targets all ATMs, and most, but not all, 
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ATDC (80, 111). A summary of similarities and differences between Lyz2Cre and CD11cCre 
are summarized in (Table 2A).  
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Figure 2-1- CD11cCre Reiz drives MHCII knockdown in both adipose tissue dendritic cells and macrophages 
(A) Terminal body weight of transgenic M11cKO mice and littermate controls on ND or HFD after 15 weeks 
of feeding. 
(B) Tissue weights of spleen, liver, eWAT, and iWAT at time of termination,  
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(C) Representative flow plot illustrating ATDC, ATM and CD11c- CD64- populations gated from CD45+ 
CD3- cells. Frequencies of each group are measured as a percentage of SVF shown on the right.  
(D) Representative flow cytometry histograms and frequencies of MHCII expression on ATDCs,  
(E) ATMs, 
(F)  CD11c+ and CD11c- ATMs as a percentage of SVF. 
(G) Representative historgrams showing MHCII expression and frequencies of MHCII expression on Cd11c= 
and CD11c+ ATMs.  
*p < 0.05, **p < 0.01, ***p < 0.0001. n = 5-17 mice/group 
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Supplemental Figure 2-1: Additional data related to Figure 2-1 	
(A) Tissue weights normalized to body weights. * p< 0.05, ** p <0.01, *** p < 0.0001 
(B) Representative flow gating of eWAT. Cells were fated on Singlets à Scatter à CD45+ à CD3- cells 
were taken for antigen presenting cell assessment. ATM = CD64+, ATDC = CD64- CD11c+. CD3+ cells 
were taken and subdivided by CD4 and CD8 expression. Treg and Tconv populations were determined by 
FoxP3 expression on cells within the Cd4 population.  
 
 
 
Supplemental Figure 2-1: Additional data related to Figure 1.
(A) Tissue weights normaliz d to body weights.
* p < 0.05, ** p <0.01, *** p < 0.0001
(B) Representative flow gating of eWAT. Cells were gated on Singlets ➔ Scatter ➔ CD45+ ➔  CD3- cells 
were taken for antigen presenting cell assessment. ATM = CD64+, ATDC = CD64- CD11c+.
CD3+ cells were taken and subdivided by CD4 and CD8 expression. Treg and Tconv populations were 
determined by FoxP3 expression on cells within the CD4 population.
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Table 2A – ATDC v ATM MHCII contribution to systemic metabolism and inflammatory 
properties in ND and HFD-fed mice 
 
               ND     HFD 
 M11cKO 
v 
WT Con 
(ATDC) 
MMKO 
v 
WT Con 
(ATM) 
M11cKO 
v 
WT Con 
(ATDC) 
MMKO 
v 
WT Con 
(ATM) 
Systemic Metabolism     
GTT AUC Unchanged Unchanged Unchanged Improved 
ITT AUC Unchanged Unchanged Unchanged Improved 
Inflammatory Properties     
ATM CD11c+ 
expression 
Unchanged Unchanged Decreased Decreased 
ATDCMHCII+ 
expression 
Complete 
KO 
Majority KO Complete KO Majority KO 
ATM MHCII + 
expression 
Majority 
KO 
Complete KO Majority KO Complete KO 
Splenic Tconv Decreased Unchanged Decreased Unchanged 
Splenic Treg Decreased Unchanged Decreased Unchanged 
Splenic CD8+ Unchanged Unchanged Increased Unchanged 
Splenic DPT Unchanged Unchanged Increased Unchanged 
eWAT Tconv Decreased Unchanged Decreased Decreased 
eWAT Treg Unchanged Unchanged Decreased Decreased 
eWAT CD8+ Increased Increased Increased Unchanged 
eWAT DPT Increased Unchanged Increased Unchanged 
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M11cKO mice have increased adipose tissue CD8+ and decreased CD4+ T cells 
Previous studies have shown that deletion of MHCII in ATMs using Lyz2Cre results in 
normal CD4+ levels in lean mice and a reduction of conventional CD4+ ATT cells in obese mice 
with subsequent metabolic improvement (80, 111). We phenotyped ATT cells by flow cytometry 
in M11cKO mice and controls fed ND and HFD (Figure 2-2A). In both, lean and obese mice 
M11cKO mice had fewer CD4+ ATTs compared to WT controls suggesting that ATDC MHCII 
is required for maintenance this population (Figure 2-2B). Analysis of Tconv and Treg within 
the CD3+ population showed that Tconv were significantly de- creased in lean and obese 
M11cKO mice while Treg were decreased only in the HFD fed M11cKO mice (Figure 2-2C 
and 2-2D). However, when Tregs are assessed as the frequency of total CD4+ T cells, neither 
diet nor genotype changed the frequency of this population (Supplemental Figure 2-2A). This 
decrease in CD4+ ATT was associated with a significant increase in CD8+ cells (Figure 2-2E) 
and an increase in CD4+ CD8+ double positive T (DPT) cells (Figure 2-2F), while CD4− CD8− 
double negative T cells remained unchanged (Figure 2-2G) in both ND and HFD mice. Since an 
increase in DPT cells is an aberration when found outside of the thymus, we assessed the thymus 
(Supplemental Figure 2-2B) and bone marrow T cells (Supplemental Figure 2-2C). M11cKO 
mice did not have increased DPT cells in either compartment and similar CD8 and CD4 single 
positive content, suggesting that these cells are not escaping thymic regulation, but may be 
forming in adipose tissue. When expressed as a percentage of the total SVF, there were no 
significant differences in total CD3+ T cell content in ND mice, but HFD fed M11cKO mice had 
a significant increase in total CD3+ T cells (Figure 2-2H). This increase was attributed to CD8+ 
49		
ATT cells as CD8+ cells are significantly increased as a percentage of the SVF in both ND and 
HFD fed M11cKO compared to littermate controls (Figure 2-2I).  
Because of the increase in CD8+ ATTs in an environment that has reduced MHCII expression, 
we assessed H2-kb (MHCI) gene expression to see if it was changed in M11cKO mice to 
compensate for decreased MHCII. However, MHCI expression was unchanged by diet or 
M11cKO in whole eWAT (Figure 2-2J). To examine any qualitative differences in CD4+ T 
cells in the M11cKO mice, CD3/TCR expression was quantified by flow cytometry. While 
CD8+ ATTs had similar CD3 expression in control and M11cKO mice (Fig. 2K), both CD4+ 
Tconv (Figure 2-2L) and Treg (Figure 2-2M) had a reduction in CD3 expression as quantified 
by median fluorescence intensity (MFI) in HFD fed mice. This suggests that lack of MHCII 
stimulus in M11cKO lead to decreased expression of the TCR on both CD4+ Tconv and Treg. In 
sum, MHCII expression on ATDC is required for the normal and high fat diet induced 
homeostasis of CD4+ ATTs and results in an increased in CD8+ ATT cells in lean and obese 
conditions.  
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Figure 2-2 – M11cKO decreases CD4+ and increases CD8+ ATTs in eWAT 
 
(A) Flow plots illustrating diffrences in CD4 and CD8 expression on Cd3+ cells. 
(B) Frequency of total CD4+ of CD3+ T cells. 
(C) Frequency of FoxP3- CD4+ (Tconv) of CD3+ 
(D) Frequency of FoxP3+ CD4+ (Treg) of CD3+ T cells, 
(E) Frequency of CD8+ of CD3+ Tcells 
(F) Frequency of CD4+ CD8+ double positive T cells (DPT) as a percentage of total CD3+ T cells,  
(G) Frequency of CD4- CD8- double negative cells as a percentage of CD3+ T cells,  
(H) Frequency of CD3+ of SVF,  
(I) Frequency of CD8+ and CD4_ T cell populations as a percentage of total SVF 
(J) RT-qPCR analysis of H2-kB (MHCI) gene expression in eWAT 
(K) Median fluorescence intensity (MFI) of CD3 in CD8+ population  
(L) MFI of CD3 in the Tconv population 
(M) MFI of Cd3 in the Treg population 
 
*p < 0.05, **p < 0.01, ***p < 0.0001. n = 5-17 mice/group 
Figure 2-2: M11cKO decreases CD4+ and increases CD8+ ATTs in eWAT. 
(A) Flow plots illustrating differences in CD4 and CD8 expression on CD3+ cells. 
(B) Frequency of total CD4+ of CD3+ T cells, 
(C) Frequency of FoxP3- CD4+ (Tconv) of CD3+ T cells, (D) Frequency of FoxP3+ CD4+ (Treg) of CD3+ T 
cells, (E) Frequency of CD8+ of CD3+ T cells, (F) Frequency of CD4+ CD8+ double positive T cells (DPT) as 
a percentage of total CD3+ T cells, (G) Frequency of CD4− CD8−double negative cells as a percentage of 
CD3+ T cells, (H) Frequency of CD3+ of SVF, (I) Frequency of CD8+ and CD4+ T cell populations as a 
perc ntage of total SVF, 
(J) RT-qPCR analysis of H2-kB (MHCI) g ne xpression in eWAT, 
(K) Median fluorescence intensity (MFI) of CD3 in the CD8+ population, (L) MFI of CD3 in Tconv cells,
(M) MFI of CD3 in Treg cells. 
*p < 0.05, **p < 0.01, ***p < 0.0001. N = 5–17 mice/group.
ND HF
D 
0
20
40
60
%
 C
D
4+
 o
f C
D
3+
  Littermate Controls
M11cKO
** ***
ND HF
D
0
1
2
3
4
2Δ
Δ
CT
MHCI
Control  
M11cKO
ns
ND
HFD
Controls Mc11KO
CD4
C
D
8
Singlets
46.5
0 100K 200K
FSC-W
0
50K
100K
150K
200K
250K
FS
C-
H
EWAT_EWAT 15_016.fcs
Scatter
95.8
0 100K 200K
FSC-A
0
50K
100K
150K
200K
250K
SS
C-
A
CD45+
44.3
0 10 3 10 5
Comp-Pacific Blue-A :: CD45
0
50K
100K
150K
200K
250K
SS
C-
A
CD3+
15.1
CD3-
77.8
0 10 3 10 4
Comp-PerCP-Cy5-5-A :: CD3
0
50K
100K
150K
200K
250K
SS
C-
A
Q1
23.5
Q2
0.58
Q3
44.7
Q4
31.3
0 10 4
Comp-APC-A :: CD4
0
10 3
Co
m
p-
FI
TC
-A
 ::
 C
D8
EWAT_EWAT 15_016.fcs
CD3+
36262
FoxP3+
27.4
FoxP3-
72.5
0 10 4
Comp-APC-A :: CD4
0
10 3
10 4
Co
m
p-
PE
-A
 ::
 C
D6
4_
Fo
xP
3
CD64+
62.8
CD64- CD11c+
14.3
0 10 3 10 4
Comp-APC-Cy7-A :: CD11c
0
10 3
10 4
Co
m
p-
PE
-A
 ::
 C
D6
4_
Fo
xP
3
Singlets
41.3
0 100K 200K
FSC-W
0
50K
100K
150K
200K
250K
FS
C-
H
EWAT_EWAT 9_010.fcs
Scatter
95.2
0 100K 200K
FSC-A
0
50K
100K
150K
200K
250K
SS
C-
A
CD45+
47.5
0 10 3 10 5
Comp-Pacific Blue-A :: CD45
0
50K
100K
150K
200K
250K
SS
C-
A
CD3+
22.1
CD3-
70.8
0 10 3 10 4
Comp-PerCP-Cy5-5-A :: CD3
0
50K
100K
150K
200K
250K
SS
C-
A
Q1
54.4
Q2
2.81
Q3
18.1
Q4
24.7
0 10 4
Comp-APC-A :: CD4
0
10 3
Co
m
p-
FI
TC
-A
 ::
 C
D8
EWAT_EWAT 9_010.fcs
CD3+
28168
FoxP3+
21.8
FoxP3-
78.2
0 10 4
Comp-APC-A :: CD4
0
10 3
10 4
Co
m
p-
PE
-A
 ::
 C
D6
4_
Fo
xP
3
CD64+
43.9
CD64- CD11c+
23.3
0 10 3 10 4
Comp-APC-Cy7-A :: CD11c
0
10 3
10 4
Co
m
p-
PE
-A
 ::
 C
D6
4_
Fo
xP
3
Singlets
48.5
0 100K 200K
FSC-W
0
50K
100K
150K
200K
250K
FS
C-
H
EWAT_EWAT 25_026.fcs
Scatter
96.2
0 100K 200K
FSC-A
0
50K
100K
150K
200K
250K
SS
C-
A
CD45+
44.8
0 10 3 10 5
Comp-Pacific Blue-A :: CD45
0
50K
100K
150K
200K
250K
SS
C-
A
CD3+
24.2
CD3-
60.9
0 10 3 10 4
Comp-PerCP-Cy5-5-A :: CD3
0
50K
100K
150K
200K
250K
SS
C-
A
Q1
16.1
Q2
0.63
Q3
30.7
Q4
52.6
0 10 4
Comp-APC-A :: CD4
0
10 3
Co
m
p-
FI
TC
-A
 ::
 C
D8
EWAT_EWAT 25_026.fcs
CD3+
6691
FoxP3+
23.9
FoxP3-
76.0
0 10 4
Comp-APC-A :: CD4
0
10 3
10 4
Co
m
p-
PE
-A
 ::
 C
D6
4_
Fo
xP
3
CD64+
19.0
CD64- CD11c+
27.7
0 10 3 10 4
Comp-APC-Cy7-A :: CD11c
0
10 3
10 4
Co
m
p-
PE
-A
 ::
 C
D6
4_
Fo
xP
3
Singlets
23.4
0 100K 200K
FSC-W
0
50K
100K
150K
200K
250K
FS
C-
H
EWAT_EWAT 22_023.fcs
Scatter
88.5
0 100K 200K
FSC-A
0
50K
100K
150K
200K
250K
SS
C-
A
CD45+
43.0
0 10 3 10 5
Comp-Pacific Blue-A :: CD45
0
50K
100K
150K
200K
250K
SS
C-
A
CD3+
23.8
CD3-
63.9
0 10 3 10 4
Comp-PerCP-Cy5-5-A :: CD3
0
50K
100K
150K
200K
250K
SS
C-
A
Q1
61.4
Q2
4.08
Q3
12.5
Q4
22.0
0 10 4
Comp-APC-A :: CD4
0
10 3
Co
m
p-
FI
TC
-A
 ::
 C
D8
EWAT_EWAT 22_023.fcs
CD3+
6495
FoxP3+
25.8
FoxP3-
74.2
0 10 4
Comp-APC-A :: CD4
0
10 3
10 4
Co
m
p-
PE
-A
 ::
 C
D6
4_
Fo
xP
3
CD64+
29.6
CD64- CD11c+
27.5
0 10 3 10 4
Comp-APC-Cy7-A :: CD11c
0
10 3
10 4
Co
m
p-
PE
-A
 ::
 C
D6
4_
Fo
xP
3
Gated on CD3+
16.1% 0.63%
30.7%52.6%
61.4% 4.08%
12.5%2.0%
23.5% 0.58%
44.7%1.3%
54.4% 2.81%
18. %4.7%
A. B.
ND HF
D 
0
500
1000
1500
2000
M
FI
 C
D
3+
 o
f C
D
8+ Littermate Controls
M11cKO
ns
ND HF
D 
0
5
10
15
20
25
%
 T
re
g 
of
 C
D
3+
Littermate Controls
M11cKO
ns **D.
ND HF
D 
0
20
40
60
80
%
 C
D
8+
 o
f C
D
3+
 Littermate Controls
M11cKO
*** ***
ND HF
D 
0
2
4
6
8
10
%
 C
D
4+
 C
D
8+
 o
f C
D
3+
 Littermate Controls
M11cKO
* ***
ND HF
D 
0
20
40
60
%
 C
D
4-
 C
D
8-
 o
f C
D
3+ Littermate Controls
M11cKO
ns ns
*
K.
M.
L.
0 10 3 10 4 10 5
Comp-PE-A :: CD64_FoxP3
0
20
40
60
80
100
No
rm
ali
ze
d 
To
 M
od
e
Sample Name Subset Name Count
EWAT_EWAT 11_012.fcs FoxP3+ 88.0 
EWAT_EWAT 12_013.fcs FoxP3+ 738 
0-10 3 10 3 10 4 10 5
Comp-710_50 (488)-A :: PerCP55 CD3
0
20
40
60
80
100
No
rm
ali
ze
d 
To
 M
od
e
Sample Name Subset Name Count
eWAT_eWAT2_003.fcs FoxP3- 3922 
eWAT_eWAT1_002.fcs FoxP3- 1846 
0-10 3 10 3 10 4 10 5
Comp-710_50 (488)-A :: PerCP55 CD3
0
20
40
60
80
100
No
rm
ali
ze
d 
To
 M
od
e
Sample Name Subset Name Count
eWAT_eWAT1_002.fcs FoxP3+ 809 
eWAT_eWAT2_003.fcs FoxP3+ 611 
0-10 3 10 3 10 4 10 5
Comp-710_50 (488)-A :: PerCP55 CD3
0
20
40
60
80
100
No
rm
ali
ze
d 
To
 M
od
e
Sample Name Subset Name Count
eWAT_eWAT10_011.fcs FoxP3- 7222 
eWAT_eWAT23_023.fcs FoxP3- 7001 
CD3
CD3
N
or
m
al
iz
ed
 to
 M
od
e
N
or
m
al
iz
ed
 to
 M
od
e
M11cKOControl
M11cKOControl
Gat d on Tconv
Gated on Treg
J.
A
rb
itr
ar
y 
un
its
ND HFD
H2-kb / MHCI
ND HF
D 
0
20
40
60
%
 T
co
nv
 o
f C
D
3+
  Littermate Controls
M11cKO
** ***C.
F. G. H.
ND HF
D 
0
10
20
30
%
C
D
3+
 o
f S
ca
tte
r Littermate Controls
M11cKO
ns *
%
C
D
3+
 o
f S
VF
CD
8+
CD
4+
0
5
10
15
20
%
 T
 c
el
ls
 o
f S
VF
ND Controls
ND M11cKO
***
HFD Controls
HFD M11cKO   
ns***I.
Controls
M11cKO
ND HF
D 
0
1000
2000
3000
M
FI
 C
D
3+
 o
f T
co
nv
Littermate Controls
M11cKO
*ns
ND HF
D 
0
500
1000
1500
2000
2500
M
FI
 C
D
3+
 o
f T
re
g Littermate Controls
M11cKO
**ns
ND HFD D HFD
ND FD D HFD
ND HFD ND HFD C 8+ CD4+
D HFD ND FD
D FD
D FD
%
C
D
4+
 o
f C
D
3+
%
Tc
on
v 
of
 C
D
3+
%
Tr
eg
 o
f C
D
3+
%
C
D
8+
 o
f C
D
3+
E.
%
C
D
4+
 C
D
8+
 
of
 C
D
3+
%
C
D
4-
 C
D
8-
 
of
 C
D
3+
%
C
D
3+
 o
f S
VF
D FD
M
FI
 C
D
3+
 o
f C
D
8+
M
FI
 C
D
3+
 o
f T
co
nv
M
FI
 C
D
3+
 o
f T
re
g
%
T 
ce
lls
 o
f S
VF
Figure 2-2
51		
 
Supplemental Figure 2-2 – Additional data related to Figure 2-2 
(A) Frequency of FoxP3+ of CD4+ ATT cells from eWAT. 
(B) Representative plots of CD4+ and CD8+ thymic T cells from control and M11cKO mice, gated on 
CD3+cells. 
(C) Representative plots of CD4+ and CD8+ bone marrow T cells from control and M11cKO mice, gated on 
CD3+ cells. 
 
 
Splenic T cell phenotype in M11cKO indicates ATT maintenance is adipose tissue specific 
We evaluated spleens of the M11cKO mice to determine if the T cell changes observed in 
adipose tissue were fat specific (Figure 2-3A). Similar to adipose tissue, splenic total CD4+, 
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Tconv, and Treg (Figures 2-3B–2-3D) cells were significantly decreased as a percentage of T 
cells in M11cKO in- dependent of diet type – although the magnitude of the decrease was not as 
significant as seen in adipose tissue. When expressed as percentage of the CD3+ population, 
CD8+ T cells were unchanged in ND M11cKO mice, but HFD led to an increased frequency of 
CD8+ T cells in the M11cKO mice (Figure 2-3E). Splenic DPT cells were increased in 
frequency only in HFD fed M11cKO mice (Figure 2-3F). Overall, the quantity of DPT cells in 
the spleen was half of that observed in M11cKO eWAT. M11cKO mice had an increase in CD4− 
CD8− double negative T cells only in ND fed mice (Figure 2-3G). As a percentage of all 
splenocytes, lean ND fed M11cKO mice had significantly decreased CD3+ T cells com- pared to 
littermate controls, however no differences in splenic CD3+ cells were seen in HFD fed mice 
(Figure 2-3H). Unlike ATTs, splenic cells showed decreased CD4+ cells as calculated by 
frequency of splenocytes in the M11cKO mice, while there were no differences in CD8+ T cells 
(Figure 2-3I). The decrease in CD4+ was not attributable to specific de- creases in splenic Treg 
or Tconv in HFD fed mice (Fig. 3J). Unlike adipose tissue, CD3/TCR expression on splenic 
CD8+ (Figure 2-3K), Tconv (Figure 2-3L), and Tregs (Figure 2-3M) are all unchanged by 
either diet or genotype. Overall, our data demonstrates ATT specific regulation in M11cKO mice 
compared to the spleen, thymus and bone marrow, and suggests there is environment specific 
signals in WAT that drive CD8+ accumulation.  
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Figure 2-3 – M11cKO decreases CD4+ T cells in the spleen. 
 
(A) Flow plots illustrating differences in CD4 and CD8 expression on CD3+ cells,  
(B) Frequency of total CD4+ of CD3+ T cells,  
(C) Frequency of FoxP3- CD4+ (Tconv_ of CD3+ T cells 
(D) Frequency of FoxP3+ CD4+ (Treg) of CD3+ T cells 
(E) Frequency of Cd8+ of CD3+ T cells,  
(F) Frequency of CD4+ CD8+ double positive T cells (DPT) of CD3+ T cells,  
(G) Frequency of CD4- CD8- double negative of CD3+ T cells,  
(H) Frequency of CD3+ cells as a percentage of splenocytes 
(I) Frequency of CD8+ and CD4+ T cells as percentage of splenocytes 
(J) Frequency of Tconv and Treg Cd4+ T cells as a percentage of splenocytes,  
(K) Median fluorescence intensity (MFI) of CD3 in Cd8+ cells,  
(L) MFI of CD3 on Tconv cells,  
(M) MFI of CD3 of Treg cells 	
*p < 0.05, **p < 0.01, ***p < 0.0001. n = 5-17 mice/group 
 
 
Figure 2-3: M11cKO decreases CD4+ T cells in the spleen. 
(A) Flow plots illustrating differences in CD4 and CD8 expression on CD3+ cells, 
(B) Frequency of total CD4+ of CD3+ T cells, 
(C) Frequency of FoxP3- CD4+ (Tconv) of CD3+ T cells, 
(D) Frequency of FoxP3+ CD4+ (Treg) of CD3+ T cells, 
(E) Frequency of CD8+ of CD3+ T cells, 
(F) Frequency of CD4+ CD8+ double positive T cells (DPT) of CD3+ T cells, 
(G) Frequency of CD4− CD8− double negative of CD3+ T cells, 
(H) Frequency ofCD3+ as a percentage of Splenocytes, 
(I) Frequency of CD8+ an  CD4+ T cells as a percentage of Splenocyte , 
(J) Frequency of Tconv and Tr g CD4+ T cells as a percentage of Splenocytes, 
(K) Median fluorescence intensity (MFI) of CD3 in CD8+cells, 
(L) MFI of CD3 in Tconv cells, 
(M) MFI of CD3 in Treg cells,
*p < 0.05, **p < 0.01, ***p < 0.0001. N = 5–17 mice/group.
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ATDCs are more efficient antigen presenting cells than ATMs 
Despite the ability of Lyz2Cre and CD11cCre drivers to delete MHCII in both ATMs and 
ATDC, there are striking differences between T cell regulation in these mice as Lyz2Cre x 
MHCIIfl/fl have normal number of CD4+ cells on a normal diet. Lyz2Cre x MHCIIfl/fl mice 
have residual expression of MHCII on ATDC, while M11cKO mice have residual expression of 
MHCII in ATMs (~12%). We wanted to assess whether these differences could be due to 
different antigen presentation capabilities of ATDCs and ATMs. We hypothesized that ATDCs 
are more potent APCs than ATMs to explain the significant loss of CD4+ ATT cells in M11cKO 
mice. To test this, we assessed FACS sorted ATDCs, ATMs, CD45+ CD11c− CD64− cells 
(containing B cells), and CD45− non-immune cells (used as a negative control). Sorted 
populations were used in an antigen specific reaction to assess their ability to induce splenic 
OTII T cell proliferation after OVA or BSA treatment. After 4 days of co-culture, CD4+ cells 
were significantly increased in OVA pulsed ATDCs, but not other adipose tissue cell types 
(Figure 2-4A). ATDC and ATMs were able to induce Tregs when pulsed with OVA, however 
this was not seen with other leukocytes or CD45− cells (Figure 2-4B). In contrast, only ATDC 
were able to induce Tconv in response to OVA (Figure 2-4C). Overall, this suggests that 
differences in Lyz2Cre v CD11cCre mediated MHCII-KO may be due to the efficiency of the 
residual population of ATDC or ATM ex- pressing MHCII in these models.  
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Figure 2-4 – ATDC are more potent antigen presenting cells than ATMs. 
4 adipose tissue cell populations were FACS sorted from pooled WAT to assess their antigen presenting capacity. 
Cells were pulsed with OVA and co-cultured with CFSE stained CD3+ OT-II splenic T cells. CD45-, CD45+ 
CD64+ (ATM), CD45+ CD11c_ CD64- (ATDC) and CD45+ CD11c- CD64- populations were compared side-by-
side. 
(A) Number of Live CD4+ cells co-cultured with the APCs pulsed with BSA or OVA,  
(B) Number of CFSE- CD25+ FoxP3+ (Treg) cells,  
(C) Number of CFSE- CD25+ FoxP3- (Tconv) cells 
 
*p < 0.05, **p < 0.01, *** < 0.0001. n = 3 biological replicates 
 
Adipose tissue inflammatory gene expression is unchanged in M11cKO mice 
We assessed pro-inflammatory cytokine gene expression in M11cKO mice. Despite 
reduced quantity of pro-inflammatory CD11c+ ATMs in M11cKO mice, Tnfa expression trends 
towards an increase in control HFD fed eWAT, and gene expression was significantly increased 
in HFD fed M11cKO mice compared to ND controls (Figure 2-5A). Ccl2/Mcp1 expression was 
significantly increased in obese eWAT and did not differ between M11cKO and WT mice 
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(Figure 2-5B). T cell related cytokine genes were assessed. In lean M11cKO mice, there was 
increased expression of Ifng compared to controls. In obese mice, there was no significant 
difference in expression in M11cKO mice (Figure 2-5C). Il2 expression was significantly 
decreased between ND and HFD fed M11cKO groups (Figure 2-5D). Collectively this data 
suggests that M11cKO do not have significant alterations in inflammatory gene expression 
compared diet matched littermate controls.  
 
Figure 2-5 – M11cKO does not change inflammatory gene expression in eWAT 	
Gene expression of whole snap frozen eWAT as assessed by RT-qPCR. Calculations were performed by 
normalizing to housekeeping gene Arbp, using 2ΔΔCT. 
(A) TNFα, (B) MCP1/CCl2, (C) IFNγ, (D) IL2.  *p < 0.05, **p < 0.01, ***p < 0.0001. n = 5-11 mice/group. 
Figure 2-5: M11cKO does not change i flammatory gene e sio in eWAT. 
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M11cKO mice have normal glucose and insulin tolerance 
To determine whether antigen presentation by ATDCs influences systemic metabolism, 
we assessed glucose tolerance in ND and HFD fed mice. The ND fed controls and M11cKO 
mice showed no significant differences in GTT. With HFD feeding, both genotypes showed 
similar degrees of fasting hyperglycemia and glucose intolerance with similar area under the 
curve (AUC) measures (Figure 2-6A). Similar to the GTT, while HFD feeding induced insulin 
resistance based on ITT, there were no significant differences between M11cKO mice and 
controls (Figure 2-6B). Although metabolic parameters were not significantly different in 
M11cKO mice, frequency of CD11c + ATMs positively correlates with insulin resistance 
(Supplemental Figure 2-3A), but not glucose intolerance (Supplemental Figure 2-3B), of both 
control and M11cKO mice. Histologic analysis of eWAT suggested architectural differences 
between HFD fed M11cKO and controls. Analysis of adipocyte size distribution showed an 
increase in small adipocytes in M11cKO mice (Figure 2-6C). Although M11cKO mice had 
decreased lipid content in adipose tissue, triglyceride storage was not preferentially shuttled to 
the liver. HFD feeding increased liver triglyceride, but M11cKO did not significantly change 
triglyceride content per gram of tissue (Figure 2-6D). Collectively this data shows a mild 
protection from HFD induced obesity in M11cKO mice associated with decreased fat mass that 
does not alter glucose or insulin tolerance.  
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Figure 2-6 – M11cKO does not alter glucose or insulin tolerance 	
(A) Glucose tolerance test of mice at 12 weeks of age and area under the curve (AUC) quantifications, 
(B) Insulin tolerance test of mice at 13 weeks of age and AUC quantifications 
(C) Distribution of adipocytes circumferences, smaller bin size indicates smaller adipocyte size. 
(D) Trigylceride content measured from snap frozen liver samples.  
 
*p < 0.05, **p < 0.01, ***p < 0.0001. n = 3-9 mice/group 
 
 
 
 
 
 
 
Figure 2-6: M11cKO does not alter glucose or insulin tolerance. 
(A) Glucose tolerance test of mice at 12 weeks of age and area under the curve (AUC) quantifications. 
(B) Insulin tolerance test of mice at 13 weeks of age and AUC quantifications. 
(C) Distribution of adipocyte circumferences, with smaller bin size indicating smaller adipocyte size. 
(D) Triglyceride content measured from snap frozen liver samples. 
*p < 0.05, **p < 0.01, ***p < 0.0001. N = 3–9 mice/group.
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Supplemental Figure 2-3 – Additional data relates to Figure 2-6. 
(A) Area under the curve (AUC) of insulin tolerance tests v ATM frequency in control and M11cKO groups,  
(B) AUC of insulin tolerance tests v ATM frequency in control and M11cKO groups. R2 and p-values were 
calculated in linear regression analyses. 
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Supplemental Figure 2-3: Additional data related to Figure 6.
( ) Area under the curve (AUC) of insulin tolerance tests v ATM frequency in Control and M11cKO groups.
(B) Area under the curve (AUC) of insulin tolerance tests v ATM frequency in Control and M11cKO groups.
R2 and p-values were calculated in linear regression analyses. 
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Discussion 
This study has several primary findings relevant to the study of immunometabolism. 
ATDC are more potent APCs compared to ATMs and other non-leukocyte cells. ATDC derived 
MHCII signals were required for CD4+ ATT cell maintenance as M11cKO mice had decreased 
CD4+ cells, and more CD8+ ATT cells in lean and obese settings. The dependency of CD4+ 
cells on DC derived MHCII was much more prominent in adipose tissue compared to other 
lymphoid organs such as the spleen.  
Similar to other studies, we observed that targeting myeloid cells with CD11cCre mice 
expands beyond DC (114). CD11cCre deleted MHCII expression on all ATDC and ~88% of 
CD11c+ and CD11c− ATMs leaving a residual MHCII+ population of ATMs. This suggests that 
Itgax is transiently expressed in ATMs or ATM precursors regardless of their CD11c surface 
expression at the time of harvest. This observation may also be related to “leaky” expression of 
the transgene. We note that use of another Itgax-cre-EGFP mouse (110) provided similar results 
of deletion of MHCII in both ATMs and ATDC (data not shown). In contrast to the M11cKO 
mice, Lyz2Cre targets all ATMs such that Lyz2Cre x MHCIIfl/fl have a residual MHCII+ 
population of ATDCs and result in significant phenotypic differences (80, 111).  
While Lyz2Cre driven MHCII-KO resulted in no changes in T cells in lean mice and 
decreased Tconv in HFD fed mice, M11cKO led to different results (summarized in Table 2A). 
Most notably ATT populations were dysregulated in M11cKO mice independent of diet type. 
The absence of ATDC MHCII expression resulted in a reduction in CD4+ Tconv and Tregs and 
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expansion of CD8+ cytotoxic T cells and CD4+ CD8+ DPT cells. An increase in CD8+ and DPT 
cells was adipose tissue specific in M11cKO mice. In this setting, the small number of MHCII+ 
ATMs was not sufficient to maintain normal CD4+ ATT cell numbers. In the spleen, we 
observed what would be considered canonical T cell dysregulation in the absence of DC 
mediated antigen presentation, as there was a decrease in Tconv CD4+ cells. Since Tconv cell 
maintenance requires low affinity “tonic” TCR and MHCII interactions, loss of antigen 
presentation by dendritic cells may have driven this decrease in the CD4+ T helper cell 
population (115). In addition, there was a significantly reduced expression of the TCR in CD4+ 
ATT cells in HFD-fed M11cKO mice. TCR expression is dynamically regulated to tune 
inflammatory capacity of T cells. Since TCR expression regulates T cell functionality, it is 
possible that although the Tconv and Treg cells in HFD M11cKO are still present, that they are 
functionally impaired and unable to mount a typical inflammatory response (116). CD3/TCR 
downregulation is observed in T cells after cognate pMHCII activation in acute/subacute models 
of antigen dependent inflammation (117-121). Our observation that obesity decreases CD3/TCR 
expression in ATT cells in KO mice suggest that either there is an increase in pMHCII signals 
from other cells in AT or that our chronic model results in a downregulation of the TCR due to a 
lack of tonic signaling. We have examined residual MHCII+ cells in the KO mice and have not 
observed an increase in surface MHCII expression in any cell type. Therefore, we hypothesize 
that in the absence of MHCII, CD3/TCR downregulation is due to a loss of tonic signals from 
APCs in adipose.  Expansion of CD8+ ATT cells with MHCII manipulation is consistent with 
other reports. MHCII-KO leads to an influx of CD8+ T cells into tumors of cancer-laden mice, 
leading to increased inflammation and smaller tumor burden (122). Although it is unknown 
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whether the increase in CD8+ T cells in M11cKO adipose tissue is due to recruitment due to 
adipose tissue secreted chemoattractants, the increased skewing of ATT towards CD8+ 
production compared to spleen suggest that local ATDC dependent signals generate this 
observation. In addition to work showing the majority of ATTs are of the T resident memory 
phenotype, work has also shown that tissue resident lymphocytes often have unique 
characteristics (123, 124)  
The appearance of ATT DPT cells was also an unusual and intriguing finding. DPTs are 
usually only found in the thymus during T cell development, but DPT cells appear in several 
dysregulated autoimmune and chronic inflammatory diseases (125). The significant increase in 
this population seems to be an ATT specific adaptation to loss of MHCII expression by ATDCs. 
Since the presence of DPT was not significantly increased globally in M11cKO mice, we 
speculate that CD8+ T cells may have some plasticity allowing them to assume a Tconv 
phenotype. This could be a compensatory mechanism that occurred due to decreased TCR 
expression on Tconv and Treg ATTs. The dependence of CD4+ ATT cells on MHCII expression 
in all ATDC (M11cKO) but not all ATMs (Lyz2Cre x MHCIIfl/fl) suggested that ATDC are 
stronger APC than ATMs or other potential APCs in adipose tissue. Our studies in FACS sorted 
population’s show that ATDCs are superior at inducing activation and proliferation of T cells 
compared to ATMs and other CD11c− CD64− leukocytes containing B cells. It is unclear if 
MHCII expression on B cells in adipose tissue may play a role in ATT maintenance or activation 
and should be considered in future studies. Some studies have suggested that preadipocytes 
express MHCII and have downstream effects on ATTs (107), however we did not see evidence 
for this in our functional assay using CD45− cells. Since these studies were performed with 
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splenic OTII T cells, further studies need to be performed assessing ATT specific characteristics 
in lean and obese adipose tissue.  
Like Lyz2Cre x MHCIIfl/fl mice, M11cKO mice have a reduction in pro-inflammatory 
CD11c+ ATMs in HFD fed mice compared to the controls, which would be suggestive of 
improved metabolic inflammation in adipose tissue. Despite this, glucose and insulin tolerance 
was not altered in M11cKO mice, while Lyz2Cre x MHCIIfl/fl mice had improved metabolism. 
This may be related to the sustained increase in CD8+ ATT in M11cKO mice, which have been 
shown to participate in obesity-induced adipose tissue inflammation (97). Indeed, analysis of 
inflammatory gene expression in eWAT showed that M11cKO mice had similar levels of Tnfa, 
Ccl2, and Il2 expression. In fact, Tnfa and Ifng were higher in M11cKO mice than controls, 
which could be mediated by the increased CD8+ ATT cells.  
The body weights of HFD-fed M11cKO mice were significantly lower than the diet-
matched littermate controls. Body weight discrepancy results in smaller fat pad mass in the 
M11cKO mice, but not spleen or liver weights. Liver triglyceride content is not significantly 
different in M11cKO mice compared to their diet matched controls, indicating that lipid storage 
capacity of adipocytes is not dysregulated. Similar to whole body MHCII-KO mice (80, 111), 
lean mass of M11cKO mice may be decreased compared to controls. Regardless of the net 
adipose tissue weight, the fat mass is not significantly smaller when it is normalized to body 
weight. This suggests that net adipose tissue weight may not be a clear predictor of metabolism 
or adipose tissue inflammation. There are several possible explanations for the different 
metabolic phenotypes observed in the Lyz2Cre v CD11cCre driven MHCII knockouts. It has 
been shown that inhibiting dendritic cell mediated antigen presentation in the gut induces 
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changes in the microbiome and associated inflammation (113). Consequently, even if there is 
attenuated inflammation in the adipose tissue, chronic inflammation from the gut could lead to 
sustained cytokine release and systemic inflammation, and subsequent metabolic disorder. 
MHCII may contribute to processes like beta-oxidation, lipolysis, and mitochondrial production, 
however it is likely that impairment of nutrient absorption via gut inflammation may underlie the 
weight differences.  
Overall diet independent and adipose tissue specific changes in M11cKO mice give 
insight into the importance of ATDC mediated antigen presentation signals. CD8+ and DPT 
ATT cells increase in ND and HFD fed M11cKO mice. However, CD11c+ ATMs are decreased 
and TCR expression is decreased on CD4+ ATTs in HFD fed obese M11cKO mice. These 
cellular changes did not significantly improve the inflammatory output of obese adipose tissue 
and also did not improve glucose or insulin tolerance. M11cKO shows that ATM and ATDCs 
have cell type specific regulation of ATTs and resultant inflammatory and metabolic phenotype 
of obese mice.  
Figure 2-7 – Chapter 2 conclusions 
Insulin signaling occurs via IRS/PI3K/AKT signal transduction, resulting in translocation of glucose transporter 
Glut4 to the cell surface. However, inflammatory signaling cascades are responsible for modulating the insulin 
signaling cascade. In inflammatory environments, cytokine signaling via TNF alpha induces phosphorylation of 
IKK and JNK which in turn activate transcription factors NFkB and AP1. Signal transduction through this pathway 
leads to transcription of additional inflammatory genes, and negative feedback signaling proteins, like SOCS. In 
addition to AP1 induction, JNK directly inhibit IRS and prevents Glut4 translocation.
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Chapter 3: Adipose Tissue T Cells Have Impaired Inflammatory Capacity in Obese Mice 
and Humans 	
This chapter is under revision at JCI Insight: 
 
Porsche CE, DelProposto JL, Geletka L, O’Rourke RO, Lumeng CN. Adipose tissue T cells have 
impaired inflammatory capacity in obese mice and humans. 
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cells from human adipose tissue. ROO facilitated human sample acquisition. CEP and CNL 
conceived of experiments, wrote, and edited the manuscript. MDRC Chemistry Core performed 
luminex assays, and the Cancer Center Immunology Core performed ELISA assays. 
 
Abstract 
Adipose tissue induced chronic low-grade inflammation is a critical link between obesity 
and insulin resistance. Despite studies implicating adipose tissue T cells (ATT) in the initiation 
and persistence of adipose tissue inflammation, fundamental gaps in knowledge regarding ATT 
function impedes progress towards understanding their role in diabetes pathogenesis and 
complications. Little is known about the antigens that activate ATT cells, functional differences 
between fat depots, or effector cytokine profiles of activated ATT populations in obesity. We 
hypothesized ATT activation and function would be dependent upon anatomic location and that 
high fat diet induced obesity would potentiate their inflammatory properties. We assessed ATT 
activation and inflammatory potential in mouse and human stromal vascular fraction (SVF). 
Surprisingly, ATTs from obese epididymal white adipose tissue (eWAT) had senescent 
characteristics. Stimulation failed to induce CD25 upregulation, ATT proliferation, or heightened 
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IFNγ and IL-2 secretion, which is seen in spleen, omentum, and lean eWAT samples. Human 
ATTs collected from bariatric surgery patients also have impaired inflammatory activation 
correlating with increased HbA1c levels. Both environmental and cell-intrinsic factors are 
implicated in ATT dysfunction. Co-culture of obese SVF in transwell plates inhibits ATT 
activation of lean samples. This suggests soluble factors from obese SVF diminish the 
inflammatory potential of ATTs. Signaling through the T cell receptor is necessary for induction 
of ATT impairment, but is independent of upregulated PD1 expression on the cell surface. In 
sum, this work suggests that obesity-induced ATT impairment is dependent upon localized 
signals from soluble factors and cell-to-cell interactions in adipose tissue, which blunt signaling 
pathways proximally downstream of the T cell receptor.  
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Introduction 
Obesity-associated morbidities such as type II diabetes are characterized by insulin 
resistance, which is mechanistically linked to adipose tissue dysfunction and inflammation (54-
56). Clinical and pre-clinical studies have identified chronic low-grade inflammation as a critical 
link between obesity and insulin resistance (57). Immune regulation and systemic metabolism 
are interconnected within white adipose tissue. Lean fat has a largely anti-inflammatory immune 
environment containing a predominance of resident adipose tissue macrophages (ATM) with 
anti-inflammatory properties and CD4+ T regulatory cells (Treg) (96). However, as excess lipid 
storage capacity is needed and adipocyte hypertrophy occurs, qualitative and quantitative 
changes in immune cells also arise. Obese diabetic individuals have a predominance of activated 
macrophages, pro-inflammatory CD4+ T conventional (Tconv) cells, and an influx of CD8+ 
cytotoxic T cells in their adipose tissue, accompanied by systemic metabolic dysfunction (72, 97, 
126). 
Conventional views of adipose tissue T cell (ATT) functionality indicate that they 
contribute to chronic low-grade inflammation and insulin resistance in obese subjects. Initial 
studies assessing ATTs in obese adipose tissue observed improved insulin sensitivity with the 
administration of neutralizing CD3+ antibody injection (67). The functions of cytotoxic CD8+, 
CD4+ Tconv, and T regulatory (Treg) ATTs have also been shown to play a critical role in 
adipose tissue inflammation. CD8+ cytotoxic ATTs are required for the development of insulin 
resistance and infiltrate adipose tissue of high-fat diet (HFD)-fed mice before macrophages (97). 
Antigen-presenting cells in obese adipose tissue have also been implicated in Tconv induced 
inflammation, which can be reversed with conditional major histocompatability complex II 
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(MHCII) knockout in ATMs but not adipose tissue dendritic cells (80, 127). Largely, ATTs with 
anti-inflammatory phenotypes (Treg, Th2) decrease (96, 128), and ATTs with pro-inflammatory 
phenotypes increase (CD8+ and Th1/Tbet+ Tconv) in murine and human obese adipose tissue (72, 
97, 128).  Tregs comprise around 40% of CD4+ ATTs in lean tissue, 2-3x more than is seen in 
lymphatic tissues (96). Adipose tissue Tregs have tissue-specific characteristics and depend upon 
the master regulator of lipid metabolism, PPARγ (75). Additionally, they have a distinct clonal T 
cell receptor (TCR) repertoire, which suggests they are maintained by antigens in lean adipose 
tissue (69). Tconv also have tissue-specific characteristics. Lean fat contains Tconv with a 
predominantly Trm phenotype (123). As HFD is given, effector memory adipose tissue Tconv 
cells with restricted TCR repertoire accumulate, suggesting recognition of antigens specific to 
obese fat (99). Strikingly, the TCR repertoire in lean and obese adipose tissue is distinct. 
However, the antigens regulating Tregs and Tconv in lean and obese tissue remain unknown. 
More recent studies call into question the activation state and function of Tconv cells in 
obese adipose tissue.  Obese adipose tissue contains more PD1+ T cells, which have been 
described as having senescent characteristics (98). Despite impaired IL2 and IFNγ production, 
PD1+ ATTs secrete increased osteopontin, contributing to inflammation independent of classical 
T cell activation and inflammation. However, understanding the disruption of canonical Th1 T 
cell functionality in obese individuals is equally important. Lymphatic T cells in obese subjects 
have less potent inflammatory responses, making viral infections such as influenza and COVID-
19 more dangerous in individuals with metabolic dysfunction (25, 26). Fewer CD69+ granzyme+ 
cytotoxic T cells and CD69+ IFNγ+ T helper cells were found in obese individuals receiving 
influenza immunizations compared to lean controls (25). Additionally, preclinical and clinical 
studies highlight that obesity results in more severe outcomes to influenza infection (28, 129). 
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More clarification regarding tissue specific functionality of ATTs is needed to understand how 
they contribute to chronic low-grade inflammation and may provide insight to mechanisms 
governing global T cell responses in obese patients. 
Studies have also been limited by a primary focus on murine white adipose tissue 
(eWAT) with limited studies assessing functional characteristics of human ATTs. Omental white 
adipose tissue (oWAT) is the prominent visceral fat depot in humans, residing in the peritoneum 
and covering most abdominal organs (130, 131). In addition to lipid storage, the oWAT plays a 
substantial role in immunologic surveillance of the peritoneum (132). ATT and B cells are 
enriched within oWAT and aggregate in structures called fat associated lymphoid clusters 
(FALCs; milky spots), which can process and induce an immune response against antigens 
(133). Understanding how type II diabetes influences human ATT function is of interest for both 
obesity-induced diabetes and response to foreign peritoneal antigens. 
Fundamental gaps in knowledge regarding tissue-specific characteristics of CD4+ Tconv 
and CD8+ adipose tissue T cell (ATT) function impedes progress towards understanding their 
role in diabetes. Many gaps remain in our understanding of how adipose tissue T cells (ATT) 
function relates to insulin resistance. We do not know tissue-specific characteristics of ATTs in 
mice or humans, including which cytokines they secrete and how they proliferate when they 
receive an activating stimulus. How obesity influences ATT inflammatory potential has not yet 
been fully elucidated. We sought to answer these questions and hypothesized that HFD feeding 
would potentiate inflammatory potential in ATTs. However, our findings indicate that obesity 
induces impairment of ATT inflammatory potential in obese mice and diabetic humans. 
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Materials and Methods 
Animal Studies 
C57BL/6J (000664), B6.BKS(D)-Leprdb/J (000697), and MHCIIfl/fl (B6.129X1-H2-Ab1tm1Koni/J) 
x LysMCre (B6.129P2-Lyz2tm1cre1fo/J) mice were obtained from the Jackson Laboratory. MHCIIfl/fl 
x Lzy2Cre  (MMKO) mice were generated by breeding Lzy2Cre with MHCIIfl/fl mice. Cre-negative 
littermates were used as controls. Male mice were fed ad libitum either a normal diet (ND; 
LabDiet PicoLab 5L0D 4.09kcal/gm 29.8% protein, 13.4% fat, 56.7% carbohydrate) or a high fat 
diet (HFD; Research Diets D12492, 5.24kcal/gm 20% protein, 60% fat, 20% carbohydrate) 
beginning at 6 weeks of age. All mouse procedures were approved by the University Committee 
on Use and Care of Animals at the University of Michigan and were conducted in compliance 
with the Institute of Laboratory Animal Research Guide for the Care and Use of Laboratory 
Animals. 
 
Isolation of Murine Adipose Tissue SVF and Flow Cytometry Analysis 
The stromal vascular fraction (SVF) was isolated from whole adipose tissue as previously 
described (111).  Briefly, adipose tissue depots were dissected and weighed. Tissue was then 
mechanically disrupted by mincing, and chemically digested by rocking tissue in 1mg/ml 
collagenase IV (Sigma Aldrich) at 37°C for 30 mins. Cells were then quenched with RPMI + 
FBS media and filtered through 100nm mesh prior to RBC lysis and subsequent filtering with 
70nm mesh filters.  
Cells were incubated in Fc Block for 5 minutes on ice before staining with indicated antibodies 
for 30 minutes at 4°C. 
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α-mouse antibodies used: AF488-CD4 [100423], APCcy7-CD8 [100713], Brilliant Violet 605-
CD279 (PD1) [135219], PE/Cy7-CD28 [102125], APC-TCR-b [109211] from Biolegend, 
PerCpcy5.5-CD3 [45-0031-82] APC-CD25 [17-0251-82], PE-FoxP3 [12-4771-82], PEcy7-Ki67 
[25-5698-82] from eBioscience, and Live/dead Fixable Dead Cell Violet Stain Kit [L34955] 
from Invitrogen. 
Stained cells were washed twice with FACS buffer and fixed for intracellular staining using a 
FoxP3 transcription kit (BD Biosciences).  Analysis was performed on an LSR Fortessa Flow 
Cytometer and analyzed with Flow Jo software (Treestar).  
 
Human samples 
Visceral adipose tissue was collected from male bariatric surgery patients with Institutional 
Review Board approval (HUM00074075) from the University of Michigan and Ann Arbor 
Veterans Administration Hospital. Tissue was finely minced using surgical scissors (DR 
Instruments, Bridgeview, IL USA; 4SB), then digested in 3mg/ml collagenase II (Life 
Technologies (Thermo Fisher), Waltham, MA USA; 17101015) for 30 minutes. Digested tissue 
was then processed in the same manner as digested murine adipose tissue to obtain single-cell 
suspensions of SVF.  
Cells were incubated in Fc Block for 5 minutes on ice before staining with indicated antibodies 
for 30 minutes at 4°C. 
α-human antibodies used: AF488-CD4 [317419], PerCPcy5.5-CD3 [300429], APC-CD25 
[356109], APCcy7-CD8 [344713], APC-PD1 [329907], PE-FoxP3 [320107] from Biolegend, 
and Live/Dead Fixable Dead Cell Violet Stain Kit [L34955] from Invitrogen. 
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Adipose tissue T cell Activation Assay 
SVF was extracted from murine eWAT or human oWAT as described in the two previous 
subsections. Splenocytes were also collected and isolated by crushing and rinsing through 70um 
mesh. SVF and splenocytes were treated with red blood cell lysis buffer (NH4Cl in Tris-HCl 
buffer) for 5 mins at room temperature, and then quenched with complete RPMI. Cells were 
counted and 4x105 SVF or splenocytes were plated in 96 well round-bottom plates and rested 
overnight. The next morning, αCD3/CD28 dynabeads (Life Technologies) were added to the 
cultures at a 1:4 bead to cell ratio (as determined by titration experiments). No cytokines or 
growth factors were added to the media to polarize T cells or stimulate cells otherwise. After 3 
days of culture in complete RPMI medium with dynabeads, 96 well plates were spun down at 
450xg for 7 minutes. Supernatants were aspirated and used for Luminex or ELISA analysis. 
Cells and dynabeads were collected in FACS buffer (PBS-/- + 0.5%BSA) and transferred to 
FACS tubes, which were inserted into EasySep magnets. Cells were transferred into new tubes, 
while magnetic beads were selectively removed using the magnet. Cells were then washed with 
1x PBS before staining with viability dye and extracellular FACS antibodies. Cells were then 
washed and stained/fixed with intracellular markers as described above. 
 
PMA/Ionomycin T cell activation 
Splenocytes and SVF were purified from spleen and eWAT and resuspended in a single cell 
suspension. Cells were plated at 4x105 cells/ well in a 96 well round-bottom plate and rested 
overnight. The next morning, 10ug/ml of Brefeldin A was added to cultures to block protein 
secretion from the Golgi apparatus. After 1 hour, SVF was stimulated with 10ng/ml of PMA and 
250ng/ml of Ionomycin. After stimulation for 4 hours, cells were collected, washed, and stained 
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for flow cytometry to assess live ATT subpopulations and intracellular IFNγ (Alexa Fluor 647 
IFN-γ [505814[ from Biolegend).  
  
Cytokine Analysis 
Luminex assays were performed on supernatants collected after 3 days of culture. Murine 
samples were analyzed with EMD Millipore’s Milliplex MCYTOMAG-70k kit. Human samples 
were analyzed using EMD Millipore’s Milliplex HCYTOMAG-60k kit. Subsequent cytokine 
secretion assays were performed on IL2, IFNγ, and MCP1 using ELISAs performed in the 
University of Michigan’s Cancer Center Immunology Core.  
 
In-vivo PD1 Blockade 
At 6 weeks of age, C57Bl/6J mice were fed ND or HFD for 18 weeks to induce ATT 
impairment. At 24 weeks of age, mice were given injections of α-mouse PD-1 (CD279) Clone 
RMP1-14 (BioXCell), or IgG2a isotype control, anti-trinitrophenol, Clone 2A3 (BioXCell) at 
10mgkg-1 every third day for 4 total injections. The day after the last injection, systemic 
metabolism was assessed by glucose tolerance test (GTT). After re-feeding and resting 
overnight, mice were sacrificed and a fraction of fresh SVF was stained for flow cytometry 
analysis to assess basal T cell differences and ensure the PD1 antibody entered adipose tissue 
and blocked PD1. The following antibodies were used: (AF488-CD4 [100423] and APCcy7-
CD8 [100713] from Biolegend, PerCPcy5.5-CD3 [45-0031-82], PE-FoxP3 [12-4771-82], and 
Alex Fluor 647 anti-rat IgG2a [407511] from eBioscience. The remaining SVF was used for an 
ATT activation assay (described above) to assess whether PD1 blockade restored ATT 
inflammatory potential.   
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Metabolic Evaluations 
Glucose tolerance tests (GTT) were performed after a 6-hour fast. Mice were injected IP with D-
glucose (0.7g/kg) and blood glucose concentrations (mg/dL) were measured at 0, 15, 30, 45, 60, 
90, and 120 mins after injection from tail nick with a glucometer.  
 
Transwell ATT Activation Assays for Soluble Factor Analysis 
To test whether soluble factors in HFD eWAT SVF contribute to ATT impairment, co-culture 
experiments in transwell plates were performed. ND SVF was isolated and plated in the bottom 
of transwell plates. 96-well 0.4um pore transwell chambers were seeded with ND or HFD SVF. 
Bottom wells and top chambers were cultured separately O/N at 37°C. The next day, upper 
chambers were co-cultured with ND SVF for 24 hours prior to αCD3/CD28 dynabeads 
stimulation ND SVF. Cells were stimulated and kept in co-culture for 3 days, at which point 
supernatants and cells were taken for ATT activation analysis as described above. 
 
Statistical Analysis 
All values are reported as mean ± SEM. Differences between groups were determined using 
unpaired, two-tailed Students t Test or two-way ANOVA with Tukey post hoc tests with Graph 
Pad Prism 5 software. P values less that 0.05 were considered significant. 
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Results 
ATT activation and inflammatory capacity is decreased with obesity 
Previous limitations in assessments of ATT function are related to poor viability of ATTs in-
vitro and the small number of cells that can be collected from a single mouse (134). To overcome 
these limitations, we devised a culture system where all stromal vascular cells from epididymal 
white adipose tissue (eWAT) were collected and cultured. ATTs were assessed within this 
heterogeneous fraction. This paradigm allowed for flow analysis of ATTs following in-vitro 
experimentation and retention of environmental signals from other leukocytes, pre-adipocytes, 
and endothelial cells. After 3 days of culture with or without αCD3/CD28 dynabeads, 
supernatants were collected and cells were assessed by flow cytometry (Figure 3-1A). Since 
Tconv and cytotoxic CD8+ T cells upregulate CD25 after receiving stimulus from an antigen-
presenting cell (86), IL-2Ra (CD25) frequency (Figure 3-1B) and MFI (Supplementary figures 
3-1A and 3-1B) was measured on Tconv, CD8+, and Treg cells from spleen and eWAT from 
mice fed normal diet (ND) or HFD for 18 weeks. We noted significant differences in T cell 
activation depending upon the tissue of origin and diet consumed. Tconv and cytotoxic CD8+ T 
cells from the spleen both increased frequency and MFI of CD25 when stimulated with 
dynabeads, as expected. HFD feeding resulted in more robust CD25 expression on CD8+ T cells 
when activated compared to stimulated ND control splenic T cells. However, ATTs had marked 
differences in their capacity for stimulation. Unstimulated ATTs had higher basal levels of CD25 
expression and dynabead stimulation failed to induce CD25 of ND ATT cells to the same 
capacity as those in the splenocyte cultures. Additionally, ATTs from HFD fed mice are resistant 
to CD25 upregulation. Unlike Tconv and CD8+ T cells, CD25 expression is constitutively 
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expressed on Tregs, as described previously (135, 136). However, CD25 expression was 
decreased on HFD eWAT Tregs independent of stimulation. Ki67 expression measured by 
frequency (Figure 3-1C) and MFI (Supplemental Figures 3-1C and 3-1D) in Tconv and CD8+ 
T cells were also dependent upon tissue of origin. In bead stimulated splenocyte cultures, Ki67 
was significantly increased in Tconv and CD8+ cells independent of diet type. However, ATTs 
were resistant to Ki67 induction in CD8+, Tconv, and Tregs in response to dynabead stimulus. 
Total live T cell numbers in cultures also indicated significant differences in proliferative 
capacity of splenic and adipose tissue T cells (Supplemental Figures 3-1E and 3-1F). While 
splenic T cell numbers significantly increased with TCR stimulus, cell numbers of ATTs present 
in in-vivo cultures remain unchanged with or without dynabead stimulation.  
 
Cytokine secretion data also indicated impaired HFD ATT inflammatory response to TCR 
stimulation (Figure 3-1D). Supernatants from ATT cell activation assays were collected for 
assessment by multiplex Luminex assays. T cell effector cytokines were secreted following 
similar trends as CD25 upregulation. In splenocyte fractions, TCR stimulation significantly 
increased cytokine secretion, and HFD feeding enhanced effector T cell inflammatory cytokine 
release of IIL2, IFNy, IL-17, and IL4 (Figure 3-1E). However, HFD has the opposite effect on 
ATT inflammatory cytokine secretion. Unlike ND SVF, which induces a significant increase of 
Th1, Th2, and Th17 cytokine release with dynabead stimulation, HFD ATTs fail to induce the 
same level of cytokine secretion in HFD SVF fractions. ND Rag1KO SVF was used for ATT 
activation assays to ensure dynabead stimulus wasn’t inducing effector T cell cytokines in the 
absence of ATTs (Supplemental Figure 3-1G). Overall, this data shows that obesity induced by 
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18 weeks of HFD feeding impairs murine eWAT T cell activation and T cell cytokine 
production, but has minimal effects on splenic T cells function. 
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Figure 3-1 – ATT activation capacity is suppressed with HFD feeding. 
(A) Flow cytometry-gating strategy used for ATT activation assays. Representative plot shows eWAT SVF 
after 3 days of co-culture with αCD3/CD28 dynabeads. 
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(B) Frequency of CD25 expression on Tconv, CD8+, and Tregs after ATT activation assays. T cells from 
splenocytes and eWAT SVF cultures taken from ND and HFD-fed mice after 18 weeks of feeding. 
(C) Frequency of Ki67 expression on Tconv, CD8+, and Tregs from splenocytes and eWAT after T cell 
activation assays. Cells fractions were assessed with or without αCD3/CD28 dynabead co-culture for 3 
days.  
(D) Luminex assessment of supernatants taken from T cell activation cultures after 3 days.  
(E) Luminex data represented by bar graphs to show cytokines secretion of Th1, Th2, and Th17 specific 
cytokines. 
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Supplemental Figure 3-1 – Additional data for ATT activation assays. 
(A) MFI of CD25,  
(B) MFI of Ki67 in CD8+ and Tconv ATT cells from eWAT after ATT activation assays.  
(C) MFI of CD25,  
(D) MFI of Ki67 on CD8+ and Tconv cells from splenocytes after ATT activation assays,  
(E) Number of eWAT cells,  
(F) Number of spenocytes seen in Live CD3+, total CD4+, Tconv, Treg, and CD8+ subpopulations in ATT 
activation assays. 
(G) Frequency of live cells in ATT activation cultures from eWAT and splenocytes,  
ND HF
D
0
400
800
1200
M
FI
 C
D
25
 o
f C
D
8+
no stim 
aCD3/CD28
ns
ns
***
***
ND HF
D
0
10000
20000
30000
40000
50000
M
FI
 K
i6
7 
of
 C
D
8+
no stim 
aCD3/CD28
ns
ns
****
****
M
FI
 C
D
25
 o
f C
D
8+
M
FI
 K
i6
7 
of
 C
D
8+
ND HFD ND HFD
Splenocytes
ND
HF
D 
  
0
10000
20000
30000
#L
iv
e 
C
D
3+
 o
f S
VF
no stim
stim
****
****
*
ns
ND
HF
D 
  
0
5000
10000
15000
#L
iv
e 
C
D
8+
 o
f C
D
3+ no stim
stim
****
****
ns
ns
ND
HF
D 
  
0
5000
10000
15000
#L
iv
e 
C
D
4+
 o
f C
D
3+ no stim
stim
****
****
*
ns
ND
HF
D 
  
0
5000
10000
15000
#L
iv
e 
C
D
4+
 o
f C
D
3+ no stim
stim
****
****
*
ns
ND
HF
D 
  
0
50
100
150
200
250
#L
iv
e 
C
D
4+
 o
f C
D
3+ no stim
stim
ns
ND
HF
D 
  
0
2000
4000
6000
8000
#L
iv
e 
C
D
3+
 o
f S
VF
no stim
stim
ns
ND
HF
D 
  
0
500
1000
1500
2000
#L
iv
e 
C
D
8+
 o
f C
D
3+ no stim
stim
ns
ND
HF
D 
  
0
500
1000
1500
#L
iv
e 
C
D
4+
 o
f C
D
3+ no stim
stim
ns
ND
HF
D 
  
0
100
200
300
400
#L
iv
e 
Tr
eg
 o
f C
D
4+
no stim
stim
ns
ns**
ND
HF
D 
  
0
200
400
600
800
1000
#L
iv
e 
Tc
on
v 
of
 C
D
4+ no stim
stim
ns
ND HF
D
0
200
400
600
800
1000
M
FI
 C
D
25
 o
f C
D
8+
no stim 
aCD3/CD28
ns
***
ns
**
ND HF
D
0
500
1000
1500
2000
M
FI
 K
i6
7 
of
 C
D
8+
no stim 
aCD3/CD28
ns
p=0.055
ns
p=0.074
A.
C.
eWAT
M
FI
 C
D
25
 o
f C
D
8+
M
FI
 K
i6
7 
of
 C
D
8+
ND FDND HFD
B.
ND HF
D
0
500
1000
1500
2000
M
FI
 C
D
25
 o
f T
co
nv no stim 
aCD3/CD28
ns
ns
****
***
ND HF
D
0
10000
20000
30000
40000
M
FI
 K
i6
7 
of
 T
co
nv
no stim 
aCD3/CD28
ns
ns
****
****
D.
ND HFD ND HFD
M
FI
 K
i6
7 
of
 T
co
nv
M
FI
 C
D
25
 o
f T
co
nv
D HFD ND HFD D HFD ND HFD ND H D#L
iv
e 
C
D
3+
 o
f S
VF
#L
iv
e 
C
D
8+
 o
f C
D
3+
#L
iv
e 
C
D
4+
 o
f C
D
3+
#L
iv
e 
Tr
eg
 o
f C
D
4+
N HFD ND H D ND HFD ND H D D HFD#
Li
ve
 C
D
3+
 o
f 
Sp
le
no
cy
te
s
#L
iv
e 
C
D
8+
 o
f C
D
3+
#L
iv
e 
C
D
4+
 o
f C
D
3+
#L
iv
e 
Tr
eg
 o
f C
D
4+
#L
iv
e 
Tc
on
v 
of
 C
D
4+
F.
No	stim	
α-CD3/CD28	
ND HF
D
0
400
800
1200
M
FI
 C
D
25
 o
f T
co
nv no stim 
aCD3/CD28
ns
**
ns
**
ND HF
D
0
200
400
600
800
M
FI
 K
i6
7 
of
 T
co
nv
no stim 
aCD3/CD28
ns
**
ns
*
ND FDND HFD M
FI
 K
i6
7 
of
 T
co
nv
M
FI
 C
D
25
 o
f T
co
nv
eWAT Splenocytes
#L
iv
e 
Tc
on
v 
of
 C
D
4+
1
0
1000
2000
3000
pg
/m
L
*** ***
p = 0.064
p = 0.063 p = 0.063
1
0
20
40
60
80
100
pg
/m
L
IL2
ND eWAT no stim 
ND eWAT stim 
ND Rag1KO eWAT stim
HFD Rag1KO eWAT stim
**** ****
HFD eWAT no stim 
HFD eWAT stim 
****
** **
IFNy IL-
pg
/m
L
WT aCD3/CD28
Rag1KO 
aCD3/CD28
WT no stim
ND HFD ND HFD
pg
/m
L
G.
E.
Supplemental Figure 3-1
81		
(H) IFNγ and IL2 secretion from WT v Rag1KO SVF with αCD3/CD28 dynabead stimulation 
(I) Bar graphs depicting heat map data in Figure 3-1D. 
 
 
ATT activation potential is decreased in diabetic humans 
Increased Th1 polarized CD4+ ATTs have been reported in obese diabetic humans (128). 
However, our murine culture system indicates ATTs from obese diabetic tissue have functionally 
impaired inflammatory properties. Therefore, we assessed human ATTs using omentum biopsies 
from BMI matched bariatric surgery patients (Table 3A).  HbA1c levels were used to classify 
patients as non-diabetic (NDM; <5.7) or diabetic (DM; >6.5). ATT activation and inflammatory 
potential were then measured using the same ATT activation assay used for murine cells. We 
observed decreased CD25+ upregulation in DM ATTs after 3 days of stimulation with 
αCD3/CD28 dynabeads (Figure 3-2A). T cell specific inflammatory cytokine release was also 
significantly lower in cells taken from DM patients. Both IL2 and IFNγ were significantly 
increased in culture supernatant from stimulated NDM ATTs, but ATTs from DM human 
samples were unable to secrete these cytokines to the same degree (Figure 3-2B). However, 
MCP1, a myeloid derived cytokine was not significantly different. We performed a Luminex 
assay to broadly assess effector cytokines from DM v NDM human SVF cultures (Figure 3-2C). 
With ATT simulation, SVF cells from DM humans had a diminished capacity to secrete pro-
inflammatory effector T cell cytokines compared to obese NDM controls. Overall, ATTs from 
DM visceral human adipose tissue have an impaired inflammatory phenotype upon TCR 
stimulation similar to obese diabetic mice. 
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Table 3A – Bariatric Surgery Enrollment Data 
 NDM (average) DM (average) t Test 
# / Sex 7/males 3/males P = N/A 
Age 51.1 58.7 P = 0.04 
BMI 44.2 55 P = 0.133 
HbA1c 5.75 8.23 P = 5.29 x10-6 
Blood glucose 94.0 165.3 P = 0.0004 
Pre-op 
Cholesterol 
155.4 169.3 P = 0.613 
HDL 39.00 47.67 P = 0.673 
LDL 89.00 82.67 P = 0.839 
 
 
 
 
 
 
 
 
 
 
 
 
 
83		
 
Figure 3-2 – Human ATT activation capacity is impaired in diabetic patients. 
(A) Frequency of CD25 expression of NDM and DM human oWAT ATTs after activation assays with 
αCD3/CD28 dynabeads.  
(B) Luminex assessment of supernatants taken from ATT activation cultures. N = 2 biological replicates/group, 
3 technical replicates. 
(C) IL2, IFNγ, and MCP1 cytokines in culture supernatants from human ATT activation assays. 
 
*p < 0.05, **p < 0.01, *** < 0.0001 
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ATT dysfunction measured by CD25 expression and cytokine secretion is independently 
regulated with chronic HFD feeding. 
Since diabetic mice and humans have ATTs that are unable to elicit robust inflammatory 
responses with TCR activation, we examined the kinetics of ATT dysfunction over the course of 
18 weeks of HFD feeding. ATT activation assays were used to assess CD25 expression and 
cytokine secretion from mice fed HFD for 1, 6, 12, and 18 weeks beginning at 6 weeks of age.  
Following 1 week of HFD feeding, CD25 expression was induced in HFD Tconv (Figure 3-3A, 
Supplemental Figure 3-2A) and CD8+ ATT (Figure 3-3B, Supplemental Figure 3-2B) to a 
similar capacity as age-matched ND controls. After 6 weeks of HFD feeding, basal CD25 
expression was increased compared to other time points. Although CD25 was increased in ND 
and HFD ATTs after stimulation, the difference in expression between untreated and TCR 
stimulated groups becomes less pronounced. By 12 weeks of HFD feeding, CD25 induction 
failed to occur after TCR stimulation, and the same trend persisted through 18 weeks. The 
impairments in ATT cytokine secretion did not correlate with CD25 expression over the time 
course. IL2 and IFNγ were measured as indicators of effector T cell cytokine secretion, and 
MCP1 were evaluated as a control for innate immune cell function (Figure 3-3C, Supplemental 
Figure 3-2C and 3-2D). IL2 and IFNγ secretion was impaired at 6 weeks of HFD feeding 
compared to age-matched stimulated controls and persisted through the later time points. MCP1 
secretion was not significantly changed based on diet or stimulus, as expected. In sum, ATT 
dysfunction was not observed with acute HFD feeding and requires an extended period of HFD 
feeding.  
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Figure 3-3 – Kinetics of ATT dysfunction 
(A) Frequency of CD25 expression on eWAT Tconv and 
(B) Frequency of CD25 expression on eWAT CD8+ T cells after ATT activation assays. Assays were 
performed after 1, 6,12, and 18 weeks of HFD-feeding.  
(C) IL2, IFNγ, and MCP1 concentration in supernatants of ATT activation assays at 1, 6, 12, and 18 weeks of 
HFD feeding. 
 
*p < 0.05, **p < 0.01, ***p < 0.0001. n = 4 biological replicates/group  
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(A) Frequency of CD25 expression on eWAT Tconv and, (B) frequency of CD25 expression on eWAT CD8+ T 
cells after ATT activation assays. Assays were performed after 1, 6, 12, and 18 weeks of HFD-feeding.
(C) IL2, IFNγ, and MCP1 conce tration in supernatants of ATT activation assays at 1, 6, 12, and 18 weeks of 
HFD-feeding.
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Macrophage MHCII signals are required for ATT activation impairment 
We hypothesized that impairment in TCR signaling pathways may explain impaired T cell 
activation capacity with chronic HFD feeding. First, Phorbol 12-myristate 13-acetate 
(PMA)/Ionomycin stimulation was used to activate ATTs independent of the TCR. In contrast to 
αCD3/CD28 stimulation, PMA/Ionomycin efficiently induced IFNγ production in HFD CD8+ 
and Tconv ATTs (Figure 3-4A). HFD CD8+ ATTs had significantly greater IFNγ production 
than stimulated ND ATTs. PMA/Ionomycin stimulation experiments suggest that HFD ATTs 
maintain their ability to produce pro-inflammatory cytokines when activated independent of the 
TCR. To test whether chronic TCR stimulation is necessary for ATT impairment (much like 
exhausted T cells in tumor microenvironments), we examined ATTs from MHCIIflfl xLysMCre 
(MMKO) mice where MHCII is absent on a majority of macrophages and dendritic cells in 
adipose tissue (Supplemental Figure 3-3A) (80). MMKO mice and WT controls were placed on 
ND or HFD diet for 12 weeks before analysis of T cell activation (Figure 3-4B). HFD fed 
MMKO mice gained significantly less weight than controls, and have decreased 
proinflammatory ATMs (Supplemental Figures 3-4B and 3-4C). While MMKO mice ATTs 
from ND mice were activated to a similar capacity in WT and MMKO cultures based on CD25 
expression, IL2, and IFNγ secretion. However, HFD induced impairment of CD25, IL-2, and 
IFNγ induction was absent in MMKO mice. Macrophage MHCII deletion seemed to only impact 
adipose tissue, as splenic T cell inflammatory capacity was unchanged in ND or HFD fed mice 
(Figure 3-4C). Overall, this data suggests that ATT impairment in HFD-fed mice requires 
insulin resistance, reaching a significant weight gain, or macrophage-derived MHCII signals.   
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Figure 3-4 – TCR signaling is required for obesity induced ATT dysfunction 
(A) Intracellular IFNγ in Tconv and CD8+ ATT cells after stimulation with PMA and Ionomycin for 4 hours. 
HFD was administered for 12 weeks. Representative histograms are shown on the left, and biological 
replicates shown on the right.  
(B) LsyMCre x MHCIIfl/fl (MMKO) mice and age-matched littermate controls were fed ND or HFD for 12 
weeks and used for ATT activation assays. 
(C) MMKO splenocytes assessed for cell surface CD25 expression and supernatants for Il2 and IFNγ 
concenrations after 3 days of αCD3/CD28 dynabead stimulation. 
 
*p < 0.05, **p < 0.01, ***p < 0.0001. n = 3-4 biological replicates/group 
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Figure 3-4: TCR signaling is required for obesity induced ATT dysfunction.
(A) Intracellular IFNy in Tconv and CD8+ ATT cells after stimulation with PMA and Ionomycin for 4 hours. HFD was 
administered for 12 weeks. Representative histograms are shown on the left, and biological repl cates shown on 
the right. 
(B) LysMCre x MHCIIfl/fl (MMKO) mice and age-matched littermate controls were fed ND or HFD for 12 weeks and 
used for ATT activation assays. 
(C) MMKO splenocytes assessed for cell surface CD25 expression, and supernatants for IL2 and IFNγ 
concentrations after 3 days of αCD3/ D28 dynabead stimulation.
* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. n = 3-4 biological replicates/group
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Supplemental Figure 3-2 – Metabolic and immunologic phenotype of HFD MMKO mice 
(A) Flow plots illustrating MCHII knockout in the primary antigen presenting cells in HFD adipose tissue 
(B) Body weights of MMKO mice 
(C) Flow plots illustrating antigen presenting cell subsets in HFD MMKO adipose tissue after 12 weeks.  
 
*p < 0.05, **p < 0.01, ***p < 0.0001. n = 3-4 biological replicates/group 
 
 
 
 
 
 
 
 
Supplemental Figure 3-3: Metabolic nd immunologic phenotype of HFD M KO mice.
(A) Flow plots illustrating MHCII knockout in the primary antigen presenting cells in HFD adipose 
tissue.
(B) Body weights of MMKO mice and controls.
(C) Flow plots illustrating antigen presenting cell subsets in HFD MMKO adipose tissue after 12 
weeks.
* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001
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T cell receptor and co-activating receptors are differentially expressed in obese mice and 
humans 
Given the impairment in obese ATT inflammatory capacity in the presence chronic peptide-
MHCII, we assessed the whether lack of TCR and co-activating receptors expression was 
responsible.  Median fluorescence intensity of TCRβ and co-activating receptor CD28 was 
measured by flow cytometry on freshly extracted eWAT and splenic Tconv and CD8+ T cells 
(Figure 3-5A). In mice fed HFD diet for 12 weeks, TCRβ was more highly expressed on Tconv 
and CD8+ cells in eWAT, and CD28 was more highly expressed in eWAT Tconv. However, 
TCRβ was not changed by HFD feeding in splenic T cells and CD28 was significantly decreased 
on splenic CD8+ cells. TCR co-inhibitory receptors were assessed by flow cytometry including 
CTLA-4 on eWAT ATTs (Supplemental Figure 3-4A) and splenic T cells (Supplemental 
Figure 3-4B). Although eWAT ATTs had higher CTLA-4 expression compared to splenic T 
cells, expression did not change with HFD feeding.  PD1 was more highly expressed on eWAT 
ATTs than splenic T cells, but the expression on splenic T cells and ATT Tconv cells was not 
changed by HFD feeding (Figure 3-5B). However, PD1 was significantly increased in HFD 
CD8+ ATTs. PD1 expression was also assessed on ATTs extracted from human oWAT (Figure 
3-5C). Even though the frequency of PD1 expressing ATTs from human oWAT was substantial, 
it was not correlated with HbA1c or diabetic status. Overall, these results suggest that loss of 
TCR and co-activating receptor expression is not the mechanism of ATT impairment with 
obesity.   
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Figure 3-5 – T cell receptor and co-receptor components are differentially expressed in obese mice. 	
Surface receptor expression was assessed on mice fed HFD for 12 weeks and age matched ND controls.  
(A) CD28 and TCRβ expression on freshly isolated Tconv and CD8+ T cells. n = 4 biological replicates/group 
(B) Frequency of PD1 expression on CD8+ T cells and Tconv from freshly isolated eWAT and splenocytes. 
Representative histograms of PD1 expression are shown on the right of each group. n = 7-8 biological 
replicates/group 
(C) Correlation of PD1 expression on Tconv and CD8+ ATTs taken from human omentum and HbA1c. n = 3-7 
biological replicates/group 
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Supplemental Figure 3-3 – CTLA4 expression on eWAT and splenic T cells 
(A) Frequency of CTLA-4 expression on freshly isolated Tconv and CD8+ eWAT ATTs and, 
(B) Spleen, measured by flow cytometry. 
 
In-vivo PD1 blockade fails to reverse ATT impairment or induce metabolic changes in 
obese mice. 
PD1 is highly expressed in eWAT ATTs, PDL1 is highly expressed on adipocytes (137), and 
HFD significantly increased PD1 expression in CD8+ cytotoxic T cells. Therefore we performed 
an in-vivo PD1 blockade to evaluate the hypothesis that PD1 expression was required for 
impaired ATT inflammatory capacity with obesity.  Obese mice (18 weeks of HFD) were treated 
with a PD1 blocking regimen or IgG2a control for 2 weeks (Figure 3-6A). PD1 blockade did not 
induce significant difference in body or organ weights (Supplemental Figures 3-5A). Glucose 
tolerance was assessed and obese mice had elevated fasting glucose levels and exhibited glucose 
intolerance (Figure 3-6B). However, PD1 blockade did not significantly change glucose 
tolerance compared to diet matched IgG2a controls. At the terminal endpoint, eWAT derived 
SVF and splenocytes were isolated and fractions were taken to assess basal T cell composition 
Supplemental Figure 3-4
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and binding of αPD1 to ATTs (Supplemental Figure 3-5B). PD1 antibody injections did not 
alter frequencies of Tconv, Treg, or CD8+ ATTs (Supplemental Figure 3-5C). However, the 
PD1 blocking antibody penetrated into adipose tissue and effectively bound to ATT cells.  ATT 
activation assays were also performed to assess the inflammatory potential of cells after the PD1 
blockade. CD25 expression was increased in stimulated ND eWAT CD8+ ATT that received 
PD1 blockade compared to stimulated isotype control. The same increase in CD25 expressing 
cells were not seen in ND Tconv populations. More importantly, PD1 blockade did not rescue 
CD25 expression/upregulation with dynabead stimulation on HFD CD8+ or Tconv cells (Figure 
3-6C). However, PD1 blockade increased CD25 expression on stimulated ND and HFD splenic 
CD8+ T cells, and Tconv from ND mice (Figure 3-6D). Since CD25 and effector T cell cytokine 
regulation seems to be regulated independently, we also assessed cytokine secretion in culture 
supernatants. IL2 and IFNγ secretion were not rescued in stimulated ATTs from HFD mice given 
αPD1. PD1 blockade also did not increase cytokine secretion in activated ATT cells from ND 
mice (Figure 3-6E). Additionally, PD1 blockade didn’t increase IL2 or IFNγ secretion in ND or 
HFD splenic T cells (Figure 3-6F). Overall, PD1 blockade can effectively penetrate adipose 
tissue and bind to PD1 expressing ATT cells. However, PD1 blockade did not rescue 
inflammatory impairment of ATT cells in obese mice.  
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Figure 3-6 – PD1 blockade does not reverse ATT impairment after 18 weeks of HFD feeding. 
(A) Illustration of in-vitro PD1 blockade timeline and interventions. 
(B) Glucose tolerance test of ND and HFD-fed mice after administration of αPD1 or IgG2a isotype infections 
(left) and glucose levels after fasting for 6 hours (right).  
(C) ATT Activation assays were performed on eWAT SVF and,  
(D) Splenocytes after PD1 blockade regimen. Frequency of CD25 expression on CD8+ T cells and Tconv 
measured 3 days after dynabead stimulation. 
(E) IL2 and IFNγ concentrations in culture supernatants from PD1 blockade ATT activation assays of eWAT 
SVF and,  
(F) Splenocytes. 
 
*p < 0.05, **p < 0.01, ***p < 0.0001. n = 3-4 biological replicates/group 
 
 
 
 
 
 
 
Figure 3-6: PD1 blockade does n t reverse ATT impairment after 18 weeks of HFD feeding.
(A) Illustration of in-vivo PD1 blockade timeline and interventions.
(B) Glucose tolerance test of ND and HFD-fed mice after administration of αPD1 or IgG2a isotype injections (left) 
and gluc se l vels after fasting for 6 hours (right). 
(C) ATT Activation assays were performed on eWAT SVF and, (D) Splenocytes after PD1 blockade regimen. 
Frequency of CD25 expression on CD8+ T cells and Tconv measured 3 days after dynabead stimulation.  
(E) IL2 and IFNy concentration in culture supernatants from PD1 blockade ATT activation assays of eWAT SVF 
and, (F) splenocytes.
* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001
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Supplemental Figure 3-4 – PD1 blockade phenotyping data of mice fed HFD for 18 weeks. 
(A) Terminal body and organ weights of PD1 blockade mice after IgG2a or PD1 antibody injections. 
(B) Flow cytometric analysis of fresh non-cultured ATT cells after PD1 blockade. 
(C) Flow cytometric measurement of T cells bound by Rat IgG2a (in-vivo PD1 antibody). 
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Soluble factors from obese eWAT impair ATT inflammatory capacity 
To test whether HFD eWAT SVF contains soluble factors that decrease ATT inflammatory 
potential, transwell co-culture studies were employed. ND eWAT SVF was cultured in the 
bottom wells, while the upper chambers were filled with media only, ND eWAT SVF, or HFD 
eWAT SVF at 1:1 cell ratio and co-cultured for 24 hours before stimulation of the ND SVF with 
aCD3/CD28 dynabeads for 3 days. Co-culture with ND SVF did not significantly alter CD25 
upregulation after stimulation on CD8+ or Tconv. However, HFD eWAT SVF significantly 
decreased CD25 expression on both cell types demonstrating that soluble factors contributed to 
impairment in T cell activation (Figure 3-7A). Also, while MCP1 secretion was not impacted by 
co-culture, IL2 and IFNy were decreased when ND eWAT ATTs were co-cultured with HFD 
SVF, but not ND SVF (Figure 3-7B).  Since leptin has been reported to contribute to T cell 
impairment in obesity, we tested if leptin signaling in T cells was necessary for ATT dysfunction 
(23). ATTs from leptin receptor-deficient Db/Db mice and Db/+ controls were assessed using 
the ATT activation assay. CD25 upregulation was not rescued in Db/Db mice (Figure 3-7C). 
IFNy secretion also failed to be restored in obese Db/Db mice, while MCP1 was secreted to 
similar quantities as diet-induced obese mice (Figure 3-7D). In sum, soluble factors from HFD 
eWAT SVF mediate ATT inflammatory potential, and leptin is not a critical mediator.  
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Figure 3-7 – Soluble factors in HFD eWAT inhibit inflammatory capacity of ND ATTs 
(A) Frequency of CD25 expression on Tconv and CD8+ ATT from ND-media only, ND-ND (ND SVF top 
chamber), and ND-HFD (HFD SVF top chamber) were copared after ATT activation assays. 
(B) IL2, IFNγ, and MCP1 concentration in culture supernatants from co-culture ATT activation assays of ND 
eWAT. 
(C) Frequency of CD25 expression on Tconv and CD8+ ATTs after ATT activation assay performed on eWAT 
SVF of 8 weeks on Db/+ and Db/Db mice. 
(D) IFNγ and MCP1concentration in supernatants from Db/Db ATT activation assay cultures. 
 
*p < 0.05, **p < 0.01, ***p < 0.0001 
Figure 3-7: Soluble factors in HFD eWAT inhibit inflammatory capacity of ND ATTs.
(A)  Frequency of CD25 expression on Tconv and CD8+ ATT from ND-Media only, ND-ND (ND SVF top 
chamber), and ND-HFD (HFD SVF top chamber) were compared after ATT activation assays.
(B) IL2, IFNy, and MCP-1 concentration in culture supernatants from co-culture ATT activation assays of ND 
eWAT. 
(C) Frequency of CD25 expression on Tconv and CD8+ ATTs after ATT Activation assay performed on eWAT SVF 
of 8 week old Db/+ and Db/Db mice. 
(D) IFNy and MCP-1 concentrations in supernatants from Db/Db ATT activation assay cultures.
* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001
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Discussion 
This study has uncovered several novel findings regarding ATT biology in the context of 
obesity-induced inflammation. To address gaps in the field, we developed an in-vitro culture 
method to allow us to assess adipose tissue depot specific characteristics of ATT inflammatory 
potential. We found that HFD dampens the inflammatory capacity of Tconv and CD8+ ATTs, 
which lose their ability to respond to a TCR stimulus. Upon stimulation with αCD3/CD28 
dynabeads, eWAT ATTs from both ND and HFD tissue fail to induce Ki67 expression, unlike 
splenic T cells. Additionally, ATTs from HFD lose their ability to increase CD25 expression on 
the cell surface or secrete pro-inflammatory cytokines including IFNy and IL2. One limitation of 
our study is that our in-vitro model cannot account for tissue architecture and adipocyte derived 
signals found in adipose tissue. However, we found that culturing ATTs within a heterogeneous 
SVF fraction allowed us to maintain necessary environmental signals that differentiate ATT cells 
from obese and lean mice.  Previous studies have demonstrated that ATTs are contributors to 
chronic low-grade inflammation in obese adipose tissue (67, 72, 97). However, more recent 
studies have suggested CD153+ PD1+ CD4+ ATTs are induced in obese tissue, express markers 
cellular senescence, and have decreased classical effector cytokine production after stimulation 
(98). While this study defines a subset of tissue resident memory CD4+ cells (using CD153) with 
senescent characteristics, the authors conclude these ATTs still mediate chronic low-grade 
inflammation due to osteopontin secretion. We performed a comprehensive analysis of effector 
cytokines secreted after T cell activation, which align with previous finding of decreased 
canonical T cell cycokine secretion in ATTs from obese mice. Instead of focusing on CD153+ 
Tconv cells, we decided to assess entire Tconv and CD8+ ATT populations since decreased 
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effector cytokine secretion after TCR simulation could be due to chronic antigen exposure and 
exhaustion. Shirakawa et al did not assess functional characteristics of Tconv activation such as 
proliferation, cell markers of activation, or perform a comprehensive panel of effector Tconv 
cytokines. While a fraction of Tconv cells may be senescent, we thought a more comprehensive 
functional assessment of ATTs would be beneficial. 
We also assessed ATT activation from the human omentum, the major visceral adipose 
tissue organ. Adipose tissue was collected from a cohort BMI matched bariatric surgery patients 
that were non-diabetic (NDM; HbA1c <5.7) or diabetic (DM, HbA1c>6.5). Although we 
hypothesized that obesity and diabetes would result in ATTs with enhanced pro-inflammatory 
characteristics as seen in previous studies by McLaughlin et al (128), we found that ATTs had 
decreased inflammatory response to αCD3/CD28 stimulus from metabolically unhealthy 
patients. Further collection of human biopsies will be helpful for making assessments regarding 
associations between ATT inflammatory response and systemic metabolism (HbA1c), blood 
glucose, and circulating lipid contents. These correlations may be able to help determine whether 
adipose tissue functions, like lipolysis, or systemic metabolic impairments play a role in ATT 
function. 
ATT impairment in diabetic human omentum and murine eWAT led us to explore this 
phenotype further. Since TCR repertoires are restricted on Tconv ATTs in obese mice, we 
hypothesized that ATTs were becoming exhausted due to continuous exposure to their cognate 
antigens, similar to T cells in tumor microenvironments (87, 99, 100). Therefore, we performed a 
timecourse comparison of ATT inflammatory potential after dynabead stimulation to assess ATT 
inflammatory capacity of ATTs after acute and chronic HFD. We found that 1-week short-term 
HFD diet failed to inhibit ATT inflammatory potential, indicating that ATT dysfunction is not an 
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acute response to diet. However, after 6 weeks of feeding, ATTs are unable to secrete increased 
IFNy or IL2 when stimulated with αCD3/CD28 dynabeads. However, they retain their ability to 
upregulate CD25 expression. This indicates that CD25 expression and cytokine secretion are 
regulated independently of each other. ATT dysfunction also occurs before macrophage 
infiltration into WAT, but after glucose sensitivity starts to change (138, 139). This suggests that 
ATT dysfunction does not correlate with systemic glucose insensitivity and impairment is not 
dependent on glucose availability alone. It also implies that influx of proinflammatory ATMs is 
not required for ATT dysfunction. 
 Since chronic HFD feeding is required for ATT impairment to occur, we hypothesized 
that ATTs were becoming functionally exhausted during prolonged periods of exposure to their 
activating antigen. Unlike dynabead stimulation assays where HFD ATTs have reduced 
inflammatory potential, activating signals from PMA/Ionomycin that bypass the TCR resulted in 
higher IFNy production than ND ATTs. Previous studies implicating ATTs in chronic low-grade 
inflammation have assessed ATT phenotype using PMA/Ionomycin stimulation, which explains 
the previous discrepancies between ATT inflammation and senescence (72, 128). Therefore, we 
tested whether chronic TCR signaling in obese adipose tissue was required for decreased 
response to αCD3/CD28 activation after 12 weeks of HFD feeding. MHCIIflfl x LysMCre knock 
out mice (MMKO) were used to substantially decrease antigen presentation to ATTs during 12 
weeks of HFD feeding. HFD MMKO mice had restored ATT inflammatory capacity upon 
αCD3/CD28 dynabead stimulus, which did not occur in WT obese controls. This suggests that 
prolonged signaling through the TCR could be required for ATT impairment in obese mice. 
However systemic metabolism could also play an important role in ATT activation capacity, 
considering HFD MMKO mice have improved insulin and glucose tolerance compared to HFD 
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WT controls. Additionally, HFD MMKO mice fail to gain as much weight as the WT HFD 
group, which is a major limitation to this experiment. Establishing whether TCR signaling or 
improved insulin sensitivity in MMKO mice result in restored ATT inflammatory capacity needs 
to be explored in further studies. 
 Since signaling through the TCR is required for ATT impairment, we assessed TCRβ, co-
activating, and co-inhibitory receptors on ATTs from lean and obese mice. TCRβ and CD28 
were expressed more highly on ATTs from HFD-fed eWAT than ND controls, indicating that 
impairment is not due to inadequate TCR expression. Co-inhibitory expression is a hallmark of T 
cell exhaustion, so PD1 and CTLA-4 expression were also assessed. Both proteins were 
expressed on a larger frequency of ATTs than splenic T cells. However, HFD only increased 
PD1 expression on CD8+ and not Tconv ATTs. Nevertheless, we decided to perform an in-vivo 
PD1 blockade to assess whether PD1 signaling was responsible for reduced ATT activation 
capacity in ND ATTs compared to splenic T cells and whether CD8+ ATTs in obese mice would 
have restored inflammatory capacity following a blockade. We found that PD1 blockade did not 
influence the GTT of ND or HFD mice and that T cell inflammatory potential was not reversed. 
Further studies will be needed to pinpoint the mechanism responsible for ATT impairment, but 
signaling pathways proximally downstream of the TCR are inhibited. Distal signaling pathways 
seem intact, since PMA/Ionomycin induces PKC signaling and calcium influx, and IFNγ 
production occurs in HFD ATTs with this stimulation (140, 141). We attempted to perform 
phospho-flow experiments to assess phosphorylation of proteins like Zap70, Lat, and Erk to 
pinpoint where TCR signal transduction is impaired. Unfortunately we had difficulty with this 
technique and alternative methods like western blots are also difficult to perform on rare cell 
populations where substrate is limited. Further studies utilizing techniques like single cell RNA 
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sequencing will allow us to explore multiple potential mechanisms driving ATT inflammatory 
impairment. 
 Since ND and HFD SVF have different environmental signals, we also assessed whether 
soluble factors in the culture conditions influenced ATT activation. Using transwell plates we 
determined that soluble factors in the HFD SVF are sufficient to decrease inflammatory potential 
of ND ATTs. We started by assessing leptin as a potential candidate since it has been implicated 
in T cell exhaustion associated with obese cancer patients (23). We utilized the leptin receptor 
mutant Db/Db mice, to assess whether leptin signaling was necessary or sufficient for inducing 
ATT impairment in obese conditions (142). ATTs from Db/Db mice had an impaired 
inflammatory phenotype similar to ATTs from diet-induced obese mice. Since leptin is produced 
by adipose tissue and secretion is increased with obesity, this finding implies that ATT 
dysfunction is independent of leptin. This is an interesting finding and suggests that ATT 
inflammatory impairment occurs due to a mechanism distinct from T cell exhaustion associated 
with cancer in people with obesity. Further studies will be required to determine which soluble 
factors from obese SVF reduce effector cytokine secretion after TCR stimulus. Determining 
whether these inhibitory factor(s) are derived from immune cells, pre-adipocytes, or endothelial 
cells will be the immediate next step. 
It is still unknown whether ATT impairment in obese mice and humans is advantageous 
or inhibits the resolution of chronic low-grade inflammation in adipose tissue. On one hand, 
decreased secretion of Th1 and Th17 associated cytokines would reduce the inflammatory tenor 
of obese individuals. Alternatively, unresolved T cell stimulation through the TCR would result 
in a lack of inhibitory signals to macrophages that would reduce their inflammatory response. It 
has been shown that weight loss restores T cell function, and this coincides with improved 
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insulin sensitivity (104). Further studies are needed to determine which soluble factors are 
responsible for ATT impairment and the precise point proximally downstream of the TCR where 
signaling is impaired. This will be of significant importance even if T cell impairment is not 
essential for obesity-induced chronic low-grade inflammation and impairment is beneficial for 
metabolic diseases. Since lymphatic T cells in obese individuals also seem to have impaired 
inflammatory characteristics that lead to increased cancer risk, decreased response to viral 
infections such as influenza, and decreased vaccine immunogenicity (29, 143, 144). Therefore, 
finding the soluble factors that lead to ATT cell impairment in obese individuals may be 
important information for resolving T cell-mediated impairments outside of adipose tissue in 
obese patients.  
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Chapter 4: Adipose Tissue T Cell Heterogeneity Revealed by Single Cell RNA Sequencing 	
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Abstract 
 Determining the compositional and functional diversity of ATT cells will be important 
for understanding their contribution to homeostasis or inflammation in lean and obese 
conditions. Different subtypes of ATTs such as Tregs or Tconvs could influence the 
inflammatory tenure of adipose tissue. Additionally, localized environmental factors could be 
responsible for gene expression, function, and heterogeneity of ATTs.  To assess these 
measurements of heterogeneity, we used single cell RNA sequencing of sorted CD3+ ATT cells 
from three distinct white adipose tissue depots.  We found that within a single depot, there are 
multiple ATT cell subsets that expand beyond Tconv, Treg, and CD8+ groups described in 
Chapter 3. Not only can we define naïve and memory subsets, we identified ILC3s, progenitors, 
and natural killer cells within the total CD3+ fraction. The frequency of each of these populations 
depended upon the depot in which they reside, and whether they were derived from mice fed ND 
or HFD. Gene expression analysis suggests ATTs in lean eWAT and iWAT are basally activated 
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to a greater extent than oWAT. HFD feeding also led to differential gene expression from cells in 
ND depots. CD4 T cell subsets from obese eWAT were enriched for CD8+ T cell exhaustion 
associated with chronic LCMV and terminal exhaustion after performing GSEA pathway 
analysis. We identified Btla, Nlrc3, Dusp6, and Dicer1 as genes that could be contributing to 
exhaustion via co-inhibitory receptor expression, inhibition of TCR signaling, and translation 
regulation. Assessing these mechanisms of impairment further will be important for 
understanding ATT dysfunction and their influence on systemic metabolism. 
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Introduction 
Several factors could contribute to ATT inflammatory impairments described in Chapter 
3, however, limitations in ATT cell number and substrate impeded our progress towards 
understanding the mechanistic underpinnings of dysfunction. One hypothesis is that localized 
environmental signals may influence ATT function. Adipose tissue depots have structural and 
function differences some of which depend upon anatomical location. Since visceral depots 
(eWAT and oWAT) are responsible for obesity mediated chronic low-grade inflammation while 
subcutaneous (iWAT) expansion is protective. Therefore, investigating depot differences in ATT 
function lean and obese states may provide insight into mechanistic differences in eWAT ATTs.  
In addition to depot differences, obesity is known to regulate the frequency of immune 
cell populations and their functions. However, ATT Activation assays performed in Chapter 3 
did not clearly distinguish in ATT subpopulations frequencies between lean and obese mice. 
Recent studies have used single cell RNA sequencing technology to assess the composition of 
adipose tissue leukocytes in relation to obesity and insulin sensitivity in humans and mice. 
TREM2+ lipid-associated macrophages were identified as induced in HFD fed mice suggesting a 
specific ATM phenotype that is distinct form the M1/M2 axis (145).  CD9+ ATMs were 
identified in mouse and human adipose tissue as potential mediators of diabetes and obesity 
(108). Single cell analysis of stromal cells from obese humans identified numerous myeloid and 
lymphoid populations that differ based on diabetes status (146).  
Most of these studies focus on total stromal cell populations of which T cells are a small 
proportion (10-25%), which decreases the power by which subtypes of ATT’s can be identified. 
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Several studies have focused on the diversity of T cells using single cell technology that have 
provided insight into molecular diversification of tissue resident Tregs. This study shows that 
genes expression of tissue Tregs originating in eWAT, colon, or muscle is significantly different 
(147). Therefore, localized signals from tissue of origin can influence gene expression of resident 
immune cells. SC RNAseq analysis has also focused on ATTs after short-term ketogenic diet 
feeding. One week of ketogenic diet changed almost doubled the frequency of ATT and B cell 
populations. Additionally, ketogenic diet increased transcription of PPARα, S1pr1, Itgae, and 
Lgals3 in γδT cells, which implicates changes in pro-longevity, cell trafficking, migration, and 
cell adhesion (148).  Despite the depth of information that can be extracted from these SC 
RNAseq analyses, there are several gaps that we wanted to address with our own big data 
collection and analysis. We wanted to assess how different white adipose tissue depots influence 
the ATT immune compartment, how chronic HFD feeding for 12 weeks influences gene 
expression and subpopulation composition, and acquire a depth of sequencing to provide insight 
into intracellular mechanisms that could be contributing to ATT impairment in both Tconv and 
CD8+ populations.  
 Cellular and functional heterogeneity of T cells has been demonstrated in lymphatic and 
adipose tissues. We hypothesized that regulation of these populations with HFD feeding could be 
contributing to the ATT impairment phenotype. Although we separately assessed Tconv, CD8+, 
and Treg cells in Chapter 3, each of these groups are probably composed on several smaller 
subsets of ATTs. Each of these three populations could also contain γδ T or innate lymphoid 
cells (ILC). γδ T cells are usually found in mucosal or barrier tissue sites and protect the host 
from infection, however these cells have also been found to play an important role in adipose 
tissue homeostasis.  Adipose tissue γδ T cells in visceral fat and are important for maintaining 
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Treg populations and are responsible for maintaining core body temperate after cold exposure 
(149).  Innate lymphoid cells (ILC) are another subset of T cells found in adipose tissue, 
including natural killer (NK) cells. Interestingly, adipose tissue NK cells lose their cytotoxic 
killing strength in obese adipose tissue similar to defects in inflammatory capacity we observed 
in CD8+ ATTs (150). They lack TCR expression and do not provide adaptive immune responses 
to specific antigens. However, their transcription factors and effector cytokines and cytolytic 
mediators similar Tconv and CD8+ cells. ILC1, ILC2, and ILC3, and NK cells are smaller 
subsets of ILCs with properties that mirror Th1, Th2, and Th17 Tconv and CD8+ cells, 
respectively. Natural killer T cells (NKT) have been found in adipose tissue and are protective 
against obesity induced chronic low grade inflammation (151). Instead of TCRs, invariant NKT 
cells recognize lipid antigens presented on Cd1d molecules instead of MHCII.  
In addition to heterogeneity of T cell subsets, adipose tissue depots have their own 
distinct functional differences due to local environmental signals. We hypothesized that white 
adipose tissue ATTs would have disparate compositions and gene expression depending upon 
anatomical locations from which the depot was collected. We decided to assess differences in 
three white adipose tissue depots. Omentum (oWAT) and eWAT were assessed to determine 
potential differences between visceral WAT. Additionally, ATTs from iWAT were collected to 
determine differences in ATT function subcutaneous adipose tissue. We found that sorting CD3+ 
cells increased the depth of sequencing in order for us to assess 9 separate clusters of ATTs. Diet 
and depot also regulated gene expression and pathway analysis, and ultimately led to specific 
targets of impairment in obese eWAT ATTs.   
Despite evidence for multiple subsets of ATTs in adipose tissue, few studies have 
performed expression analysis on lean or obese mice. Although adipose tissue immune cells have 
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been analyzed using SC RNAseq, previous studies have failed to obtain a high enough 
proportion of cells in single cell datasets needed to distinguish these smaller populations from 
gross CD8+ and CD4+ cells. Differences in state of activation are also of interest for true Tconv 
and CD8+ subsets. Although it has been shown that ATTs mostly have a memory phenotype, 
with few naïve cells, confirming this with an unbiased analysis would be of interest and could 
contribute to differences in ATT inflammatory capacity seen with HFD feeding (80).  In order to 
achieve deeper sequencing of ATT populations, we decided to sort CD3+ cells from SVF prior to 
single cell RNA sequencing analysis. This analysis allowed us to identify 9 distinct clusters of 
ATTs. Diet and depot also regulated gene expression and pathway analysis, and ultimately led to 
specific targets of impairment in obese eWAT ATTs.  
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Materials and Methods 
Mice 
Male mice on a C57B/6J background were purchased from Jackson Laboratory (000664). At 6 
weeks of age, mice were either kept on normal diet (ND; LabDiet PicoLab 5L0D 4.09kcal/gm 
29.8% protein, 13.4% fat, 56.7% carbohydrate) or switched to high fat diet (HFD; Research 
Diets D12492, 5.24kcal/gm 20% protein, 60% fat, 20% carbohydrate) for 12 weeks.  
ATT cell acquisition for sequencing 
The stromal vascular fraction (SVF) was isolated from whole adipose tissue as previously 
described (Chapter 2 Materials and Methods). CD3+ cells were sorted from 3 adipose tissue 
depots (eWAT, oWAT, and iWAT) from lean and obese mice. ATT cells were stained for FACS 
sorting using a Sony MA900 (see Table 4A for antibody details).  
Table 4A: Antibodies used for CD3+ ATT cell sorting.  
Antigen/Target Fluorophore Clone Company  Catalog #  
Live/dead Brilliant Violet-450 N/A Invitrogen  L34955  
CD45 APC 30-F11 
 
eBioscience  47-0451-82  
CD3 PE 145-2C11 eBioscience  12-0031-82  
 
Single Cell RNA sequencing 
CD3+ cells were collected in duplicate from ND and HFD eWAT, oWAT, and iWAT. Samples 
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were taken to the University of Michigan Advanced genomics core for library construction with 
the 10x Genomics platform (V2.0) and sequencing (Next-Seq).  
Data analysis 
Count matrixes were generated with Cellranger (10x Genomics) with post-processing with 
Seurat (v3) (152). Ribosomal and mitochondrial genes were removed prior to analysis and cells 
were filtered to remove cells with <200 unique genes identified.  Following transformation of the 
data, integrated analysis of all the depots and conditions was performed. ATT clusters were 
defined by identifying genes significantly enriched in each cluster compared to the other cells 
independent of diet and depot and comparing with gene profiles in the Immunological Genome 
Project (ImmGen) (153).   Differentially expressed (DE) genes were identified using Wilcoxon 
rank sum test adjusting for false discovery rate.  DE genes were defined as adjusted p-value of 
<0.05 and log2 Fold changes >0.3.  Gene pathway enrichment was analyzed using the biological 
pathways PATHER gene ontology (GO) database. Data sets were then separated by depot of 
origin and DE genes for ND and HFD ATTs were assessed for each cluster and each depot.  
Additional packages used for data analysis to try to remove contaminants include Cellbender, 
Liger, and SoupX (154-156). 
Btla analysis 
The stromal vascular fraction (SVF) was isolated from whole eWAT as previously described 
(Chapter 2 Materials and Methods). CD3+ cells were sorted from four lean and obese mice. ATT 
cells were stained for FACS analysis and sorting using a Sony MA900. Btla, CD4, and CD8 
antibodies were added into the sorted cells so BTLA expression could be analyzed on 
subpopulations of CD3+ ATTs. Sorted CD3+ cells were taken for RNA extraction using a Qiagen 
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RNA micro kit. cDNA was generated from RNA using high-capacity cDNA reverse 
transcription kits (Applied Biosystems). Power SYBR Green PCR Master Mix (Applied 
Biosystems) and the StepOnePlus System (Applied Biosystems) were used for real-time 
quantification PCR 
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Results 
Adipose tissue T cells are comprised of 9 distinct subsets 
SC RNAseq analysis shows that ATTs can be divided into more granular subpopulations 
than CD4+ Tconv, CD4+ Treg, CD8+, and double negative (DN) populations that we typically 
define by flow cytometry (Figure 4-1A). 12,447 cells from ND (n = 4 mice pooled) and 4,309 
cells from HFD (n = 2 mice pooled) were collected for SC RNAseq analysis. This allowed a 
much more detailed analysis of ATTs than previous SC RNAseq analysis on bulk CD45+ cells 
from adipose tissue. We defined each subset of CD3+ cells based upon the genes that were most 
enriched in each cluster using cell type specific genes delineated by literature and ImmGen 
(Figure 4-1B). A population of cells expressing markers of proliferation (Stmn1 and Mki67) was 
identified that expressed low levels of Cd4 and Cd8a consistent with their identification as 
double negative cells with immature/stem like properties (DNstem). CD4 Tregs (Foxp3), natural 
killer (NK) cells (Klra7), and ILCs (Tnfsf11) were identified (Figure 4-1C). CD4Trm, CD8Trm, 
and NK1 cells expressed Tbx1/Tbet consistent with a Th1 polarized T cells. ILCs were also 
further defined by Rorc expression consistent with identification as ILC3s.  Markers of 
activation, like pro-inflammatory cytokines and proliferation were used to gauge basal function 
of these subsets. CD4Trm, CD8Trm and NK1 cells expressed the highest levels of pro-
inflammatory cytokine genes (Ifng, Il2). The NK2 subcluster has characteristics of naïve T cells 
including expression of Sell and Dapl in the absence of Ifng and Il2. DNstem cells were the only 
population and proliferating in basal conditions (Figure 4-1F).  
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Figure 4-1 – SC RNAseq of CD45+ CD3+ cells reveals 9 distinct ATT subsets. 	
(A) TSNE plot of different ATT clusters based upon similarity of gene expression. 
(B) Each cluster was compared and enriched genes for each group were used to determine the identity of each 
group. This heatmap shows gene of interest used to determine each cluster is shown.  
(C) Violin plots showing gene expression markers associated with T cell and ILCs. 
(D) Violin plots of naïve and memory T cell markers 
(E) Violin plots of transcription factors used to distinguish Tconv and ILC subsets 
(F) Violin plots of effector cytokines and markers of proliferation used to classify T cell activation and 
inflammation of ATT subsets. 
A. B.
C.
E.
T cell subset identifiers
F. Activation markersTranscription Factors
D. Naive/Memory Markers
Figure 4-1
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Proportions of ATT subsets are dependent upon depot and diet  
ATTs from eWAT, iWAT, and oWAT all contained the 9 ATT clusters defined above (Figure 
4-2A). We wanted to assess how diet regulated the proportion of ATT subtypes (Figure 4-2B). 
We have previously assessed total CD4 Tconv, CD4 Treg, total CD8+, and DN populations in 
eWAT of ND and HFD fed mice using flow cytometry. In HFD mice, we see increased 
frequency of total CD3+ ATTs, with increased CD8+, decreased Treg, and unchanged total CD4+ 
Tconv and DN populations (Figure 4-2C). We see similar trends in eWAT ATT subpopulations 
defined by SC RNAseq of CD3+ cells (Figure 4-2D). In eWAT from HFD mice, the proportion 
of CD4Treg decrease and CD8Trm increase relative to ND mice. DN populations like NK1 and 
NK2 are not changed with HFD, while ILC3s decrease. Naïve cell populations also decrease, 
consistent with previous studies (80). The proportion of CD4Trm cells slightly decreased in HFD 
mice and DNstem cells significantly increase.  
Subpopulation changes with HFD are also dependent upon depot of origin. Notably, iWAT has 
fewer naïve cells (CD4Nv and CD8Nv) and ILC3s compared to eWAT, while CD4Trm and NK1 
populations are more prominent in iWAT. The decreases in CD4Tregs and increases in CD8Trm 
observed in eWAT are not seen in iWAT. The ATT subtypes in oWAT differ significantly from 
both iWAT and eWAT.  oWAT is enriched for both CD4Nv and CD8Nv ATT types and diet 
type has less pronounced changes in the frequencies of the oWAT subpopulations.  
Gene expression differences in ATT subsets suggest iWAT and eWAT have higher gene 
expression of inflammatory cytokines like Ifng and Il2 than oWAT. (Figure 4-2F). Overall 
oWAT ATTs seem to be in a quiescent state compared to the other depots.  eWAT and iWAT 
have higher expression of cytokine (Il2, Ifng, Il10) and chemokine (Ccl4), genes as well as genes 
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downstream of the TCR signaling cascade (Jun). However, ILC3 cells in oWAT may be more 
active in homeostatic conditions than those in eWAT and iWAT since they have higher 
expression of Jun, Ccr6, and Cd83.  
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Figure 4-2 – Depot and diet influence compostion and function of ATTs. 
(A) TSNE plots of ATTs from eWAT, iWAT, and oWAT 
(B) TSE plots of ATTs from ND and HFD (12weeks of feeding) from eWAT 
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(C) Flow cytometry assessment of ATT cell composition with 12 weeks of HFD feeding 
(D) SC RNAseq assessment of ATT cell composition in ND and HFD fed mice after 12 weeks of feeding. 
(E) Heatmap illustrating gene expression differences in each ATT cluster depending upon depot of origin. E = 
eWAT, I = iWAT, O =oWAT 
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Gene expression of CD4+ and CD8+ ATTs are differentially regulated by depot of origin  
DE genes from eWAT, oWAT, and iWAT CD8Trm cells were assessed by pathway 
enrichment analysis to identify functional differences between depots. Compared with iWAT and 
eWAT, oWAT depots had few DE genes to generate statistically significantly upregulated 
pathways suggesting that the oWAT signals may not influence the function of CD8Trm 
specifically.  Differences between iWAT and eWAT provided insight into their function. We 
were able to assess 158 genes enriched in iWAT and 1,329 enriched genes in eWAT when 
comparing the CD8Trm clusters, which yielded significantly differentiated signaling pathways in 
PANTHER. CD8Trm cells from eWAT were enriched in signaling pathways suggesting 
suppressed inflammation. Regulation of chromatin silencing and regulation of T cell 
differentiation were enriched in eWAT CD8Trm, whereas T helper differentiation, catalytic 
activity, and intracellular signal transduction were enriched in iWAT CD8Trm (Figure 4-3A).  
A similar trend towards anti-inflammatory/suppressed eWAT phenotype relative to 
iWAT was observed for CD4Trm cells. The top 6 most significantly enriched pathways in 
eWAT included regulation of type 2 immune responses, peptide-tyrosine dephosphorylation, and 
negative regulation of DNA recombination. Pathways enriched in iWAT included positive 
regulation of JUN kinase, hormone-mediated signaling pathway, and response to cytokine 
demonstrating activation of TCR signaling pathways and hormone responses (Figure 4-3B).  
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Figure 4-3 – Memory cell pathway enrichment differences in eWAT and iWAT 	
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(A) Top 6 DE pathways in CD4Trm cells from iWAT and eWAT determined by PANTHER biological 
processes. 
(B) Top 6 DE pathways in CD8Trm cells from iWAT and eWAT determined by PANTHER biological 
processes. 
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Differences in CD4Nv cells were also of interest and provide insight into the functional 
capacity naïve ATT cells. In eWAT, CD4Nv cells have enriched expression of glycolipid 
metabolic process, and negative regulation of RNA polymerase II. iWAT CD4Nv cells once 
again were enriched for pathways indicating a more active pro-inflammatory pathways such as 
cellular response to cytokine stimulus, positive regulation of transcription, and positive 
regulation of molecular function (Figure 4-4A).  Finally, CD8Nv cells from eWAT and iWAT 
both suggested suppressed inflammatory capacity, however they are potentially related to 
separate mechanisms (Figure 4-4B). In eWAT CD8Nv histone H3-K4 trimethylation and 
chromosome condensation are enriched, while in iWAT CD8Nv negative regulation of response 
to stimulus, regulation of RNA polymerase II, and negative regulation of metabolic processes are 
enriched. In sum, differences in CD4 and CD8 subsets indicates that eWAT ATTs have 
suppressed inflammatory characteristics compared to iWAT resident ATTs. 
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Figure 4-4 - Naïve cell pathway enrichment differences in eWAT and iWAT 
(A) Top 4-6 DE pathways in CD4Nv cells from iWAT and eWAT determined by PANTHER biological 
processes. 
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(B) Top 5-6 DE pathways in CD8Nv cells from iWAT and eWAT determined by PANTHER biological 
processes. 
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Obesity mediated CD4Trm ATT impairment is associated with T cell exhaustion 
 In addition to gene expression differences between depots, differences between ND and 
HFD mice was of vital interest.  Understanding mechanisms responsible for ATT impairment 
seen in Chapter 3 was explored by comparing each of the nine ATT subsets in ND and HFD 
eWAT. DE genes in ND eWAT CD8Trm cells indicated enrichment of inflammatory and 
proliferation pathways such as IL1b production, positive regulation of T cell proliferation, and 
positive regulation of GTPase activity (Figure 4-5A). CD4Trm cells in ND eWAT also are 
enriched for genes related to T cell activation and inflammation including cellular response to 
GM-CSF, activation of MAPKKK activity, and T cell co-stimulation genes (Figure 4-5B). 
Similar to other reports, our ability to detect significant DE genes induced in HFD ATT subsets 
was limited by significant ambient contamination of the HFD datasets with macrophage specific 
genes (e.g. Cd84, Lyz2) (148).  This in combination with fewer HFD ATTs that were sequenced 
resulted in very few DE genes enriched in HFD ATTs. For example, in the CD4Trm cluster 
where ND v HFD cells were compared, there were 1,578 DE genes in ND cells and 34 DE genes 
in HFD ATTs where significance was defined by an adjusted p-value of <0.05.  However, 
comparing 2 clusters within a single diet yielded better results. We decided to compare CD4Trm 
v CD4Nv to differentiate function differences between memory and naïve ATTs in eWAT 
(Figure 4-5C). We identified CD4Trm and CD8Trm cells in HFD eWAT resembled exhaustion 
of CD4+ and CD8+ T cells as defined in the context of chronic LCMV infection, respectively 
(157). Several individual genes enriched in HFD ATTs were significantly enriched and point to 
potential mechanisms of dysfunction. We identified specific genes of interest that could 
contribute to exhaustion including: Btla, Nlrc3, and Dicer1. Each gene would contribute to 
exhaustion using different cellular mechanisms and caused by disparate triggers including 
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intracellular TCR signaling regulation, co-inhibitory receptor expression, and mRNA regulation 
(Figure 4-5D). Additionally, genes responsible for signaling downstream of the TCR, such as 
Map4k3, Nfkb1, Akt3, and Ifng were all enriched in ND ATT subsets. We sorted CD3+ ATTs 
from ND and HFD eWAT and performed qPCR on candidate genes that could be contributing to 
T cell exhaustion. We observed an increase of Btla expression in HFD derived ATTs, and 
expression was not detected in ND derived cells (Figure 4-5E). Additionally, BTLA expression 
was assessed by flow cytometry, where increased frequency was observed in total CD4+ ATT 
and DN populations. In sum, diet influences gene expression differences in eWAT derived 
CD4Trm and CD8Trm clusters obesity inducing T cell exhaustion signatures in CD4Trm and 
Cd8Trm cells.  
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Figure 4-5 – HFD induces an exhaustion phenotype in CD4Trm and CD8Trm cells 
(A) Top 6 PANTHER pathways enriched in ND v HFD CD8Trm, 
(B) Top 6	PANTHER	pathways	enriched	in	ND	v	HFD	CD4Trm, 
(C) GSEA analysis of HFD CD4Trm and CD9Trm gene expression compared to previously published 
transcriptomes of exhausted CD4+ and CD8+ T cells respectively, 
(D) Gene expression of potential target genes responsible for T cell exhaustion and canonical downstream TCR 
proteins in ND and in HFD ATTs. H = HFD, N = ND 
(E) qPCR of  Btla from FACS sorted CD3+ eWAT ATTs, 
(F) Flow cytometry analysis of BTLA expression on CD4+ and DN eWAT ATTs. 
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Discussion 
SC RNA sequencing has provided us multiple insights into the heterogeneity of adipose 
tissue stromal cells. In this chapter, we focus on the diversity of ATTs based on depot and 
chronic HFD feeding in mice, which has not been the focus of previous studies in the field. 
Previous reports have evaluated changes in ATT after 1 week of ketogenic diet where 
pronounced expansion of NK, ILC, and γδ T cells and reduced IL1b expression was observed 
(148).  Although early expansion of ATTs is metabolically beneficial after 1 week of ketogenic 
diet, chronic feeding results in insulin resistance similar to HFD. However, SC RNA analysis 
was not used to evaluate the composition or gene expression of ATTs during an insulin resistant 
state. 
By sorting CD3+ ATTs from mice fed HFD for 12 weeks and age matched ND controls 
we were able to sequence more than 15,000 cells and gain in depth insight into this rare cell 
population. We were able to identify 9 subsets of ATTs that overlap with populations that have 
been implicated in obesity mediated chronic low-grade inflammation literature. Although there 
were some limitations in analyzing the sequencing data, such as macrophage gene contamination 
and decreased depth of sequencing in HFD samples, we were still able to make conclusions 
regarding the composition and gene signatures of CD3+ ATTs. 
 Using basic glycoprotein and transcription factor expression, we were able to broadly 
identify CD4+ Tconv, CD4+ Treg, CD8+, and double negative (DN) cell groups that we have 
observed with flow cytometry. However we observed multiple subsets of cells reside within 
these larger classifications. Sell, Cd44, and Cd69 identified naïve and tissue resident memory 
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cells within both CD4+ Tconv and CD8+ positive subsets. In addition, we observed several 
populations of cells that comprise the DN compartment, including ILCs. We were surprised to 
ILC subsets in our analysis since they canonically do not express CD3. Whether there was a 
problem with our sort, or there are ILC-like cells in adipose tissue that have similar gene 
expression is something that will need to be assessed in later studies. Furthermore, previous 
studies have implicated adipose tissue ILC2 cells as important mediators of homeostasis in lean 
tissue, but few studies implicate ILC3 (158). Interestingly, DE genes in this cluster also 
resembled γδ T cells when top 200 genes were run through ImmGen. Therefore γδ T cells may 
also be integrated in this cluster and further subdivision would reveal both ILC2 and γδ T cells in 
this subcluster (149). Two NK populations were observed, however they lacked expression of 
the invariant NKT marker Cd1d. The NK1 cluster has higher expression of inflammatory 
cytokines like Ifng and Il2 while NK2 cells seem to be either quiescent or inactivated based on 
the expression of naïve T cell markers like Sell and Dapl. ILC3s also seem to comprise the DN 
subpopulation and were more transcriptionally different from the other clusters. In addition to 
these known ATT subpopulations, we identified another population that has yet to be explored. 
DNstem population contained stem cell like properties and expressed Stmn1. This cluster was 
only population that displayed proliferative properties without stimulation and expressed Mki67. 
It was also observed in ketogenic diet studies where it was identified as a multi-lineage 
proliferative population (148). 
Diet and depot differences were also prominently found with the SC RNAseq analysis. 
ND and HFD ATTs were sequenced from eWAT, iWAT, and oWAT. The proportion of each 9 
subclusters was calculated in each depot from ND and HFD mice. The regulation of each eWAT 
population was compared to analysis performed using flow cytometry of ND and HFD mice fed 
129		
for 12 weeks to determine whether our SC RNAseq analysis was consistent with previous 
studies.  Flow and SC RNAseq of eWAT ATT analysis remained consistent for some 
populations. For example, CD8Trm cells increase and Treg decrease with HFD feeding in both 
flow and sequencing analyses. Additionally, CD4Nv and CD8Nv clusters decrease with HFD in 
SCRNA as has been shown in previous flow analysis (80). However, there were also some 
inconsistencies. Tconv cells in flow analysis are not significantly changes in flow analysis. Since 
we know that CD4Nv decrease, it was surprising to see that CD4Trm also decreased in the SC 
RNAseq analysis. Clarifying whether net decrease of Tconv cells seen in SC RNAseq is 
biologically accurate, or whether subsets other than CD4Nv and CD4Trm contribute total CD4 
ATT will need to be determined in future studies. The DN cells are also more difficult to 
interpret. While NK1 and NK2 populations were unchanged with HFD feeding, ILC3s 
decreased, but DNstem increased. Having a better understanding of DN stem and their activity in 
ND and HFD mice will be important for understanding ATT regulation in the future. It is also 
unclear where double positive T cells (DPT) observed in flow analysis fit into the clusters 
delineated using SC RNAseq. We hypothesize that DNstem have the capacity to develop into 
DPTs and CD4+ cells in obese mice, and the function of this population should be explored 
further.  
Differences in subpopulation regulation were also distinct depending upon depot of 
origin. Compared to eWAT, iWAT had fewer Tregs and HFD did not significantly change their 
composition. There were also fewer iWAT ILC3s and CD8Trm were not increased with HFD 
feeding in iWAT feeding. oWAT differed significantly from eWAT and iWAT. There were 
significantly more CD4Nv and CD8Nv cells in oWAT than the other depots. There were also 
fewer changes to ATT subpopulation composition with HFD. oWAT is known to have a higher 
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density of fat associated lymphoid clusters (FALCs), lymph node-like structures where T cells 
and B cells aggregate around APCs (132). These structures network with the lymphatic system, 
making access to naïve T cells more abundant that depots like eWAT where FALCs are scarce. 
eWAT has also been shown to be a reservoir for memory T cells developed against viral 
infections (123). Distribution and regulation of ATT subpopulations correlate with functional 
differences in eWAT and oWAT. ATT activation assays performed on ND and HFD ATTs 
indicated that HFD induced ATT impairment was specific to eWAT Tconv and CD8+ cells, 
since oWAT ATTs were able to upregulate CD25+ after co-stimulation with αCD3/CD28. 
Exploring gene expression differences between each cluster and depot could explain these 
functional differences. Basal gene expression analysis showed that ATTs from oWAT did not 
express genes indicating activation, such as Ifng, Il2, Il10, and Jun. Since there are more naïve 
cells in oWAT, and inflammatory gene expression is low, it seems that maintaining quiescence 
helps maintain ATT activation in HFD conditions. 
We assessed CD8Trm, CD8Nv, CD4Trm, and CD4Nv populations in more depth, since 
these groups are most likely the bulk of CD8+ and CD4+ Tconv cells were studied in chapter 3. 
DE genes from eWAT and iWAT CD8Trm were analyzed using PATHER biological processes 
analysis to determine pathway enrichment for each group. eWAT CD8Trm cells have properties 
of suppressed inflammation including regulation of chromatin silencing and regulation of T cell 
differentiation. In iWAT, pathways related to T helper differentiation, catalytic activity, and 
intracellular signal transduction were enriched, suggesting CD8Trm have pro-inflammatory 
properties. An anti-inflammatory/suppressed eWAT phenotype was observed in CD4Trm cells, 
however significantly enriched pathways were different than CD8Trm cells. In CD4Trm cells, 
pathways related to the regulation of type 2 immune responses, peptide-tyrosine 
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dephosphorylation, and negative regulation of DNA recombination were observed in eWAT, 
while pathways related to the positive regulation of JUN kinase, hormone-mediated signaling 
pathway, and response to cytokine consistent with activation of TCR signaling pathways were 
observed in iWAT. This suggests impairment of HFD CD4 and CD8 ATTs seen in obese eWAT 
may be induced by separate mechanisms. Naïve cell populations also provide insight into 
differences due to depot. CD8Nv cells from eWAT were enriched for histone H3-K4 
trimethylation and chromosome condensation, while in iWAT negative regulation of response to 
stimulus, regulation of RNA polymerase II, and negative regulation of metabolic processes. 
Since these cells are naïve, it would be expected that they would be quiescent and not upregulate 
pathways involved in activation or inflammation. However, enrichment of anti-inflammatory 
pathways observed in naïve cells was disparate from those seen in CD8Trm from eWAT. 
Whether inflammatory suppression in naïve cells is due to quiescent states, and whether 
differential suppression is due to inherent cellular characteristics or environmental surroundings 
would be interesting to address.  
Finally, we compared gene expression of ND and HFD ATTs from eWAT to gain insight 
into potential mechanisms of inflammatory impairment. We were particularly interested in 
assessing clusters of cells that compose Tconv and CD8+ populations that we tested in Chapter 
3, and focused on CD8Trm and CD4Trm since they are prominent in HFD adipose tissue. ATTs 
in obese tissue had few genes differentially regulated compared to ND ATTs. Since there were 
fewer HFD ATTs sequenced, limited DE genes could be due to decreased depth of sequencing. 
To overcome this limitation we compared CD4Trm and CD4Nv cells in eWAT of ND and HFD 
adipose tissue. When DE genes upregulated in HFD CD4Trm compared to ND CD4Trm, and 
HFD CD8Trm to ND CD8Trm, we observed enrichment for GSEA pathways related to CD4+ 
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and CD8+ T cell exhaustion, respectively. HFD CD4Trm and CD8Trm relationship to T cell 
exhaustion was seen when compared to gene sets related to chronic LCMV infection (157). The 
hallmarks of T cell exhaustion include overexpression of cell surface inhibitory markers, 
downregulation of gene transcription of molecules involved in signaling from TCR and cytokine 
receptors, and transnationally, metabolic and bioenergetics deficiencies (159). Specific genes 
that could be responsible for T cell exhaustion include Btla, Nlrc3, Dusp6, and Dicer1 (160-
162). With qPCR of sorted eWAT ATTs from ND and HFD mice, we show that Btla is 
significantly upregulated in ATTs from HFD mice. Flow cytometry confirmed that HFD CD4+ 
and DN ATTs have significantly increased expression of BTLA in these subpopulations. 
Investigating whether BTLA blockade could reverse ATT exhaustion should be investigated 
further. Additionally, other predicted mechanisms and their influence on TCR signaling should 
be performed in future studies to elucidate the mechanisms responsible for ATT exhaustion. 
Further studies exploring whether other ATT clusters from obese mice have similar exhaustion 
phenotypes and if clusters in iWAT or oWAT have similar characteristics will also provide 
insight into functional heterogeneity of ATTs. 
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Chapter 5: Conclusions and Future Directions 
Summary 
 Prior to starting this work, we had the goal of resolving several gaps in knowledge related 
to ATT biology including the nature of activating signals from myeloid cells, the capacity of 
ATT to respond to activating signals, and diversity of ATTs dependent upon depot of dietary 
conditions. The results of the work presented in this dissertation fills these gaps and challenges 
current dogma that adipose tissue T cells (ATTs) are activated in terms of cytokine secretion and 
proliferation in the context of obesity. In chapter 2, we found that there were profound systemic 
metabolic and inflammatory differences in transgenic mouse models depending on whether 
MHCII is deleted from ATMs or ATDCs expresses MHCII. Previous studies have shown that 
LysMCre x MHCIIfl/fl mice that lack MHCII expressing ATMs have improved GTT, ITT, and 
reduced pro-inflammatory CD11c+ ATMs with HFD feeding. However, with loss of MCHII on 
ATDCs there is a gross dysregulation of ATT cells, and unchanged systemic GTT and ITT in 
obese mice.  Although systemic metabolic dysfunction may be the result of MHCII deficiency in 
organs other an adipose tissue, this study suggests that ATDCs are required for providing signals 
to maintain CD4+ and CD8+ ATT homeostasis. ATDCs are more efficient APCs and loss of 
MHCII signals required for tonic signaling is also detrimental to chronic low grade inflammation 
and insulin sensitivity in obese mice.  
In Chapter 3, we hypothesized that ATTs cells have tissue resident functions independent 
of adipose tissue APCs and influence obesity mediated inflammation. ATTs are regulated in the 
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complex heterogeneous niche of white adipose tissue, and obesity regulates their function. 
Unlike previous findings, we show that activation in terms of cellular markers, proliferation, and 
cytokine secretion is impaired in obese murine eWAT and human oWAT.  Antigen presentation 
is required for ATT impairment to occur over the course of 12 weeks of HFD feeding, and 
soluble mediators from obese SVF drive impairment phenotypes of ATT activation. Although 
the T cell exhaustion marker PD1 was increase on CD8+ ATTs in obese adipose tissue, PD1 
blockade failed to reverse ATT inflammatory impairment.  
In Chapter 4, we utilized single cell RNA sequencing to evaluate potential signaling 
pathways and gene expression regulation to determine possible mechanisms of dysfunction. 
Since obesity influences cellular metabolism and inflammation, there are multiple pathways that 
could influence obesity induced ATT impairment. In addition to finding several gene targets of 
ATT impairment in murine eWAT, we found ATT context is important, as oWAT show no 
impairments in ATT activation and inflammation. However, in eWAT we identified there were 
several possible mechanisms to explain ATT impairment.  CD4Trm and CD8Trm in obese mice 
are enriched for CD4+ and CD8+ exhaustion pathways identified in the context of chronic LCMV 
infection. We confirmed with both transcriptional and protein levels that BTLA is increased in 
HFD ATTs, and perusing BLTA blockade will be an interesting target to peruse in the future. 
Additionally, inflammasome and mRNA regulating proteins like Nlrc3 and Dicer1 will be 
interesting targets to investigate further. Verifying Nlrc3, or Dicer1 upregulation and potential 
transgenic mouse models will help assess whether ATT impairment in obese adipose tissue is 
physiologically beneficial or detrimental.  
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Figure 5-1 – Concluding model of obesity induced ATT exhaustion 
 
Objectives, Major Findings, and Implications for Chapter 2 
ATM mediated antigen presentation has been implicated in ATT activation, 
inflammation, and insulin resistance in obese adipose tissue. This suggests the network between 
innate and adaptive immune systems is important in regulation of chronic low-grade 
inflammation. (80). However, dendritic cells, not macrophages, are the primary antigen-
presenting cell subtype in lymphoid organs while their antigen presenting capabilities was 
unknown in adipose tissue. Therefore, our objective was to assess ATDC to ATT networks and 
determine whether ATDC are responsible for ATT mediated inflammation as is seen with 
ATMs, or whether they maintain anti-inflammatory signals in the context of obesity. We 
hypothesized that ATDCs and ATMs were responsible for activation and maintenance of Tregs 
and pro-inflammatory Tconv cells, respectively. 
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Our findings showed that ATMs and ATDCs have distinct differences in ATT 
maintenance, however differential polarization of CD4 T cells does not seem to be a primary 
mechanism. Instead, it seems that ATDCs are more efficient APCs and are better at activating T 
cells with small concentrations of antigen. These findings have several important implications 
for interpreting previous studies of MHCII mediated ATT activation and future directions. While 
reducing antigen presentation with the MHCIIfl/fl x LysMCre (MMKO) does not significantly 
regulate ATT homeostasis, MHCIIfl/fl x CD11cCre (M11cKO) results in gross Tconv, Treg, and 
CD8+ dysregulation. Therefore, in MMKO mice, MHCII presentation by ATDCs is required for 
maintaining tonic signals needed to maintain ATT homeostasis.  However knocking out MHCII 
presentation by highly efficient ATDCs, as seen in M11cKO, removes signals needed to 
maintain CD4+ Tconv and Treg ATTs. Therefore, breaking the network connecting innate and 
adaptive immune systems through antigen presentation is effective at reducing obesity induced 
inflammation and improving systemic metabolism only when ATDC MHCII can maintain tonic 
signals required fro CD4 homeostasis. 
This study adds to previous literature implicating ATDCs as contributors to chronic low-
grade inflammation in obese adipose tissue. ATDC mediated MHCII expression does not 
significantly alter glucose or insulin tolerance in ND or HFD mice. This suggests that T cell 
homeostasis may not be essential for adipose tissue inflammation, factors like CCR7 mediated 
ATDC trafficking and signals from PPARy by are more critical components of chronic low-
grade inflammation.  
There are several important limitations of using MHCIIfl/fl x CD11cCre (M11cKO) mice. 
Although it was our intention to assess ATDC mediated ATT inflammation and insulin 
resistance in obese mice, it is clear that MCHII signals are also knocked down in other cell types 
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like macrophages. Additionally disruption of dendritic cell mediated antigen presentation in 
other tissues like the gut makes conclusions regarding systemic inflammatory and metabolic 
measures unclear.  While gene expression of Il1b and Ccl2 in adipose tissue is not reduced in 
HFD M11cKO mice, it is unclear whether adipose tissue specific inflammation contributes to 
statistically unchanged GTT and ITT results in HFD WT and M11cKO cohorts. Dendritic cell 
mediated antigen presentation is important for gut homeostasis, and M11cKO resulted in rectal 
prolapse and GI inflammation that makes interpreting systemic inflammation and metabolism 
difficult (113). Experimentally, there are several studies that would help strengthen this study. 
Evaluating T cell specific inflammatory cytokines such as IL2 and IFNy from in the blood and 
gut would make it clear which tissues contribute to inflammation in M11cKO mice. 
Additionally, assessing intracellular cytokine production/polarization and proliferation of ATTs 
would help determine function differences in WT and M11cKO mice. Unfortunately, there are 
not technologies that allow us to knockdown MHCII specific to adipose tissue, but SC RNAseq 
may reveal better Cre drivers for ATDC specific MHCII knockout mice in the future.  
This study raises important questions that should be addressed in the future including: 
1) What mechanism(s) drives increase of CD8+ and CD4+ CD8+ double positive ATTs in 
M11cKO mice? We hypothesize that DNstem cells identified in Chapter 4 may be 
responsible for ATT expansion, and understanding their function may be important.  
2) Does the inflammatory capacity of M11cKO ATTs differ from WT ATTs in lean and 
obese mice? Determining whether inflammatory capacity of M11cKO ATTs remains 
intact (like MMKO mice in Chapter 3) would be of interest.  
3) What is the function of DN and DPT ATT cells in lean and obese adipose tissue? 
Although some studies have explored function of ILC cells that could comprise the DN 
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population, the complexity of this population is not well understood. Defining how DN 
and DPT cells arise in AT, and how obesity regulates their inflammatory function will be 
next steps in understanding ATTs. 
Addressing these questions will be important next steps in understanding how ATTs are 
regulated in adipose tissue, and their contribution to chronic low-grade inflammation. 
 
Objectives, Major Findings, and Implications for Chapter 3 
Although understanding adipose tissue leukocyte networks like APCs and ATTs are 
important for comprehending obesity mediated adipose tissue mediated chronic low-grade 
inflammation, basic knowledge of cell function is also required. Our objective for this chapter 
was to determine ATT specific characteristics after activation via TCR and CD28 specific 
activation. We hypothesized that there would be function differences compared to splenic T cells, 
and that ATTs would have enhanced inflammatory output in obese environments.  
 Despite previous studies indicating ATTs contribute to obesity-mediated inflammation, 
our findings have led us to challenge this dogma. ATTs were cultured within the stromal 
vascular fraction from adipose tissue and stimulated in a T cell specific with αCD3/CD28 
dynabeads.  We found activation in terms of CD25 (IL-2rα) cell surface expression and cytokine 
secretion were blunted in ATTs from obese adipose tissue compared to lean ATT and splenic T 
cell controls. LysMcre x MHCIIfl/fl mediated antigen presentation is required for development of 
ATT impairment, and soluble factors secreted by HFD SVF can also decrease inflammatory 
capacity of ATTs. Similar to what is known about T cell exhaustion after chronic antigen 
stimulation in other settings (e.g. tumor infiltrating lymphocytes), we observed HFD induced 
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impairments in T cell proliferation, cytokine production, and expression of activation markers in 
both mice and humans.  
 Recent studies from other groups find phenotypes that are similar to ours, but come to 
different conclusions. Shirakawa et al. determined that there is a higher frequency of PD1+ CD4 
Tconv cells in obese eWAT that have reduced IFNy and increased osteopontin (Spp1) production 
(98). Ultimately, they conclude that CD4Tconv in obese eWAT are senescent but contribute to 
chronic low-grade inflammation via osteopontin secretion. Although we both see canonical 
inflammatory impairment in ATTs from obese tissue, senescence and exhaustion are disparate 
modalities for impairment. Senescence does not account for chronic exposure to activating 
antigens or the consequences for impaired canonical T cell inflammatory properties. 
Furthermore, our SC RNAseq analysis of CD4Trm and CD8Trm subsets did not detect 
enrichment of senescence markers described by Shirakawa (Cdkn1a, Cdkn2b, Satb1, Eef1a1) in 
HFD groups. However, there are reports that show obesity induces T cell exhaustion in the 
spleen and liver of mice fed HFD for 10 months (23). They determine that although obesity 
induces PD1+ expression, T cell exhaustion, and increases the risk for cancer, obese mice are 
also more responsive to PD1 blockade and recover with immunotherapy treatment. This suggests 
unlike ATTs, obesity does not result in terminal exhaustion in in T cells outside of adipose 
tissue. Whether this is due to different environmental signals or activating antigens will be 
interesting to explore in future studies.   
 Although these findings are provocative, there are several limitations that should be 
considered. First, ATT activation assays required immune and stromal cells from adipose tissue 
to maintain viability of the cells over the course of 3 days. Non-T cells in this culture could 
influence the cytokine secretion and proliferation data. Since the composition of ND and HFD 
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SVF are different, there could be factors in the culture conditions that contribute to our 
observation of ATT inflammatory impairment. This could be viewed as a benefit, since it models 
signals ATTs would receive in vivo, however, it also does not cleanly distinguish ATT cell 
function. Therefore it is difficult to determine to pinpoint whether ATTs or surrounding cells are 
responsible for reduced ATT functionality in obese tissue. Although there are multiple cell types 
within SVF that could influence ATT function, we remove adipocytes. Adipose tissue 
parenchymal cells are potentially important mediator of CD8+ ATT function since they 
expression MHCI and PDL1. Additionally, it is possible that differences in lipid composition in 
ND and HFD SVF could influence ATT functional outcomes. However complex, each of these 
possible contributions to ATT impairment are testable and could lead to a mechanistic driver of 
ATT impairment in future studies.   
 There are several important questions regarding ATT impairment in obese adipose tissue 
that should be explored in the future. Determining the mechanisms for ATT impairment is 
essential and was a primary goal investigated further in chapter 4. Unraveling whether ATT 
impairment is due to metabolic dysregulation such as insulin resistance, co-inhibitory receptor 
expression (other than PD1), or impairments in intracellular signaling mechanisms are important 
to understand. Importantly, CD8 and Tconv cell impairments may be due to discrete 
mechanisms, which will be interesting to dissect in the future. If constant antigen exposure is 
necessary for Tconv impairment, focusing on antigens from the SVF or gut may be of interest. 
However, if CD8+ ATTs have characteristics of exhaustion, adipocyte composition presentation 
of endogenous antigens by MHCI should be investigated. 
 Once mechanisms of ATT impairment have been established, we will be able to evaluate 
whether reduced inflammatory capacity is beneficial in the context of chronic low-grade 
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inflammation.  Currently we can imagine that either reduced ATT inflammatory capacity is 
beneficial because it limits pro-inflammatory cytokine secretion like IFNγ and IL2. However, 
reduced ATT inflammatory capacity may also prevent maintenance of adipose tissue 
homeostasis. Additionally, honing in on kinetics of in-vivo ATT activation with HFD will be 
important. In-vivo activation occurs before 6 weeks of HFD feeding where we first saw 
impairments in cytokine secretion. Pinpointing when ATTs first recognize their cognate obesity 
antigen(s) responsible for Tconv activation will critical for studying the antigens responsible for 
Tconv activation. Once adipose tissue antigens are found, we will have the ability to study 
obesity as an autoimmune disease of the adipose tissue. Additionally, we will be able to 
determine whether stopping ATT activation prior to 6 weeks of HFD feeding will abrogate 
chronic low-grade inflammation with chronic HFD feeding.    
 
Objectives, Major Findings, and Implications for Chapter 4 
This study was the first to perform in depth SC RNAseq on ATTs from mice receiving a 
chronic 12-week regimen of HFD. Previous studies by the Dixit Lab have performed SC 
RNAseq on ATTs from mice fed a ketogenic diet for 1 week, revealing increased ATT cell 
composition with decreased Il1b expression (148). As we observed in Chapter 3, there are 
functional differences in ATTs depending upon duration of HFD feeding.  Understanding the 
diversity of ATTs in the context of cellular subsets, depot differences, and diet induced gene 
expression differences was our overall objective of Chapter 4. Each of these three factors helped 
us comprehend the function of ATTs and how they are regulated by localized environmental 
signals and obesity. We found nine distinct ATT subtypes in SC RNAseq analysis of murine 
eWAT, oWAT, and iWAT. While most of the ATT cell subsets have been identified previously, 
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our comprehensive analysis of composition and gene expression in lean and obese mice provide 
us with extensive data to explore. 
We decided to focus on ATT clusters we believed to comprise the CD4+ Tonv and CD8+ 
groups where we observed inflammatory ATT impairment in Chapter 3. Comparing resident 
memory (CD4Trm) to naïve (CD4Nv) within ND and HFD groups allowed us to assess a 
sufficient number of DE genes to perform pathway analysis for each group. Strikingly, we saw 
CD4Trm and CD8Trm cells from HFD eWAT were enriched for CD4+ and CD8+ T cell 
exhaustion observed in chronic LCMV infections (157).  An exhausted phenotype observed in 
freshly isolated CD4Trm and CD8Trm explains functional findings of ATT inflammatory 
impairment observed in Chapter 3. Exhaustion results in inhibition of T cell proliferation, IL-2R 
expression, and cytokine secretion that cannot be reversed with PD1 blockade, reflecting results 
observed in eWAT ATTs. We have verified BTLA is upregulated in HFD cells and is a good 
target to investigate in immunotherapy moving forward. We have also pinpointed specific genes 
like Nlrc3, Dusp6, and Dicer1, which could mediate molecular aspects of T cell exhaustion such 
as inhibition of TCR signaling pathways, and translation defects. Each of these mechanisms will 
also be explored further in the future. 
 Data from this analysis also provides information about CD3+ ATT subsets of which we 
did not perform in depth analysis in this dissertation. The function and identity of DNStem cells 
in SC RNAseq and have been of interest. There is not currently literature that explores the 
function or development of these cells in lean or obese states. Since they possess gene expression 
signatures indicating progenitor function, it would be interesting to assess whether they are 
responsible for increases in T cell compartments observed after 1 week of ketogenic diet 
observed by the Dixit group (148). We also hypothesize these progenitor-like cells may develop 
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into the CD4+ CD8+ double positive T (DPT) cells observed in M11cKO mice from Chapter 2. 
We did not have sufficient information or substrate to investigate the origin of DPT cells in 
Chapter 2, but further analysis of DNStem may lead to some hypotheses regarding their ability to 
transform into canonical T cell subtypes.   
While SC RNA seq of ATTs from 3 depots in lean and obese mice provides a wealth of 
data that will need to be explored in more detail in future studies, there are several limitations 
that should be noted. Since ND and HFD ATT sorting and sequencing were done separately, 
there were fewer ATTs sequenced from the obese adipose tissue. The CD3+ cells from HFD 
mice also had universal contamination with macrophage genes, which is a problem that has been 
seen previously in the field. There were also some questionable findings in regards to cell types 
found after the CD3+ sort. Why there were NK and ILC3 cells that are known lack CD3 
expression is unknown. Future studies can investigate whether there was a technical mistake with 
our sort, or there are CD3+ subsets of ATTs with gene expression similar to ILCs and NK cells 
can be assessed in flow cytometry. 
 
Final Thoughts 
Obesity induced ATT exhaustion is a novel finding that can reshape the way we think 
about chronic low-grade inflammation. While previous studies suggested that antigen 
presentation via MHCII contributes to ATT inflammation and insulin resistance in the context of 
obesity, it appears that chronic exposure to antigen ultimately results in decreased inflammatory 
potential of T cells. Understanding the juxtaposition of chronic low-grade inflammation with T 
cell exhaustion will be important for understanding how obesity can simultaneous induce 
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inflammatory mediated insulin resistance and result in impairment of T cell inflammatory 
responses resulting in increased morbidity and mortality in the context of infections and cancer. 
 Moving forward, identifying the antigen(s) responsible for ATT activation and their 
ultimate exhaustion still need to be identified. This will allow us to understand whether ATTs 
play an important role in initiating inflammation via mechanisms like the recruitment of innate 
immune cells and the metabolic result of exhaustion. Alternatively, it is possible that ATTs do 
not play an essential role in adipose tissue induced chronic low-grade inflammation and 
subsequent insulin resistance.  
 However, understanding ATT exhaustion could be critical for understanding obesity-
induced morbidity outside the scope of type II diabetes.  People with obesity have a higher risk 
for worsened outcomes to viral infections and are more prone to cancer, two diseases that are 
highly dependent upon antigen specific responses from T cells. Further exploration of 
mechanisms responsible for exhaustion will be important to detail and investigate in lymphatic T 
cells.  If T cell impairments associated with obesity are systemic and occur with similar kinetics, 
it will be important to investigate the gut as a possible source of antigen. However, if ATT 
exhausting is unique, adipocytes may be important to peruse. 
 Ultimately, regardless of the source of antigen, mechanisms governing ATT exhaustion, 
and the role of ATTs in chronic low-grade inflammation, future studies will provide us with 
information that will help shape our strategies for treating both metabolic and immune 
morbidities associated with obesity.  
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